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SUMMARY 
Future system  for  the  free movement  of medicinal  products 
In  the  European  Community 
Following  the  Intensive  consultations which  have  taken  place over  the  past  two 
years,  the  Commission  Is  now  presenting  Its  proposals  for  the  future  system 
for  the  free  movement  of  medicinal  products  (both  for  human  and  veter lnary 
use)  within  the  Community.  These  consultations  have  shown  the  existence  of 
wide  support  for  the  main  features  of  these proposals,  Including: 
-the establ lshment  of  a  new  European  Agency  for  the  Evaluation  of  Medicinal 
Products; 
-the  creation  of  a  new 
biotechnology  products 
central lzed  Community  procedure, 
and  veterinary  medicines  used 
compulsory  for 
as  performance 
enhancers,  and  aval lable  on  an  optional  basis  for  other  Innovatory  medicinal 
products,  leading  to  a  Community  authorization,  val ld  throughout  al 1 
12  Member  States; 
-a decentralized  procedure,  based  on  the  principle  of  mutual  recognition, 
which  wl  II  allow  the  progressive extension of  a  marketing  authorization  from 
one  Member  State  to  the  others,  wl th  Important  safeguards  to  ensure  that 
there  Is  no  dl Iutton  of  the  strict  standards  of  qual lty,  safety  and 
efficacy. 
The  new  Agency  will  be  made  up  of  the  existing  Committee  for  Proprietary 
Medicinal  Products  and  the  Committee  for  Veterinary  Medicinal  Products,  with 
substantial  additional  logistical  and  administrative  support.  Its  task  will 
be  to  coordinate  the  work  of  evaluation  and  supervision  of  medicinal  products 
being  conducted  In  Member  States  to  avoid  duplication  of  effort,  but  at  the 
same  time  ensure  that  alI  relevant  factors  are  taken  Into consideration during 
the  authorization process,  and  the  subsequent  supervision of  medicines  through 
adverse  reaction  monitoring  (pharmacovlgllance)  and  Inspection  and  control  of 
manufacturers. - 6  -
In  the  case  of  appl lcatlons  submitted  through  the  central lzed  procedure, 
following  the  evaluation of  the  appl lcatlon,  the decision on  whether  or  not  to 
grant  authorization  will  be  taken  by  the  Commission,  In  cooperation  with  the 
Member  States.  Thereafter,  the  Community  wll I  be  responsible  for  the 
monitoring  of  the  product,  and  the  technical  updating  of  the  authorization. 
In  the  case  of  veterinary  medicinal  products  Intended  for  use  as  performance 
enhancers  In  farm  animals,  consideration  Is  being  given  to  Community 
arrangements  to assess  the  Impact  of  their  use. 
However,  It  Is  the  decentral lzed  procedure  which  wl  I I  continue  to  be  the  most 
widely  used  after  1992.  In  this  procedure,  the  Agency  wl  II  only  be  Involved 
If  there  Is  a  disagreement  between  Member  States about  the  qual lty,  safety or 
efficacy  of  a  medicinal  product.  In  this  case,  the  Agency  will  provide  an 
Independent  scientific  evaluation  of  the  Issues  Involved,  and  a  binding 
arbitration  procedure  at  Community  level  wl  I I  follow.  The  monitoring  of  the 
product  will  remain  the  responsibility  of  the  Individual  Member  States.  By 
1996,  this  procedure  wl  I I  become  the  most  commonly  used  for  obtaining 
authorization  for  products  Intended  for  use  In  more  than  one  Member  State. 
Both  procedures  will  come  Into  force  In  1993,  and  will  be  reviewed,  In  the 
I lght  of  experience,  In  1999-2000. - 7  -
Future system for  tha  free movement  of med!elnal  products 
In  the  European  Community 
1.  GENERAL  CONSIDERATIONS 
1.1.  State of  consultations 
During  the  preparation of  these  prOposals,  the  services of  the  Commission 
hav~  engaged  In  an  lntens!ve  round  eof  consultations  with  the  Member 
States,  representatives  of  the  pharmaceutical  Industry,  representatives 
of  consumer  groups  and  the Consultative Committee  for  Consumers,  .and  with 
European  representatives  of  the  various  health  professions  concerned,  In 
particular,  pharmacists,  doctors  and  veterinarians.  Three  consultation 
documents  have  been  Issued  by  the  Commission  or  Its servtces: 
-the Report  on  the Activities  o~  the  Committee  for  Proprietary Medicinal 
Products  (COM  (88)  143  final  of  22  March  1988); 
-the "Memorandum  on  the  future  system  for  the authorization of  medicinal 
products  in  the  European  Community,  Apr I I  1989"; 
- a  further  dIscuss I  on  document  on  the  future  system  of  December  1989 
(I I 1/8267/89  Rev.  2.). 
All. the  detailed  comments  received  In  response  to  these  documents  have 
been  carefully  analysed  and  taken  Into  consideration  during  the. 
formulation  of  these  proposals. 
1.2.  The  objectives of  the  future  system 
Following  this  lengthy  consultation  exercise,  there  now  appears  to  be 
general  agreement  on  the  objectives  of  the  future  system.  These 
objectives  can  be  presented  from  three  points  of  view,  without,  however, 
attempting  to  present  them  In  any  order  of  priority: 
-from  the  point  of  view  of  the  protection  of  public  health  within  the 
CommunIty; 
-from the  Industrial  pol Icy  point  of  view; 
- from  the  point  of  view  of  the  Interests  and  objectives  of  the 
CommunIty. - 8  -
From  the  point  of  view of  public  he~lth: 
a)  A  scientific  evaluation  of  dossiers  for  authorization  by  the  best 
European  experts which  can  be  recognized  throughout  the  Community; 
b)  Criteria  of  qual lty,  safety  and  efficacy  based  upon  rigorous 
requirements  Imposed  by  harmonized  Community  legislation; 
c)  Clearly  defined  political  and  legal  responsibilities  for  each 
authority  deal lng  with  the  authorization  of  medicinal  products  In  the 
Community  and  the  refusal  or  withdrawal  of  products  from  the  market; 
d)  A  capacity  to  authorize  the  marketing  of  a  new  medicinal  product  as 
rapidly  as  possible  so  that  It  can  be  available  to  all  patients 
throughout  the  Community; 
e)  A capacity  to  restrict or  withdraw  a  medicinal  product  from  the  market 
throughout  the  Community  as  rapidly  as  possible  on  the  basis  of 
reliable  Information  collected  through  a  European  pharmacovlgllance 
network  (adverse  effects)  and  surveillance  network  (defect lve  lots, 
counterfeiting); 
f)  Identical  publ lshed  Information  on  the  conditions  of  marketing  a 
medicinal  product  val ld  throughout  the  Community: 
-a single  summary  of  product  characteristics; 
- identical  labelling  and  patient  Information  leaflet  In  the  different 
languages  of  the  Community; 
-same  legal  status  for  obtaining  the  prroduct  (hospital  use  only, 
prescription only,  self-medication, ... ); 
g)  A  reinforcement  of  preclinical  and  clinical  research  facilities  In 
Europe,  so  as  to  develop  the expertise  and  knowledge  necessary  for  the 
protection of  publ lc  health; - 9  -
From  the  point  of  view of  Industrial ·policy: 
a)  Uniform,  clear  and  well-known  reQuirements  for  the  presentation  and 
content  of  application  dossiers  (EEC  Guidelines  and  Notice  to 
AP.P I I  cants); 
b)  Deposit  of  a  single  fl le,  If  possible  to  a  single  competent  authority 
In  order  to  protect  confidentiality  and  reduct  the  admlnlstr~tlve 
.burden  (sma I I  number  of  copIes;  sImp I If I  cat I  on  of  admInIstratIve 
reQuirements); 
c)  Simple,  transparent,  fair  and  non-bureaucratic  procedu~es,  respecting 
the  time  I lmrts  establ !shed  by  Community  law; 
d)  Objective  crJterla  for  evaluation,  based  exclusively  on  the  Qual lty, 
safety  and  efficacy of  the  product,  expressed  In  evaluation  reports; 
e)  Rights  to  a  hearing,  to  detailed  reasons  for  decisions  and  appeal 
mechanisms  for  the  appl !cant; 
f)  Reasonable  registration  fees  corresponding  to  the  true  level  of 
control  and  verification undertaken  by  the  competent  authority. - 10  -
Aspects of  specific Community  Interest: 
a)  the  possibility  of  European  concertatlon  with  Innovatory  companies 
during  the  research  and  development  stage; 
b)  the  pool lng  of expertise for  the  evaluation of  Innovatory  products  and 
the  promotion of  cooperation between  Member  States; 
c)  a  single scientific evaluation valid  for  the  whole  Community; 
d)  allowing  companies  with  a  Community  vocation  direct  access  to  a 
Community-scale  market,  while  maintaining  local/regional  s·ystems  for 
other  fIrms; 
e)  to  provide  a  credible  European  authorization,  which  may  be  an  aid  to 
exports; 
f)  a  single  management  of  Community  authorizations  (renewals  and 
variations); 
g)  coordination  of  the  Implementation  of  Community  obligations  (GMPs, 
GLPs,  GCPs  etc); 
h)  updating  and  International  harmonization of  testing  requirements. - 11  -
1.3.  The  two  Community  procedures 
1  t  appears  that  these  objectIves  can  best  be  met  by  a  nuanced  approach 
Involving  two  procedures;  one  decentralized  and  the  other  centralized. 
The  prImary  obJect 1  ve  of  the  decentra II zed  procedure  wIll  be  to  enab I  e 
pharmaceutical  companles·to  Increase progressively  their  penetration  from 
one  nat lona 1  mar!-:'.et  to · an  IncreasIng  number  of  Member  States.  The 
object lve  of  th.;,  centralized  Community  procedure.  on  the  other  hand,  Is 
to  provide  major  Innovatory  products  with  direct  access  to  a  Community-
scale market.  The  scope  of  these  community  procedures  wl  II  be  revised  In 
the  light  of  the  experience  acquired  after  a  reasonable. period  of.  time 
ra.g.  for  the  year  2000). 
The  decentral lzed  procedure  wl  I I  continue  to  be  the most  frequently  used, 
even  after  1992.  A company  which  has  obtained authorisation  1n  one  Member 
State  will  be  able·  to  apply  for· the  acceptance  of  the  authorization  In 
one  or  more  of  the  other  Member  States.  If  the  Member  States  concerned 
consider  that  they  cannot  accept  the  authorizat-Ion.  and  If  after 
consultation  with  the  first  Member  State,  .they  are  unable  to  reach 
bilateral  agreement,  the  matter  will  be  referred  for  an  arbitration  at 
Community  level. 
The  centralized  procedure·wlll  be  compulsory,  In  the  first  Instance.  for 
medicinal  products  derived  from  biotechnology  and  veterinary  medicines 
intended  for  growth  or  yield  promotion  purposes.  but  also  avallabJe,  as 
an  option,  for  other  high  technology  medicinal  products .and  new  chemical 
entitles. - 12  -
1.4.  The  reinforced  CPMP/CVMP 
So  far  as  the  mechanism  for  evaluating  appl lcatlons  for  authorization  Is 
concerned,  It  appears  clear  that  the  Community  wl  I I  have  to  draw  heavl ly 
on  the  resources  and  experience  existing  within  the  Member  States.  It 
does  not  appear  feasible  to  create  a  complex  set  of  new  and  lndependant 
structures  at· Community 
level.  Rather  the  aim 
level  to  duplicate  those  existing  at  national 
should  be  the  creation  of  a  technical  and 
administrative secretariat  with  the  necessary  resources  to coordinate  and 
avoid  duplication  of  existing  efforts.  In  short,  the  primary  emphasis 
should  be  on  a  pooling  of  resources  at  Community  level,  rather  than 
establ lshlng  a  massive  European  Drug  Administration. 
In  practical  terms,  this  means  that  the  primary  responsibility  for  the 
evaluation of  appl lcatlons  wl  II  remain  with  the  Committee  for  Proprietary 
Medicinal  Products  and  the  Committee  for  Veterinary  Medicinal  Products, 
aJ_belt  with  Increased  resources  and  responsibilities.  In  the  case  of  the 
decentra I I zed  procedure  It  appears  that  the  prImary  task  of  the  two 
Committees  will  remain,  as  now,  the  resolution  of  disagreements  which 
have  arisen  during  the  examination  of  appl lcatlons  for  authorization  at 
national  level,  with  Important  difference  that  the  opinions  of  the  two 
Committees  wll I  also  be  addressed  to  the  Community  Institutions  for  the 
adoption of  binding decisions  at  the  Community  level. 
In  the  case  of  appl !cations  submitted  through  the  central lzed  procedure, 
It  appears  essential  that  the  two  Committees  be  given  the  capacity  to 
undertake  a  single evaluation  of  new  appl lcatlons  which  wl  I I  be  accepted 
throughout  the  Community,  because  only  In  this  way  can  the  waste  of 
resources  resulting  from  paral lei  evaluation  of  appl lcatlons  be  avoided. 
Because  of  the  limited  expertise  available,  the  actual  evaluation  of 
appl lcatlons  wl  I I  usually  be  undertaken  by  the  same  rapporteurs  who  have 
so  far  undertaken  such  evaluations  on  behalf  of  the  Member  States.  The 
evaluation wl  I I  be  subjected  to  a  system of  peer  review within special 1st 
.working parties before  submission  to  the  Committees  for  the  adoption of  a 
formal  opinion.  In  the  new  system  however,  the  rapporteurs  will  have  to 
be  selected  by  the  CPMP  or  the  CVMP  from  among  panels  of  experts  and 
rapporteurs  designated  by  the  national  competent  authorities,  and  will 
work  on  behalf of  the  Community  as  a  whole. - 13  -
1.5.  The  need  for  an  Agency 
The  progressive  Introduction  of  the  two  new  Community  authorization 
procedures  will  result  In  a  very  substantial  Increase  In  the  workload  of 
the  CPMP/CVMP,  which  are  likely  to  undergo  maJor  changes  over  the  next 
few  years ..  If  the  two  Committees  are  to  be  able  to  function  effectively 
and  with  proper  coordination  between  them,  It  Is  essential  that  they  be 
given  th.e  proper  logistical  support  and  resources  to  make  the  new 
procedures  work.  After  considerable  reflection,  the  Commission  has 
concluded  that  for  managerial  and  budgetary  reasons  these  functions  would 
be  undertaken  better  within  an  Independent  European  Agency  for  the 
Evaluation of  Medicinal  Products  rather  than  within  the Commlslon  Itself. 
First,  It  Is  Important  to  emphasize  the  sheer  scale  of  the  task.  of 
evaluating  applications  for  new  high  technology  medicinal  products.  A 
typical  appl lcation  for  authorization  for  an  Innovatory medlclne.costs  In 
the  region of  100  ml  II lon  ECU  to  prepare  and  runs  to  tens of  thousands  of 
pages.  Although  the  detailed  evaluation  of  each  application  will  be 
undertaken  by  a  smal I  number  of  highly  Qual If led  rapporteurs  working  on 
behalf  of  the  Community,  the  logistics  Involved  In  preparing  assessment 
reports,  summaries  of  product  characteristics  and  label 1 lng  and  patient 
leaflets for  12  Member  States are considerable. 
Moreover,  the  authorization  of  medicinal  products  Is  not  a  once  and  for 
all  process.  Manufacturers  are  constantly  changing  the  formulation  of 
their  products  In  order  to  try  to  Improve  them,  and  also  seek.  to  amend 
the  terms  of  an  Indication,  In  order  to  allow  the  use  of  the  product  for 
new  therapeutic  Indications.  It  has  been  estimated  that  on  average  two 
appllcat Ions  are  made  each  year  to  amend  or  vary  the  terms  of  each 
marketing  authorization.  This  Implies  that  within  a  relatively  short 
period  of  time,  the  workload  Involved  In  managing  existing  Community 
authorizations  wl  II  exceed  the workload  of  assessing  new  appl !cations  for 
authorization. - 14  -
In  addition  to  the  workload  resulting  from  appl lcatlons  by  the 
pharmaceutical  Industry  to  amend  the  terms  of  an  authorization,  account 
must  also  be  taken  of  the  continuing  supervision  of  the  manufacturer  by 
the  regulatory  authorities,  Ln  particular  through  the  monitoring  of 
adverse  reaction  reports,  and  Inspections  and  controls  of  manufacturers. 
Particularly,  In  the  case of  the centralized system,  arrangements must  be 
made  for:.the  proper  exercise  and  coordination  of  these  responsibilities 
at  the  Community  level,  which  Implies  a  need  for  substantial  resourcss. 
For  the  reasons  noted  below,  It  Is  difficult  at  the  present  time  to 
assess  In  detal I  the  I lkely  workload  which  wll I  result  from  the 
Introduction  of  the  new  procedures.  It  Is  therefore  Important  to  ensure· 
that  the  administrative  arrangements  which  are  adopt~d  are  sufficiently 
flexible  to  allow  for  the  rapid  recruitment  and  redeployment  of 
personnel,  as  a  function of  nesd. 
Finally,  It  Is  Interesting  to  note  that  within  the  Member  States  the 
evaluation  of  medicinal  products  is  frequently  entrusted  to  agencies· or 
Institutes  which  are  themselves  autonomous  of  the  organs  of  the  central 
government.  The  Commission  considers  that  the  arguments  which  have  led 
Member  States  to  take  this  course  of  action  are  also  valid  for  the 
Community. 
The  existence at  Community  level  of  high-level  Independent  expertise,  due 
to  an  Improved  cooperation  between  competent  authorities  after  the 
setting-up  of  the  Agency,  Is  an  Important  contribution  to  the 
reinforcement  of  consumer  confidence  in  marketing  authorizations  granted 
for  human  or  veterinary medicinal  products. - 15  -
2.  THE  AUTHORIZATION  OF  MEDICINAL  PRODUCTS  AFTER  i992 
As  noted  above,  .there  will  be  three  procedures  for  the  authorIzatIon  of 
medicinal  products  after  1992:  decentralized  and  centralized  Community 
procedures  and  national  registration procedures. 
2.1.  The  decentralized  procedure  (see  table  I) 
The  decentralized  procedure  Is  based  upon  the  principle  of  mutual 
recognition  of  national  authorizations,  but  with  Important  safeguard 
clauses  to allow for  the  public  health  Issues  raised  by  the authorization 
of  medicinal  products,  whether  human  or  veterinary.  The  proposals  for  the 
decentralized procedure  take  account  of  the  experience  acquired  under  the 
multi-State  procedure  establ l~hed by  Directive 83/570/EEC  and  of  the more 
I lmlted  experience  acquired  In  the  authorization  of  veterinary  medicinal 
products  under  Directive  81/851/EEC.  In  addition,  the  Commission  has 
decided  to  try  to  ensure  that  the  decentralized  procedure  Is  as  simple 
and  flexible  as  possible  In  order  to  facl I ltate  progressive  access  to  a 
Community  scale  market  for  small  and  medium  sized  companies.  UnlIke  the 
existing  Community  procedures,  there  Is  therefore  no  minimum  threshold 
number  of  Member  States  nor  Is  there  any  restr let ion  on  the  number  of 
times  the  procedure  may  be  used  In  respect  of  the  same  product. 
In  order  to  use  the  decentralized  procedure;  the  company  concerned  must 
first  submit  an  application  for  authorization  to  one  or  more  Member 
States  In  accordance with  the  current  requirements  laid  down  by  Community 
legislation.  The  reasons  for  which  companies  wl  I I  be  permitted  to  submit 
this  Initial  appl lcatlon  to  more  than  one  Member  State  are  further 
discussed  In  section 2.2  below.  The  Member  State(s)  concerned  examine  the 
appl lcatlon  In  accordance  with  the  normal  procedures  currently  used  and 
decide  whether  or  not  to  grant  author lzat ion.·  Before  grant lng 
authorization  for  any  new  medicinal  product,  each  Member  State  wll 1  be 
required  to  prepare  a  detailed  assessment  report  for  the  product 
concerned,  and  approve  the  technical  summary  of  product  characteristics 
(SPC)  proposed  by  the  appl lcant  together  with  the  text  of  the  Iabeii lng 
and  the patient  Information  leaflet  (package  Insert). - 16  -
When  a  company  applies  for  recognition  of  the  Initial  authorization  by 
one  or  more  of  the  other  Member  States of  the  CommunIty.  It  w  II I  have  to 
submit  an  Identical  application  to  that  accepted  by  the  first  Member 
State,  Including  the  same  appt tcatlon  dossier,  the  same  summary  of 
product  characteristics  and  the  same  formulation  and  trade  mark,  unless 
there  are obJectively  Justified  reasons  for  a  difference.  In  addition  the 
other  Member  State(s)  concerned  wll I  receive  the  assessment  report 
directly  from  the  authorities of  the  first  Member  State  to  authorize  the 
product. 
In  accordance  with  the  principle  of  mutual  recognition,  the  countries 
concerned  by  the  decentral tzed  appl lcatlon  should  usually  recognise  the 
authorization  granted  by  the  first  Member  State  within  a  period  of 
90  days.  However,  a  series of  safeguard  clauses  wl  I I  allow  Member  States 
to  oppose  mutual  recognition  If  they  consider  that  the  medicinal  product 
concerned  presents  risks  to  publ lc  health. 
In  this  case,  the  Member  State  concerned  wl  I I  be  expected  to  forward  Its 
own  assessment  report  of  the  product,  together  with  the  reasons  for  Its 
objections  to  the  first  Member  State,  the  other  Member  States  concerned 
by  the  appl lcatlon  and  the  appl lcant.  There  then  follows  a  period  of  60 
days  which  Is  allowed  for  bt lateral/multi lateral  discussion  of  the 
application  between  the  rapporteurs  and  co-rapporteurs  of  the  Member 
States  concerned  and  the  appl lcant  In  order  to  try  to  find  an  acceptable 
solution  to  the  problem.  Only  If  It  Is  not  possible  to  reach  a  solution 
during  this  phase  Is  the  matter  referred  through  the  Agency  to  the  CPMP 
or  the  CVMP  for  an  opinion. - 17-
In  this case,  the  rapporteur  from  the  first  Member  State  to authorize  the 
product  and  the  co-rapportuers  from  the  other  Member  States  concerned 
wl  I I  present  an  agreed  statement  of  the  Issues  Involved,  and  submit  al 1 
their  assessment  reports  to  the  Agency.  In  addition,  the  applicant  will 
be  required  to  submit  a  full  copy  of  the  application  to  the  Agency.  As 
appropriate,  the  CPMP/CVMP  wl  II  nominate  experts  to  consider  the 
outstanding  objections  and  review 
characteristics,  the  label I lng  and 
the  draft  summary 
package  Insert  and 
'of 
the 
product 
various 
assessment  reports.  The  conclusions  of  these  experts  would  then  as 
appro~rlate  be  submitted  to  the  various  expert  panels  before  submission 
to  the  CPMP/CVMP  for  the  adoption  of  an  opinion.  This  opinion  would 
become  binding  for  the  Member  States  concerned  following  the  regulatory 
mechanism  out I lned  In  section  2.4.  However,  It  sbould  be  noted  that  the 
final  decision  at  the  end  of  the  decentral lzed  procedure  wl  I I  be  binding 
only  on  those  Member  States  concerned  by  the  application,  and  will  not 
prevent  another  Member  State  from  subsequently  raising  additional 
objections  to  the  product. 
2.2.  Relationship  between  the  decent r a I I  zed  procedure  and  national 
authorization  procedures 
One  of  the  more  difficult  questions  to  arise  during  the  consultation 
process  c.oncerned  the  relationship  between  the  existing. national 
authorization  procedures  and  the  new  Community  decentralized  procedure, 
In  particular,  whether.  It  should  be  possible  for  companies  to continue  to 
submit  paral lei  appl !cations to  two  or  more  Member  States for  lndependant 
assessment  after  1992. - 18  -
After  careful  consideration  the  Commission  has  concluded  that  during  the 
Initial  phase of  the  decentral lzed  procedure,  before  any  Member  State  has 
authorized  the  product,  It  would  be_  appropriate  to  continue  to  allow 
companies  to submit  appl lcatlons  In  paral lei  to  two  or  more  of  the Member 
States.  In  practice,  to  limit  the  Industry  to  choosing  only  one  Member 
State for  the  Initial  application would  g-Ive  that  country  an  unacceptable 
unilateral  power  of  decision  on  the  access  of  a  product  to  the  Community 
market.  Moreover,  In  principle  It  appears  desirable to encourage  a  degree 
of  c~mpetltlon between  the  regulatory authorities of  the  Member  States. 
However,  the  possibility  of  submitting  parallel  applications  Is  subject 
to  two  Important  restrictions. 
First,  with  effect  from  1993  onwards,  where  a  Member  State  Is  aware  that 
another  Member  State  Is  undertaking  a  detal led  evaluation  of  the 
medicinal  product  concerned,  It  wl  I I  be  able  to  suspend  Its  own 
evaluation  and  walt  for  the  detailed  assessment  report  from  the  other 
Member  State.  This  provision  wl  I I  provide  the  Member  States  with  a  means 
of  el lmlnatlng  any  unnecessary  dupl lcatlon  of  effort  and  waste  of  scarce 
scientific resources. 
Second,  from  1996  onwards,  It  will  no  longer  be  possible  to  pursue 
paral lei  appl !cations  after  one  Member  State  has  authorized  the  product 
concerned.  Once  the  first  authorization  Is  granted,  all  other  pending 
applications  will  automatically  be  transformed  Into  applications  for 
mutual  recognition  under  the  decentralized  procedure,  thus  guaranteeing 
uniform  decisions  throughout  the  Internal  market. 
It  follows  that  after  1996,  national  registration  procedures  will  be 
limited  to  the  Initial  phase  of  the  decentralized  procedure,  and  for 
pure I y  loca I  products  whIch  are  not  Intended  for  export  to  any  other 
Member  State. 
These  t~ansltlonal  arrangements  are  necessary  In  order  to ensure  that  the 
Agency  can  take  up  Its  responslbll ltles  on  a  progressive  basis,  and  to 
avoid  any  unnecessary  disruption  to current  registration procedures  whl  le 
the  new  Community  procedures  are  being  phased  ln. 2) 
- 19  -
2.3.  The  central !zed  procedure  (Table  1 I) 
The  proposals  for  the  new  centralized  Community  authorization  procedure 
take  Into  account  the  practical  experience  acquired  during  the  operation 
of  the  existing  procedures  establ lshed  for  biotechnology-high  technology 
medicinal  products established by  Directive  87/22/EEC. 
The  use  of  the  procedure  will  be  compulsory  for  the  vast  maJorIty  of 
medicinal  products  derived  from  biotechnology,  listed  In  Part  A  of  the 
Annex' to  the  regulation.  In  addition,  In  a  new  departure,  the  use  of  the 
centralized  procedure  will  also  be  compulsory  for  veterinary  medicinal 
products  which  are  Intended  to  Increase  the  productivity  of  food-
productlng  animals,  because  of  the  specific  Community  Interest  which 
these  products  represent. 
In  addition,  the  procedure  will  be  available  on  an  optional  basis  for 
other  high-technology  medicinal  products  I lsted  tn  Part  B of  the  Annex, 
and,  In  a  further  new  departure,  to  other  products  containing  a  new 
chemical  entltlty. 
These  restrictions  on  the  scope  of  the  centralized  procedure  appear 
necessary  In  the  first  Instance  to  ensure  the  progressive  establishment 
of  the  Agency  and  a  smooth  transfer  of  respons·lbllltles  from  the  Member 
States  to  the  Community.  The  scope  of  the  central I zed  procedure  wl  11  be 
reviewed  In  the  I lght  of  experience  In  1998-99,  when  the  posslbl I ity  of 
extending  It  to other  categories  of  products,  either  on  an  optional  or  a 
compulsory  basis,  wi  I I  be  reconsidered. 
Appl !cations  for  authorization  wll I  be  submitted  directly  to  the  Agency. 
The  exact  form  of  the  appl !cation,  together  with  such  practical 
Information  as  the  fees  payable,  linguistic  requirements,  and  the 
presentation of  the  Information wll I  be  set out  In  a  Notice  to  Appl !cants 
to  be  prepared  by  the  Agency. - 20  -
The  appl lcatlon  wl  I I  then  be  referred  to  the  CPMP  or  the  CVMP  as 
appropriate  for  review.  For  each  appl lcatlon  a  rapporteur  wl  11  be 
appointed  to  undertake overal I  responslbl I lty  for  the  coordination of  the 
review  of  the  product,  and  experts  will  be  appointed  to  assist  the 
rapporteur  In  the  evaluation  of  Individual  parts  of  the  file.  These 
rapporteurs  and  experts  wl  I I  be  appointed  by  the  Committee  responsible, 
from  I I sts  of  experts  provIded  by  the  Member  States.  They  w  I I I  however 
report  directly  to  the  Committee  and  not  to  their  Individual  national 
authorities. 
Working  under  the  supervision of  the  CPMP/CVMP  and  consulting  Its  expert 
advisory  panels  as  appropr late,  the  task  of  the  rapporteur  will  be  to 
prepare  an  asse~sment  report  for  the  product  concerned,  and  to  review  the 
draft  summary  of  product  characteristics  and  the  labelling  and  package 
Inserts  for  the  medicinal  product  concerned  proposed  by  the  appl lcant. 
These  drafts  will  then  be  presented  to  the  CPMP/CVMP  for  Its  scientific 
opinion,  which  will  become  binding  following  the  regulatory  mechanism 
described  In  section  2.4. 
The  overal I  time  allowed  for  the  preparation of  the opinion of  the  Agency 
by  the  relevant  committee  Is  210  days,  although  this  would  be  suspended 
by  any  time  allowed  to  the  appl lcant  to  reply  to  questions  posed  by  the 
Committee. - 21  -
2.4.  The  mechanism  for  binding  Community  decisions 
In  accordance  with  the  principles  underlying  the  Community  treaties,  the 
tasks  of  the  new  Agency  are  purely  advisory,  and  It  Is  neither  possible 
or  appropriate  to  delegate  to  the  Agency  the  power  to  take  decisions  on 
the  authorization of  new  medicinal  products which  would  be  binding on  the 
Community  and  the  Member  States.  Such  decisions  can  only  be  taken  by  the 
existing Community  Institutions. 
In  proposing  a  mechanism  for  the  adoption  of  binding  decisions  on  the 
authorization  of  medicinal  products  within  the  Community,  the  Commission 
.has  sought  to ensure  that,  as  far  as  possible,  decisions  are  taken on  the 
basts  of  the  objective  scientific  criteria  of  qual tty,  safety  and 
efficacy.  It  was  also  thought  Important  to  protect  the  Integrity  of  the 
Agency  by  ensuring  that  at I  questions  of  a  scientific nature are  resolved 
within  the  Agency  structure  and  are  not  subject  to a  second  review during 
the  decision-making  process.  In  addition  consideration  has  to  be  given  to 
the  very  1  arge  number  of  decIsIons  I ll<e I  y  to  be  requIred,  probab I  y  we II 
in  excess  of  500  per  year· by  2000,  particularly  when  decisions  on 
variations  and  amendments  to  existing  authorizations  are  taken  Into 
consideration . 
.  ··'  .. 
At  the  conclusion  of  Its  evaluation  the  CPMP/CVMP  wl  II  forward  to  the 
Commission,  to  the  Member  States  and  the  appl !cant  Its opinion  consisting 
of: 
-the assessment  report  on  the  product,  and  In  the  event  of  a  favourable 
opinion; 
- the  summary  of  product  character 1st lcs, 
languages; 
In  alI  nine  Community 
-the  label 1 lng  and  package  Insert  for  the  product,  also  In  nine 
languages. - 22  -
Following  receipt  of  the  opinion,  the  Commission  will  have  30  days  to 
prepare  a  draft  of  the  decision  to  be  taken.  In  the  vast  majority  of 
cases  this  draft  wl  I I  reflect  the  scientific  opinion  transmitted  by  the 
Agency.  Because  of  Its  general  obligation  to  supervise  the  legality  of 
all  the  work  undertaken  by  the  Agency  taking  Into  consideration  the 
objectives  of  Community  pol lcles,  the  Commission  must  reserve  the  right 
In  exceptional  circumstances,  not  to  follow  the  opinion.  In  such  cases, 
however,  the  Commission  will  have  to  provide  detailed  reasons  for  not 
following  the opinion. 
The  draft  decision  will  be  circulated  to  all  Member  States  and  to  the 
appl lcant.  The  Member  States  wll I  have  30  days  to  submit  detal led 
written  reasons  explaining  any  objections  to  the  draft  decision.  If  no 
objections  are  received  within  the  30  day  tlmel lmlt,  the  Commission  wl  II 
adopt  the  decision  to grant  or  refuse  a  European  marketing  authorization. 
If  object Ions  are  received,  the  Commission  will  have  to  consider,  In 
consultation with  the  staff of  the  Agency,  whether  these objections  raise 
new  scientific  Issues  which  have  not  yet  been  fully  explored  within  the 
relevant  Committee.  If  this  Is  the  case,  the  Commission  will  refer  the 
appl lcatlon  back  to  the  Agency  with  a  request  that  the  Committee 
concerned  reconsider  Its opinion  within  a  60  day  period. 
However,  should  It  appear  that  alI  the  scientific  Issues  have·  been 
adequately  addressed,  the  Commission  wl  I I  refer  the  draft  for  a  decision 
to  be  taken  on  the  basis of  a  qual I fled  majority  vote within  the  Standing 
Committee  on  Medicinal  Products  for  Human  Use  or  the  Standing  Committee 
on  Veterinary  Medicinal  Products  using  the  so-called  'regulatory 
committee  procedure'  (variant  3a  of  Councl I  Decision  87/373/EEC  of 
13  July  1987  laying  down  the  procedures  for  the  exercise  of  Implementing 
powers  conferred  upon  the  Commission). - 23  -
2.5.  !ransparency of  admlnls~ratlve procedures 
At  the  present  t lme,  the  Community  pharmaceutical  directives  already 
the  transparency 
In  particular,  the 
for  all  negative 
decisions.  These 
contaIn  sever  a I  provIsIons  desIgned  to  ensure 
authorization  procedures  for  medicinal  products. 
authorities  are  required  to  give  datal led  reasons 
decisions,  . to  grant  appeal  rights  and  to  publIsh 
requirements  wl  11  also apply  to  both  Community  registration procedures. 
During  the  decentral lzed  procedure,  app! lcants  wl  I I  be  given  the  right  to 
participate  In  discussions  between  the  Member  States during  the  bilateral 
phase.  In  both  the  centralized  and  decentralized  procedures  they  will 
have  the  right  to  submit  oral  or  written  responses  to  questions  posed  by 
the  CPMP/CVMP  during  the evaluation of  the  product,  and  a  formal  right  of 
appeal  prior  to  the  transmission  of  the  opinion  of  the  Agency  to  the 
Member  States  and  to  the  Commission.  The  appl lcant  may  also  be  given  an 
opportunity  to  make  representations  to  the  regulatory  Committee,  at  the 
discretion of  that  Committee. 
In  addition,  appl lcants  wl  I I,  of  course  have  the  formal  rights of  redress 
against  acts of  the  ~ommission or  the  Counci I  conferred  by  Articles  173, 
175  and  215  of  the  EEC  Treaty. 
In  addition  to  the  appeal  rights·  given  to  pharmaceutical  companies, 
efforts are  also  being made  to  Increase  the  openness of  the  authorization 
process  for  the  general  public.  It  Is  envisaged  that  the  assessment 
reports  prepared  by  the  Agency  will  be  made  available  to  the  public,  If 
necessary  after  edit long  to  remove  any  commercially  confidential 
Information.  Moreover,  the  Agency  wl  I I  be  under  a  general  obligation  to 
develop  appr.oprlate  contacts  with  the  general  publ lc  and  consumer, 
patient  and  professional  representatives. - 24  -
2.6.  Status of  marketing  authorizations 
a)  European  Marketing  Authorizations 
European  market lng  author lzat Ions  which  have  been  granted  following 
the  central lzed  procedures  will  apply  throughout  the  Community,  and 
have  the  same  status  In  each  Member  State  as  marketing  authorizations 
granted  In  accordance  with  nat lonal  procedures.  They  will  apply  for 
five  years,  renewable  on  appl lcatlon at  least  three months  In  advance. 
European  marketing  authorizations  may  be  amended  only  by  the 
Commission,  after  the  opinion  of  the  CPMP/CVMP  has  been  obtained,  In 
accordance  with  the  procedures  described  above. 
Although  In  principle  a  Community  marketing  authorization  based  on  the 
criteria of  qual lty,  safety  and  efficacy  wl  I I  be  val ld  throughout  the 
Community,  there  are  occasional  circumstances  which  may  justify 
restrictions  on  the  use  of  a  medicinal  product  which  satisfy  these 
criteria. 
In  the  case  of  medicinal  products  for  human  use,  It  Is  proposed  to 
Include  In  the  basic  Directive  65/65/EEC  an  Article  to  enable  Member 
States  to  prohibit  the  use  of  a  product  on  their  territory  for 
objectively  defined  reasons  of  publ lc  order  or  publ lc  pol Icy.  Such  a 
provision  appears  necessary,  In  particular,  In  order  to  take  account 
of  the  rather  dIfferent  poI I  c I  es  of  the  Member  States  In  reI at I  on  to 
birth  control.  However,  Member  States  wl  I I  be  obi lged  to  Inform  the 
Commission  whenever  this exception  Is  Invoked,  and  the  Commission  wl  11 
be  able  to  Intervene  In  cases of  abuse. 
The  use  of  Immunological  veterinary  medicinal  products  may  also 
present  certain  difficulties  result~ng  from  differences  In  animal 
disease  status  within  the  different  regions  of  the  Community.  In 
order  not  to  Interfere  with  the  operation  of  disease  eradication 
programmes,  It  Is  necessary  to  enable  the  Member  States  to  prohibit 
the  use  of  certain  types  of  vaccines  on  alI  or  part  of  their 
territory,  notwithstanding  that  they  satisfy  the  criteria  for 
authorization,  and  are  In  fact  used  In  other  regions  of  the  Community. - 25  -
Moreover,  within  the  veterinary. medicines  sector,  the  grant  of  a 
~uropean  Market lng  Author lzat ion  will  In  no  way  effect  the  operation 
of  particular  legislation  prohibiting  or  restricting  the  use  of 
certain  types  of  veterinary  medicine,  resulting  from  the objectives of 
the  Common  Agricultural  Pol Icy. 
In  exceptional  cases,  where  there  Is  a  serious  new  risk  to  public 
health,  a  Member  State may  Impose  temporary  restrictions on  the  use of 
a  product  covered  by  a  European  marketing  authorization  provided  that 
the  CPMP/CVMP  and  the  Commission  are  Informed  of  the  measure  and  the 
detailed  reasons  for  It,  at  the  latest  on  the  working  day  following 
the  lmposlt ion  of  the  measure.  The  CPMP/CVMP  will  be  required  to 
consider  urgently  the  measures  taken  by  the  Member  States  and  to  give 
Its  opinion  on  them.  The  CPMP/CVMP  opinion  wl  I I  be  circulated  to  the 
Commission,  the  Member  States  and  the  person  responsible  for  marketing 
In  accordance  with  the  procedures  described  above,  but  with  shorter 
time  1 lmlts  to  take  account  of  the  urgency.  The  Member  State which  has 
adopted  temporary  measures  may  maintain  them  In  force  untl I  such  time 
as  a  deflnltfve  decision  Is  adopted. 
b)  Acceptance· of· national  authorlzitlons· 
Where  authorizations  have  been  accepted  following  the  decentralized 
procedure,  with  or  without  referal  to  the  CPMP/CVMP,  the 
responsibility  for  the  management  of  the  author lzatlon  will  lie  with 
the  Member  State  which  first  authorized  the  product.  All  relevant 
pharmacovlgl lance  data  shal I  be  submitted  to  that  authority  for 
consideration  with  a  copy  to  all  other  Member  States  concerned.  All 
proposals  to  amend  the  terms  of  a  marketing  authorization  shall  be 
submitted  to  the  Member  State  which  first  authorized  the  product.  The 
decision  of  that  Member  State  will  be  notified  to  all  the  Member 
States  which  have  accepted  the  authorization.  In  the  event  of 
objections  (which  remain  unresolved  even  after  multi-lateral 
discussions)  from  the other  Member  States  about  possible  amendments  to 
the  terms  of  a  marketing  authorization,  the  matter  wl  I 1 be  referred  to 
the  CPMP/CVMP  for  arbitration. - 26  -
c)  National  procedures after  1992 
The  facility  of  purely  national  authorization  procedures  will  rem;~ln 
for  companies  too  small  to  avail  themselves  of  the  Internal  market, 
and  for  products  of  local  Interest.  The  procedures  for  granting 
marketing  authorization  wl  I I  remain  unchanged. 
in  the  case of  products  authorized before  1993,  the  Member  States wl  11 
remain  responsible  for  the  management  of  authorizations.  However,  the 
Member  States  and  the  Commission  will  continue  to  have  the  right  to 
request  an  appl lcatlon  to  be  examined  by  the  reinforced  CPMP/CVMP  In 
.specific  cases  where  the  Interests  of  the  Community  are  Involved, 
particularly  when  divergent  decisions  have  been  made  (Directive 
75/319/EEC  as modified,  Articles  11  and  12). - 27  -
3.  EUROPEAN  PHARMACOVIGILANCE 
The  term  "Pharmacovlgtlance"  Is  meant  to  cover  the  cOile~tlon  of 
Information  on  adverse  drug  reactions  (AORs),  at  pre~and post~ ~arketlng 
stage,  the  scientific evaluation of  these  AOR  reports  and _thEt  regulatory 
decIsIons  whIch  may  have  to  be  tal< en  fo I I  owIng  theIr analysts.  These 
regulatory  decisions  may  Include  In  extreme  cases  wlthdr~wal  or 
suspension  of  the  marketing  authorization,  but,  .more  ·often,,  a 
modification  of  the  legal  status  of  the  drug  and  amend!f!~hts  or  warnings 
In  the  summary  of  products  characterIstIcs, ·  I  al:)e I II ng  and  package 
leaflet. 
3.1.  Pharmacovlgl lance  experience  In  the  EEC 
Pharmacovigllance  Is  a  major  Issue  for  the  current  functioning  of  the 
CPMP  or  the  CVMP,  as  well  as  for  any  future  system  of  authorization  of 
medicinal  products  In  Europe. 
Arising  from  Its  mandate  under  Directive  75/319/EEC,  and  Its  public 
hea I th  respons lb Ill ty,  the  CPMP  has  for  many  years  been  concerned  wl th 
.  ~  .  . 
Issues of  pharmacovlgl lance.  The  original  system  of  routine  discussion  at 
meetings  and  manual  exchange  of  data  has  been  superseeded  by.a number  of 
Innovations,  namely: 
- a  rapid alert  system  using  fast  communication  methods; 
-a  drug  Information  monitor  which  Identifies  selected  products  and 
updates  the  Information  at  each  CPMP  meeting; 
- pharmacovlgl lance  hearings  WIth  companies,  fo I lowed  by  CPMP 
phar~acovlgl lance opinions; 
-standardization  of  summary  of  product  characteristics  for  products  of 
significant  Community  Interest. 
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In  December  1988,  the  Commission  circulated  to  the  Member  States  a 
detailed  questionnaire  relating  to  their  pharmacovlgllance  system.  The 
Commission  Issued  thereafter,  In  September  1989,  a  report  on  the  present 
situation  of  pharmacovlgllance  In  the  European  Community  (111/3577/89). 
Furthermore,  In  1989,  the  Commission  has,  In  consultation  with  the  CPMP, 
established  an  ad  hoc  Pharmacovlgllance  working  party,  which  meets  In 
para I lei  with  the  CPMP.  This  new  working  party  has  two  essential  advisory 
roles  to  the  Commission  and  the  CPMP,  first  on  general  questions  of 
· pharmacovlgl lance  methodology,  second  to  assist  the  CPMP  for  the 
scientific evaluation of  ADR  data  related  to specific medicinal  products. 
Our lng  the  last  12  months, 
lnformat lon  on  30  medicinal 
the  CPMP  has  exchanged  pharmacovlgl lance 
products.  S I  nee  Ju I  y  1986,  the  CPMP  has 
adopted  6  formal  pharmacovlgl lance opinions. 
In  the  veterinary  medicines  sector,  Increasing  Importance  Is  being 
attached  to  that  question,  and  the  CVMP  has  recently  establ lshed  Its  own 
working  party  to  exchange  Information  and  try  to  harmonize  methodology 
on  pharmacovlgl lance  questions. 
3.2.  ADR  reporting 
The  legal  status,  requirements  and  structure  of  national 
pharmacovlgl lance  systems  vary  considerably  throughout  the  Community. 
Besides  spontaneous  pharmacovlgllance,  there  are  several  types  of 
structured pharmacovlgl lance,  based  on  the  recrultement  of  physicians  for 
the monitoring of  specific medicinal  products.  In  this context,  It  should 
be  noted  that,  In  addition  to  spontaneous  pharmacovlgl lance,  three  Member 
States  may  require  by  law  that  pharmacovlgl lance  be  a  condition  for  the 
granting of  a  marketing  authorization.· - 29  -
In  most  of  the  Member  States.  reporting  by  the  medical  veterinary 
professlon(s)  and  by  pharmacists  Is  voluntary.  For  routine  reporting  by 
companies  a  6  month  frequency  Is  the  emerging  pattern.  For  serious  ADRs, 
time  limits  and  frequency  of  reporting  vary.  Where  reporting  Is 
mandatory,  sanctions  may  be  taken  for  not  doing  so.  Causal lty  Is  either 
assessed  by  expert  Judgement  alone  (staff  of  the  centres,  expert  panels 
and  committees)  or  In  combination  wl.th  an  algorithm.  The  body  reviewing 
1  nformat Jon  has  access  to  the  marketIng  authorIzatIon  doss ler.  Member 
States  do  not  systematically  relate  adverse  drug  reactions  to  data  on 
drug·usage.  This  can  however  be  done  In  cases  of  concern. 
Experience  has  shown  that  pharmacovlgllance  centres should  be  situated as 
close  as  possible  to  the  source  of  the  reports.  As  far  as  spontaneous  ADR 
reports  are  concerned,  regional  or  national  centres  wl  I I  remain  the  most 
Important  I Ink  between  the  source  of  the  report  and  any  Community 
coordination  system of  pharmacovlgl lance. 
3.3.  Future  obi lgatlons on  pharmaceutical  companies 
The  authorization  holder  will  be  required  to  ensure  that  the  authority 
which  granted  the  authorization  Is  Informed  of  any  serious  adverse  drug 
reaction  resulting  from  the  use  of  a  medicinal  product  In  humans  or 
animals  i~  accordance  with  the  terms  of  the  authorization.  Such 
InformatIon  sha l I  be  communIcated  by  the  company  wIth l n  15  days  of 
receipt.  The  authorization  holder  shal I  have  permanently  his  own 
pharmacovigl l~nce contact  point,  responsible  for: - 30-
-the organization  and  malntalnence  of  a  system  for  collecting  adverse 
reaction  data,  from  whatever  source,  and  the  maintenance  of  a  register 
of  alI  reported ADRs. 
-supplying  alI  relevant  Information  to  the  competent  authorities  In  the 
Community  regarding  the  benefit/risk  assessment  Including  Information 
on  the  volume  of  sales  or  prescription  as  well  as  reports  on  ADRs 
occurring outside  the  European  Community; 
-preparation  and  submission  of  regular  reports  to  the  authority  which 
authorized  the medicinal  product;  (e.g.  every  6  months  during  the  first 
two  years of  marketing  and  annually  for  the  next  three  years). 
-the  preparation  and  submission  of  post-marketing  studies,  when  these 
are  required  as  a  condition of  the authorization. 
3.4.  An  Increasing  role  for  the  Community 
Each  Member  State  will  required  to  designate  a  national  center  as  a 
contact  point  for  the  Community.  National  or  Regional  centres  should  be 
establ lshed  for  the  col lectlon  of  ADRs  and  the  evaluation  of  both 
spontaneous  reports  and  reports  submitted  by  the  holders  of  market lng 
authorization.  Companies  should  be  notified  by  the  national  center of  al 1 
spontaneous  reports  they  receive,  and  should  be  given  a  possibility  to 
comment  on  them. 
The  technical  aspect  of  the  exchange  of  Information  between  Member  States 
as  wet  I  as  the  causal lty  assessment  method  should  preferably  be 
harmonized  at  Community  level.  Systems  utilized  by  WHO  or  CIOMS  should 
normally  be  adopted  by  the  Community  pharmacovlgl lance  network.  As  from 
1993,  pharmacovlgllance  data  will  have  to  be  evaluated  with -a  view  to 
harmonizing  decisions  and  actions  applicable  In  all  the  Member  States. 
The  EEC  pharmacovlgllance  network  Is  thus  clearly not  Intended  to  replace 
neither  the  national  nor  the  WHO  system,  but  to  optimize  and  harmonize 
pharmacovlgllance  activities  In  the  EEC.  When  reQuired  under  Directive 
89/341/EEC,  the  Community  will  also  bring  to  the  attention  Information 
wh)ch  may  affect  the  protection  of  publ lc  health  In  third  countries  via 
the  World  Health Organization. - 31  -
Current  experience  In  the  CPMP  shows  that  pharmacovlgl lance  Information 
Is  sometimes  transmitted  too  late,  when  a  national  decision  has  already 
been  taken.  Community  legislation should  provide  for  regular  transmission 
of  evaluated  data  and  for  Immediate  transmission  by  the  national  centres 
of  all  lnformat ion  on  ser lous  ADRs.  A routine  lnformat lon  exchange,  e.g. 
covering  alerts  on  non-serious  AORs  and  the  rapid  alert  system  would 
continue  to  run  In  parallel.  The  rapid  alert  system,  recently 
Implemented,  wl  I I  have  to  be  Improved,  using  electronic  mall.  A 
pharmacovlgllance  Information  should  be  considered  as  an  alert  If,  In 
case  of  confirmation,  It  Implies  the  modifications  of  the  conditions  of 
marketing authorization.  In  order  not  to overload  the  system,  only  laerts 
concerning  serious  ADRs  should  be  transmitted  via  the  "Rapid  Alert 
System". 
The  legal  obligations  of  the  Member  States~  which  are  currently  set  out 
In  Articles  30  a~d  33  of  Dlrectlva 75/319/EEC  and  ArtiCles  3~ and  42  of 
Directive  81/851/EEC,  have  been  reviewed  In  the  context  of  the  two 
Commu'nlty  procedures.  The  nature  and  frequency  of  the·  Information 
transmitted  to  the  reinforced  CPMP/CVMP  stru6ture  has  been  better 
de f I  ned.  Any  decIsIon  made  at  CommunI t y  I  eve I  on  the  bas Is  of  a  CPMP 
pharmacovlgllance- opinion  should  be  preceded  by  an_  appropr late 
consultation with  the  concerned  companies. - 32  -
4.  SUPERVISION  AND  SANCTIONS 
4.1.  Access  to  Inspection  reports 
The  rapporteurs  for  the  application  will,  where  necessary,  be  able  to 
request  a  copy  of  the  most  recent  Inspection  report  covering  the 
manufacturer  concerned,  for  decentral lzed  and  central lzed  appl !cations. 
Where  a  manufacturer  Is  establ lshed  In  a  third  country,  appropriate 
multi-lateral  arrangements  wl  I I  also  have  to  be  made  to  ensure  that  the 
rapporteurs  working  on  behalf  of  the  CPMP/CVMP  have  access  to  Inspection 
reports  and  other  relevant  documents,  In  the  same  way  as  rapporteurs 
currently working  for  the  Individual  Member  States. 
During  Its  evaluation  of  a  live  rONA  vaccine,  manufactured  In  a  third 
country,  the  CVMP  considered  that  an  Inspection  of  the  manufacturing 
plant  was  deslreable  In  order  to  verify  the  guarantees  offered  relating 
to  the  qual lty  and  safety of  the  product  concerned.  During  discussions on 
the  proposal  to  extend  the  veterinary  medicines  directives  to  cover 
Immunological  products,  the  Councl I  has  also  requested  that  arrangements 
shou I  d  be  made  to  enab I  e  coordInated 
third  countries  to  be  undertaken  on 
appropriate  cases. 
Inspect Ions  of  manufacturers 
behalf  of  the  Community 
In 
In 
It  has  therefore  appeared  necessary  to  Include  within  the  administrative 
structure  of  the  Agency  a  responslbl I lty  for  coordinating  the  discharge 
of  the  various  inspection  functions  of  the  Member  States,  both  within  the 
Community  and  In  third countries. - 33  -
4.2.  Supervision of  manufacturers,  withdrawal  of  authorization and  sanctions 
In  accordance  with  the  general  principles  laid  down  In  the  Community 
pharmaceutical  directives,  the  primary  responslbll lty  for  the  supervision 
of  manufacturers  I les  with  the  competent  authorities of  the  Member  State 
In  which  the  manufacturer  Is  establ lshed.  In  the  case  of  products 
Imported  from  third  countries,  this  responslbl I lty  wl  I I  I le  on  the 
authorities of  the  Member  State where  the  tests and  controls  necessary  on 
Importation  are  carried out,  unless  an  appropriate  arrangement  has  been 
made  between  the  Community  and  the  third country  concerned  to ensure  that 
the  product  Is  manufactured  In  accordance with  Community  requirements  and 
the  necessary  controls  are  conducted  In  the  third  country.  In  case  of 
doubt,  provision  Is  made  for  coordinated  lnspec.tlons  using  Inspectors 
from  two  or  more  Member  States or  Inspectors  employed  by  the  Agency. 
The  grounds  for  the  suspension  or  withdrawal  of  .a  European  marketing 
authorization  are  the  same  as  for  the  suspension  or ·withdrawal  of  a 
national  authorization.  However,  a  European  authorization  can  be 
withdrawn  only  by  the  Community,  following  the  opinion  of  the  Agency  and 
the  appllcat I  on  of  the  procedures  descrIbed  In  sect ion  2.4.  In  case  of 
urgency,  however,  a  Member  State would  be  able  to  temporarl ly  suspend  the 
use  of  a  medicinal  product,  provided  that  the  matter  was  Immediately 
referred  to  the  Commission  for  appl lcatlon of  the Community  procedures. 
In  addition  to  withdrawal  of  the  marketing  authorization,  certain  forms 
of  misconduct  may  expose  the  authorization  holder  or  the  applicant  to 
criminal  or  administrative  sanctions,  In  accordance  with  the  law  of  the 
member  State concerned.  Since  there  Is  no  specific Community  penal  taw,  a 
clause  has  been  Included  which  makes  misconduct  by  the  appl !cant  for  or 
holder  of  a  European  marketing  authorization  I table  to  the  same  penalties 
as  the  holder  of  a  national  authorization  In  the  Member  State concerned. - 34  -
5.  THE  EUROPEAN  AGENCY  FOR  THE  EVALUATION  OF  MEDICINAL  PRODUCTS 
The  establ lshment  of  a  new  European  Agency  for  the  evaluation  of 
medicinal  produc,ts  will  be  essential  In  order  to  enable  the  Community 
Institutions  to  discharge  the  major  new  responsibilities  Imposed  upon 
them·as  a  result  of  the  Introduction  of  the  new  Community  authorization 
procedures  and  the  additional  responsibilities  In  the  field  of 
ph~rmacovlgllance and  the  supervision of manufacturers. 
In  the  early  years,  the  establishment  of  the  Agency  will  Inevitably 
result  In  a  significant  Increase  In  the  overall  level  of  public 
expenditures  associated  with  the  authorization  and  supervision  of 
medicinal  ~roducts.  In  order  to  ensure  the  orderly  phasing  In of  the  new 
Co!llml,lnlty  procedures  alongside  national  procedures,  some  degree  of 
dupllcatl.on  will  be  necessary  at  first.  However,  In  the  longer  term  the 
pooling  of  resources  at  Community  level  and  the  elimination  of  wasteful 
dupl lcat!on of effort  In  the  evaluation of medicinal  products  wl II  result 
lri  significant  reductions  In  the  overall  cost  to  society  of  authorizing 
and  supervising  medicinal  products  through  reduced  expenditures  at 
n.at lona I  I e~e  I. 
In  a I I  Memb!3r  States,  the  costs  of  regIsterIng  pharmaceut I ca I  products 
·are  met  In. part  from  fees  paId  by  the  pharmaceut I ca I  Industry.  However, 
ln.most  Member  States,  these  fees  are  paid  Into  the  general  national 
budget  and  are  not  speclflcal ly  devoted  to  the  costs of  the  authorization 
system.  It  Is  therefore  difficult  to  know  what  proportion of  the  cost  of 
the  system.  Is  met  by  fees.  Moreover,  In  the  case  of  medicinal  products 
for  human  use,  this  question  Is  to  some  extent  academic,  since  the  costs 
of  fees  are  undoubtedly  passed  on  to  the  consumer/patient,  and,  therefore 
frequ·ently  met  by  the  State  under  the  national  health  Insurance  system. - 35  -
For  the  Introduction  of  the  future  system,  the  Commission  considers  that 
those  costs  which  are  directly  attributable  to  the  evaluation  of 
applications  for  authorization  of  new  medicinal  products  should  be 
covered  by  fees  from  the  pharmaceutical  Industry.  On  the  other  hand,  the 
general  activities  undertaken  by  the  Agency  In  respect  of 
pharmacovlgl lance,  the  provision of  Information  about  medicinal  products, 
Inspect ion  and  standards  should  be  financed  by  a  general  contr I  but ton 
from  the  Community  budget,  under  a  new  budgetary  I lne  to  be  created  In 
the operations part  of  the  budget.  Given  the  difficulty of  making  precise 
estimates of  the  workload  of  the  Agency,  at  least  In  the  early years,  the 
exact  fee  structure  wl  I I  be  determined  by  a  special  financial  regulation, 
to  be  adopted  following  consultation of  the  pharmaceutical  Industry. 
5.1.  Functions of  the  Agency 
Under  the  direct  supervision  of  the  CPMP/CVMP,  placed  at  the  top  of  Its 
scientific structures,  the  European  Medicines  Agency  wl  I I  be  responsible 
for: 
-the  coordination  of  the  evaluation,  on  a  scientific  basis,  of  the 
qual tty,  safety  and  efficacy  of  medicinal  products  which  are  submitted 
In  accordance  with  Community  authorization procedures; 
-the  production  of  evaluation  reports,  summaries  of  product 
characteristics  and  label I lng  and  package  Inserts  for  these  medicinal 
products; 
-the  continuing  supervision  of  medicinal  products  authorized  for  use 
within· the  Community,  and  the  provision  of  advice  on  appropriate 
regulatory  action  to  be  taken  In  respect  of  such  products; 
-coordinating  the  exercise  by  the  Community  and  the Member  States of  the 
various  supervisory  responslbl I ltles  concerning  the  manufacture  and 
testing  of  medicinal  products,  Including  GMPs,  GLPs,  GCPs,  batch 
controls etc; 
-advising  the. Member  States  and  the  Community  Institutions  on  at I 
questions  relating  to medicinal  products; 
-advising on  maximum  residue  levels  for  veterinary medicines. - 36-
The.  Agency  will  also  be  responsible  for  promot lng  better  cooperat lon 
between  public  control  laboratories  (collaborative  tests,  methods  and 
reference  preparatIons)  In  close  cooper at I  on  wl th  the  European 
Pharmacopoeia.  Furthermore,  the  Agency  should  become  an  Interface  between 
national  pharmacovlgl lance  centres  throughout  the  Community. 
5.2.  Structure of  the  Agency 
Besides  Its  scientific  committees  at  the  top  of  the  structure 
(CPMPiCVMP),  the  Agency  shall  have  an  executive director,  who  wl  I I  report 
to an  administrative  board. 
a)  Scientific bodies:  CPMP,  C'mP  and  Scientific Councl I 
The  examination  of  scientific  questions  submitted  to  the  Agency  for 
opinion  wl  I 1 be  the  responslbl I lty of: 
-the  Committee  for  Proprietary  Medicinal  Products,  for  medicinal 
products  for  use  In  humans; 
- the  Committee  for  Veterinary  Medicinal  Products,  for  medicinal 
products  for  veterinary use. 
Both  Committees  wl  I I  consist  of  scientific  advisors  nominated  by 
Member  States  and  meet  every  month/2  months.  These  Committees  may 
request  the establ lshment  of  special lsed  working  parties  and  panels of 
experts  to  assist  In  the  evaluation  of  scientific  questions  submitted 
to  the  Agency  for  opinion.  In  order  to  assist  the  Agency  In  the 
exercise  of  Its  responslblllt les,  the  Member  States  will  communicate 
to  the  Agency  and  maintain up-to-date  I lsts of  experts with  particular 
competence  In  the  various  areas  of  the  evaluation  of  medicinal 
products.  The  services  of  experts  will  be  performed  on  the  basis  of 
mandates  which  wl  I I  be  confered onto  them  by  the  CPMP/CVMP.  They  wl  I 1 
be  reimbursed  by  the  Agency,  In  accordance  with  a  scale  to  be  fixed  by 
Councl 1 regulation  for  the  various  tasks  Involved. - 37  -
In  order  to  maintain  high  scientific  standards  In  the  operations  of 
the  Agency,  the  CPMP  and  CVMP  should  have  the  possibility  to  tal<e 
advice  from  a  high_  level  Scientific  Council  of  5  personalities  of 
International  repute  (Nobel  prize  etc.)  nominated  by  the  Council  of 
Ministers  upon  proposal  from  the  Commission.  This  Council  would  meet 
once  or  twice  a  year  to  deal  with  difficult  ethical  or  scientific 
Questions  referred  to  It  by  the  CPMP/CVMP  and  to evaluate  globaly  the 
scientific statements of  the  Agency. 
b)  Administrative  board 
The  administrative  board  wl  I 1 consist  of  two  representatives  from  each 
Member  State  and  of  the  Commission.  One  representative  wl  I I  be 
specifically  responsible  for  matters  relating  to  medicinal  products 
for  human  use  and  one  for  veterinary  medicinal  products.  The  mandate 
of  the  representatives  shal 1  be  for  three  years,  renewable.  The 
administrative  board  will  elect  Its  president  for  a  period  of  three 
years  and  shal I  adopt  Its own  Internal  rules of  procedure.  Each  member 
of  the  administrative  board  wl  I I  have  one  vote.  The  decisions  of  the 
administrative  board  wl  I I  be  adopted  by  a  two-thirds  majority  of  Its 
members.  The  secretariat  of  the  administrative  board  wl  II  be  provided 
by  the  Agency.  Each  year  the  administrative  board  wl  II  adopt: 
-the report  of  activities  for  the  past  year 
- the  programme  of  work  for  the  following  year 
- the  draft  annual  accounts  for  the  past  year 
-the draft  estimate of  Income  and  expenditure  for  the  following  year. 
c)  Secretariat  of  the  Agency 
An  executive director  In  charge of  the  secretariat  of  the  Agency,  wl  I I 
be  nominated  by  Council,  upon  a  proposal  from  the  Commission,  for  a 
renewable  period  of  five  years.  The  executive  director  will  be  the 
legal  representative of  the  Agency,  responsible  for: - 38  -
-the routine  administration of  the  Agency 
-the  preparation  of  the  Income  and  expenditure  report,  and  the 
administration of  the  budget  of  the  Agency 
-all  matters  relating  to  the  personnel  of  the  administrative  and 
technical  secretariat. 
The  technical  and  administrative  staff  of  the  Agency  wl  11  be 
responsible  for  providing  all  necessary  logistical  support  for  the 
CP~P  and  the  CVMP,  and  for  assisting  In  the  discharge  of  the  various 
responslbl I ltles of  the  Agency  as  described  In  section 5.1. 
5.3.  Finance  and  Resources 
a)  Estimated  Workload 
The  establ lshment  of  an  administrative  and  technical  secretariat  wl  11 
be  progressive,  based  Initially  on  the  anticipated  workload;  In  the 
medium  term,  the  real location of  workload  via  the  reinforced  CPMP/CVMP 
wl  I I  globally  tend  to  reduce  the  workload  of  the  12  competent 
authorities. 
The  CPMP  has  done  a  survey  (I I 1/1625/88)  estimating  the  average  number 
of  first  appl lcatlons  for  NCE  products  (new  chemical  entitles)  In  the 
Community  as  50  per  annum.  Of  these,  approximately  20%  could  be 
considered  as  high  tech.  For  each  NCE  the  rate  Is  approximately  6 
variations  In  the  first  five  years.  Industry  sources  have  confirmed 
these  fIgures.  From  the  experIence  of  the  concert at ion  procedure,  It 
would  be  reasonable  to  project  approximately  15  new  High  tech/biotech 
appl !cations  a  year,  with  at  least  a  similar  rate of  variations as  for 
NCE's.  As  the  secretariat  would  also assist  the  reinforced  CPMPin  Its 
role  as  a  forum  of  arbitration  In  the  decentralized  procedure,  the 
number  of  referrals  must  be  estimated.  With  the  opportunity  of  a 
Single  Internal  Market,  the  number  of  appl lcatlons  through  the 
decentralized  procedure  Is  likely  to  Increase  dramat lcally.  Already 
now,  the  mult-state  procedure  Is  showing  a  60%  annual  Increase  In 
appl l~atlons  (1988- 31;  1989- 50).  C~rrently,  alI  appl !cations  are 
referred  to  the  CPMP.  Thus  a  workload  of  at  least  150  dossiers  for 
human  medicines  a  year  could  be  anticipated after  1992. - 39  -
So  far  as  veterinary  medicines  are  concerned,  Initially  much  of  the 
·workload  for  .the  reinforced  CVMP  will  result  from  the  setting up  of  a 
centralized  Community  procedure  for  the  establ lshment  of  maximum 
residue  levels.  Over  the  period  1993-1997,  the  toxicology  data  for 
approximately  150  compounds  wl  II  have  to  be  reviewed.  Since  It  Is 
Intended  that  from  1992  onwards,  all  appl !cations  for  NCE's  Intended 
for  use  In  food-productlng  animals  wl  II  be  submitted  to  a  centralized 
Community  procedure  for  the  determination of  maximum  residue  level,  It 
may  be  that  there  will  also  be  a  greater  take  up  of  the  centralized 
procedure  for  applications  for  marketing  authorization.  It  Is 
therefore  prudent  to  estimate  that  10  appl !cations  for  NCE's  wl  II  be 
referred  to  the  central Jzed  procedure,  together  with  5  biotech 
appl lcatlons,  making  15  In  total.  In  addition,  approximately  25 
referrals  a  year  could  be  expected  Initially  under  the  decentralized 
procedure,  although  this  could  rise  very  substantially  should  the 
decentral lzed  procedure  prove  an  attractive  option  for  extending  the 
terms  of  existing authorization  Into minor  species. 
b)  Resources 
The  responslbl I I ties of  the  Agency  and  It's permanent  secretariat  wl  I 1 
encompass  a  range  of  activities.  In  estimating  personnel  resource 
·requirements,  the  following  functions  must  be  considered. 
-management  of  the  dossiers,  Including  val !dation  of  European 
dossiers  and  variations; 
-administration of  the  reinforced  CPMP/CVMP; 
-administrative  and  technical  support  of  the  reinforced  CPMP/CVMP, 
Its working  parties and  expert  panels; 
-administrative operation of  expert  groups,  contracts etc; 
-coordination of  pharmacovlgl lance  activities; 
- establ lshment  of  veterinary  residue  I lmlts; 
- Implementation of  Community  certification procedures  In  the  areas of 
GMP,  GCP,  GLP  etc.; 
-support  for  the  pharmaceutical  data  bank; 
-personnel  and  administration  (Interpretation and  translation,  legal, 
accountancy  and  Informatics,  archives  and  publ lcatlons,  etc.). - 40  -
The  number  of  meetings,  meeting  rooms  and  facl I ltles  would  relate  to 
workload  but  a  core  requirement  would  be: 
- 2  meetings  per  annum  of  the  administrative board; 
- 1  meeting  per  month  of  the  2 scientific committees  (CPMP/CVMP)  ; 
-panel  meetings  of  rapporteurs  and  experts  to  assess  an  appl lcatlon 
(experts  released  for  week  long  meetings); 
-working party meetings of  experts  (8  W.P.  X  4  times  per  annum); 
-ad hoc  meetings of  partrcular  scientific experts  and  drafting  groups 
lfor  example,  5  experts,  15  meetings  per  year). 
Estimates  of  the  necessary  resources  are  set  out  In  the  financial 
statement  annexed  to  this proposal. - 41  -
6.  OTHER  AMENDMENTS  TO  COMMUNITY  PHARMACEUTICAL  LEGISLATION 
In  addition  to  the  Incidental  changes  to  the  existing directives  relating 
to  human  and  veterinary  medicinal  products  resulting  from  the 
establ lshment  of  the  new  Community  registration  procedures,  several  other 
detal led  changes  to  the  legislation are  also  proposed. 
6.1.  Tlmel lmlt  for  the  evaluation of  appl !cations  by  Member  States 
The  tlmel lmlt  of  120  days,  plus  a  further  90  days  In  exceptional 
circumstances,  allowed  for  the  evaluation  of  appl !cations  by  Member 
States  was  first  laid  down  In  1965.  However,  since  that  time,  the  amount 
of  Information  to  be  provided  In  an  application  and  Its  complexity  has 
Increased  substantially.  In  practice,  all  Member  States  are  finding  It 
Increasingly difficult,  If  not  Impossible  to meet  their  obi lgations under 
Community  Law  In  this  respect,  and  a  period  of  210  days  has  become  the 
general  rule.  The  Commission  Is  therefore  proposing  to  extend  the  period 
allowed  for  review  by  Member  States  to  210  days.  However,  In  return,  the 
Commission  wl  I I  expect  the  Member  States  to  respect  these  new  dead I lnes 
scrupulously,  and  reserves  the  right  to  Institute  proceedings  under 
Article  169  of  the  Treaty  against  any  Member  State  which  does  not  comply 
with  the  new  time  I lmlts. 
6.2.  Environmental  assessment 
In  view  of  the  Increasing  awareness  of  the  effects of  medicinal  products 
on  the  environment,  the  Commission  Is  proposing  that  In  appropriate  cases 
an  appl !cation  for  authorization  for  a  medicinal  product  for  human  use 
Include  an  assessment  of  the  potential  risks  presented  by  the  product  for 
the  environment.  The  detal Is  of  the  Information  required  wl  II  be 
specified  In  the  Annex  to  Directive  75/318/EEC  on  the  testing 
requirements  for  medicinal  products  for  human  use. 
So  far  as  veterinary medicinal  products  are  concerned,  similar  provisions 
have  already  been  proposed  by  the  Commission  and  are  currently  under 
consideration  by  the  councl I  (COM  (88)  779  final). 
So  far  as  I I  ve  vaccInes  contaInIng  genet I  ca I I y  mod If I  ed  organ 1 sms  are 
concerned,  Counc I I  DIrectIve  90/220/EEC ·of  23  Apr II  1990  sha 1 1  app 1  y 
(O.J.  No  L  117  of  8.5.90). - 42  -
6.3.  Imports  from  third countr'ies 
Proposals  are  Included  to  ensure  that  medicinal  products  Imported  from 
thIrd  countrIes  are  manufactured  In  accordance  wIth  standards  of  good 
manufacturing  practice  at  least  eQuivalent  to  those  laid  down  by  the 
CommunIty. 
6.4.  Conditional  marketing  authorizations 
At  the  present  time,  the  directives  relating  to  human  and  veterinary 
medicines  do  not  make  any  express  provision  for  conditions  to  be  attached 
tu  a  market lng  author lzat Jon,  such  as  a  reQuirement  to  conduct  further 
studies  after  authorization.  However,  experience  has  shown  that  Phase  IV 
studies,  which  are  conducted  in  patients  after  authorization  of  the 
product,  and  under  practical  conditions  of  use  may  'provide  Information 
which  Is  valuable  for  re-evaluating  the  overal I  benefits  and  risks  of  an 
Individual  medicinal  product.  It  Is  therefore  proposed  that  It  should  be 
possible  to attach  such  conditions  to  the  terms  of  a  national  or  European 
marketing  authorization  for  a  medicinal  product  for  human  or  veterinary 
use. - 43  -
7.  SPECIAL  PROVISIONS  FOR  VETERINARY  MEDICINAL  PRODUCTS 
7.1.  Residues 
.In  February  ~989,  the  Commission  presented  proposals  for  laying  down 
Community  procedures  for  the establ lshment  of  maximum!  residue  levels  for 
residues  of  veterinary  medicines  In  foods.  These  proposals  are  currently 
under  consideration  In  the  Council,  and  it  Is  therefore  necessary  to 
consider  the  relationshiP  between  the  proposed  procedure  for  the 
estaollshment  of  MRLs  with  the  new  Community  authorization  procedures 
provided  for  by  the  present  proposals. 
In  recent  years  some  concern  has  been  expres~ed  by  consumers  that 
foodstuffs  from  animals  which  are  used  In  clinical  trials  of  veterinary 
medicines  are  being  sold  for  human  consumption,  thereby  exposing  the 
consumer  to  residues  of  experimental  substances  whose  properties  are  not· 
fully  known. 
However,  for  economic  r~a~ons,  It  Is  often  Impossible  to  run  large-scale 
trIa is  Involving  hundreds  or  thousands  of  animals  unless  It  Is  possible 
to sel I  the  animals  for  human  consumption. 
In  practice,  alI  Member  States  have  developed  national  systems  for 
monitoring  the  conduct  of  cl lnlcal  trials  ln.anlmals  and  for  removing  any 
rlslc  to  the  consumer.  In  order  to  provide  equivalent  guarantees  at  the 
Community  level,  the  Commission  Is  proposing  that  It  should  not  be 
permitted  to  let  foodstuffs  from  trial  animals  enter  the  human  food  chain 
unless  the  safety  of  the  compound  concerned  has  been  evaluated  at  the 
Community  level  and  residues  have  been  found  to  be  without  risk  for 
pub I I  c  hea I th. 
In  the  case of  other  categories of  veterinary  medicinal  product,  It  will 
be  up  to  the  manufacturer  to  decide  whether  to  submit  the  appl lcatlon  for 
the  establ lshment  of  a  maximum  residue  level  before  the  submission of  the 
appl tcatlon of  authorization,  or  ~t  the  same  time. - 44  -
7.2.  Link  between  the  veterinary medicines  legislation  and  the  feed  additives 
Directives 
For  h 1  stor I  ca I 
r·  reasons,  a  number  of  pharmaco I  og I  ca I I  y  actIve  compounds 
are  authorized  for  use  In  the  Community  as  additives  to  animal 
feedlngstuffs  under  Directive  70/524/EEC  rather  than  as  veterinary 
medicinal  products.  In  accordance  with  Directive  70/524/EEC,  a  decision 
on  the  transfer  of  the  coccldlostats  and  other  medicinal  substances  from 
that  Directive  to  the  veterinary medicines  directives shal I  be  taken once 
the  level  of  harmonization  In  the  veterinary  medicines  sector  has 
attained that  applicable  to additives. 
The  Introduction  of  the  new  Community  procedures  provided  for  by  these 
proposals  wl  I I  undoubtedly  be  a  major  factor  In  this  respect.  However,  a 
number  of  other  difficult  questions  wl  I I  need  to  be  resolved,  In 
particular  whether  the  authorizations  urider  Directive  70/524/EEC,  which 
are  granted  by  substance,  should  be  converted  Into  European  marketing 
authorizations,  which  are  granted  for  Individual  products  produced  by 
specific manufacturers. 
In  any  case,  It  Is  essential  to  ensure  that  any  transfer  of  these 
products  from  one  regulatory  regime  to  the  other  does  not  result  In  any 
lowering of  the  level  of  harmonization  already  achieved,  any  reduction  In 
the  level  of  protection of  health  or  any  disruption  for  the manufacturers 
of  the  products  concerned. 
For  these  reasons,  the  Commission  Is  not  proposing  the  Immediate  transfer 
of  these  compounds.  Instead,  the  Commission  Is  proposing  that  a  full 
report  on  the  Issues  raised  by  the  transfer  should  be  presented  within 
three  years  of  the  entry  Into  force  of  the  new  system  In  order  to  enable 
the  Councl I  to  take  a  decision  In  ful I  knowledge  of  the  facts. - 45  -
8.  FINAL  REMARKS 
In  accordance  with  the  provisions  of  Articles  SA  and  ac  of  the  Treaty 
establishing  the  European  Economic  Community,  the  Commission  requests  the 
member  States  to  take  the  measures  necessary  to  comply  with  this  package 
of  proposals  by  1  January  1993. 
The  Commission  has  taken  Into  account  the  requirements  of  Article  ac  of 
the  Treaty  and  has  concluded  that  no  special  provision  seems  to  be 
justified at  this stage. 
The  Commission  has  also  studied  the  question  of  the  high  levels  of 
health,  safety,  environmental  and  consumer  protection  equlred  by  the 
terms  of  Article  100  A,  paragraph  3.  It  has  done  so  following 
consultation of  the  Industrial  and  social  partners  concerned,  and  In  the 
II ght  of  an  ana I ys Is  of  the  rIsks  Inherent  In  thIs  area  and  of  the 
current  technical  capabilities· of  the  European  Industry.  The  proposals 
take  full  account  of  these  considerations  In  the  light  of  the  overall 
objectives of  this  provision of  the  Treaty. - 46  -
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TABLE  I  PROPOSED  DECENTRALIZED  PROCEDURE 
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210  assessment  report  May  suspend  evaluation 
days  \V  summary  of  product  .. 
lFIRST  AUTHORIZATION  I  .,  APPLICATION  FOR  RECOGNITION 
/ 
Certified  identical  dossier 
/  Assessment  report;  S.P.C. 
' 
lserious  object ions I  within  90  days  !no  object ions  '  , 
.  't' 
~BILATERAL PHASE! 
60  days  .......  ··"- . i"'.  /  / 
-"'  !serious  ob·jectionsl  I no  objections  / 
ICPMP/CVMP  ARBITRATION 
I 
90  days  - detailed  statement  of 
objections  from  Member  States 
- fu 11  dossier 
\/ 
]  CPHP/CVMP  OPINION] 
unfav!urable 
\  ,  favourable 
+'  =---- I  COMPANY  APPEAL!  Within  30  days  transmission  of  - opinion 
"' 60  days  - assessment  report 
- summary  of  product 
I  SECOND.  OPINION I  - labelling  and  package  insert  -, 
' 
_.  .,  to  Commission,  Member  States 
.,..,  ,  and  applicant 
[  30  days 
DRAFT  COMMISSION] 
DECISION 
I\  /  ~30 
\v 
30  days  days 
I  Detailed  OPPOSITION I  I No  OPPOS IT I ONr--
from  Member  State 
scient~  ~er  __ 
~NEW  CPMP/CVMP  OPINION!  'Draft  measures  to:]  ,;  STANDING  COMMITTEE 
1'  J-
NO  QUALIFIED  MAJORITY  QUALIFIED  MAJOR I~ 
in  favour  of  draft  in  favour  of  dr-aft 
decision  decision 
'+'  \ v 
COUNCIL  DECISION I  COr1MISSION  DECISION  L~ 
' 
30  days  \ 
,  !FINAL  NATION~~ 
DECISION - 48  -
TABLE  II:  CENTRALIZED  PROCEDURE 
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-obi lgatlon  to establish a  system 
-definitions of  ADR  and  serious  ADR 
-col lectlon of  data  by  Industry 
-reporting of  data  by  Industry 
-reporting by  practitioners 
-reporting by  Member  States  to  CPMP/CVMP 
- gu I  de I I  nes 
- compulsory  referral  to  CPMP/CVMP 
65/65 
7(1) 
4(6a) 
9b 
10(2) 
75/319 
22(1) 
29a 
29b 
29c 
29d 
29e 
29f 
29g 
29h 
81/851 
8(1) 
N/A 
14b 
15(2) 
30(1) 
42a 
42b 
42c 
42d 
42e 
42f 
42g 
42h - 55  -
PROPOSAL  FOR  A COUNCIL  REGULATION  (EEC) 
laying  down  Community  procedures  for  the 
authorization and  supervision of  medicinal  products 
for  human  and  veterinary  use  and  establ lshlng  a  European 
Agency  for  the  Evaluation  of  Medicinal  Products - 57  -
Proposal  for  a 
COUNCIL  REGULATION  <EECl 
laying  down  Community  procedures  for  the 
authorization and  supervision of medicinal  products 
for  human  and  veterinary use  and  establ lshlng  a  European 
Agency  for  the  Evaluation of  Medicinal  Products 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to  the  Treaty establishing  the  European  Economic  Community, 
and  In  particular Article  100a  thereof; 
Having  regard  to  the  proposal  from  the  Commission<1>, 
In  cooperation with  the  European  Pari iament<2>, 
Having  regard  to  the opinion of  the  Economic  and  Social  CommltteeC3), 
Whereas  It  Is  Important  to  adopt  measures  with  the  aim  of  progressively 
estabi lshing  the  Internal  market  over  a  period expiring on  31  December  1992; 
whereas  the  internal  market  shal I  comprise  an  area without  Internal 
frontiers  In·  which  the  free  movement  of  goods,  persons,  services  and  capital 
Is  ensured; 
(1) 
(2) 
(3) - 58  -
Whereas  Councl!  Directive 87/22/EEC  of  22  December  1986  on  the  approximation 
of  national  measures  relating  to  the  placing  on  the  ·market  of  high 
technology  medicinal  products  particularly  those  derived  from 
biotechnology  (4)  has  established  a  Community  mechanism  for  concertatlon, 
prior  to  any  national  decision  relating  to  a  high-technology  medicinal 
product,  with  a  view  to  arriving  at  uniform  decisions  throughout  the 
CommunIty; 
Wherc-1s  the  experIence  acquIred  as  a  resu It  of  DIrectIve  87  /22/EEC  has 
shown  that  It  Is  necessary  to  establish  a  centralized  Community 
authorization  procedure  for  technologically  advanced  medicinal  products,  In 
particular  those  derived  from  biotechnology;  whereas  this  procedure 
should  also  be  available  to  persons  responsible  for  marketing  medicinal 
products  containing  new  active  substances  which  are  Intended  for  use  In 
human  beings or  In  food  producing-animals; 
Whereas  In  the  Interests of  publ lc  health  It  Is  necessary  that  decisions  on 
the  authorization  of  such  medicinal  products  should  be  based  on  the 
objective  scientific  criteria  of  the  quality,  the  safety  and  the  efficacy 
of  the  medicinal  product  concerned  to  the  exclusion  of  economic  or  other 
considerations;  whereas,  however,  Member  States  should  exceptionally  be 
able  to  prohibit  the  use  on  their  territory of  medicinal  products  for  human 
use  which  Infringe  objectively  defined  concepts  of  public  order  or  public 
moral lty;  whereas  moreover  a  veterinary  medicinal  product  may  not  be 
authorized  by  the  Community  If  Its  use  would  contravene  the  rules  and 
obJectives  lald,down  by  the  Community  within  the  framework:  of  the  Common 
Agricultural  Polley;. 
(4)  OJ  No  L 15,  17.1.87,  p.  38. 
,. 
L' - 59  -
Whereas,  !n  the  case  of  medicinal  products  for  human  use,  the  criteria  of 
quality,  safety  and  efficacy  have  been  extensively  harmonized  by  Council 
Directive  65/65/EEC  of  26  January  1965  on  the  approximation  of  provisions 
laid  down  by  law,  ~egulatlon or  administrative  action  relating  to medicinal 
products<S>,  as  last  amended  by  Directive  •..  / ...  /EEc(6)  and  Second 
Counci 1  Directive  75/319/EEC  of  20  May  1975  on  the  approximation  of 
provisions  laid  down  by  law,  regulation  and  administrative  action  relating 
to  proprietary  medicinal  products<7>  as  last  amended  by  Directive 
..  / ...  /Eec<8>,  and  by  Council  Directive  75/318/EEC  of  20  t.tay  1975  on  the 
approximation  of  the  laws  of  the  Member  States  relating  to  analytical, 
pharmaco-tox I  co I og I ca I  and  c II n I ca I  standards  and  pr_?toco Is  In  respect  of 
the  testing  of  medicinal  products<9)  as  last  amended  by  Directive 
. .1 .. ./Eec<10): 
Whereas  In  the  case  of  veterinary medicinal  products,  the  same  results  have 
been  achIeved  by  Counc I I  DIrectIve  81/851 /EEC  of  28  September  1981  on  the 
approximation  of  the 
medicinal  products<11} 
law~  of  the  Member  States  relating  to  veterinary 
as  last  amended  by  Directive  ..  / ...  /EEc(12)  and 
by  Councl I  Directive 81/852/EEC  of  28  September  1981  on  the  apprpxlmatlon of 
the  laws  of  the  Member  States relating  to analytical,  pharmaco-toxlcologlcal 
and  cl lnlcal  standards  and  protocols  In  respect  of  the  testing of  veterinary 
medicinal  productsC13)  as  last  amended  by  Directive  ..  / ...  /EEc(14); 
(5)  OJ  No  22,  9.2.65,  p.  369/65. 
(6) 
(7)  OJ  No  L  147,  9.6.75,  p.  13. 
(8) 
(9)  OJ  No  L  147,  9.6.75,  p.  13. 
( 10) 
(11)  OJ  No  L  317,  6.11.81,  p.  1. 
( 12) 
(13)  OJ  No  L  317,  6.11.81,  p.  16. 
( 14) - 60  -
Whereas  the  same  criteria must  be  appl led  to medicinal  products which  are  to 
be  authorized  by  the  Community; 
Whereas  only  after  a  single  scientific  evaluation  of  the  highest  possible 
QUal lty  of  alI  the  benefits  and  risks  of  technologically  advanced  medicinal 
products,  should  a  marketing  authorization  be  granted  by  the  Community  by  a 
rapid  procedure  ensuring close cooperation  between  the Commission  and  Member 
States; 
Whereas  Council  Directive  ..  / ...  /EEC  has  provided  that  In  the  event  of  a 
disagreement  between  Member  States  about  the  qual lty,  safety or  efficacy of 
a  medicinal  product  which  Is  the  subject  of  the  decentralized  Community 
authorization  procedure,  the  matter  should  be  resolved  by  a  binding 
Community  decision  following  a  scientific evaluation of· the  Issues  Involved 
within  a  European  Medicines  Evaluation  Agency;  whereas  similar  provisions 
have  been  laid  down  .In  respect  of  veterinary  medicinal  products  by  Councl I 
Directive  ..  / ...  /EEC; 
Whereas  the  Community  must  be  provided  with  the  means  to  undertake  a 
scientific  evaluation  of  medicinal  products  which  are  presented  for 
authorization  In  accordance  with  the  central lzed  Community  procedures; 
whereas,  furthermore,  In  order  to achieve  the effective harmonization of  the 
administrative  decisions  taken  by  Member  States  In  relation  to  Individual 
medicinal  products  which  are  presented  for  authorization  In  accordance  with 
decentralized  procedures,  It  Is  necessary  to  provide  the  Community  with  a 
means  of  resolving  disagreements  between  Member  States  about  the  QUality, 
safety and  efficacy of  medicinal  products; - 61  -
Whereas  It  Is  therefore  necessary· to  estab I Ish  a  European  Agency  for. the 
Evaluation of  Medicinal  Products  ("the Agency"); 
Whereas  the  primary  task  of  the  Agency  should  be  to  provide  scle.ntlflc 
advice of  the  highest  possible qual lty  to  the  Community  Institutions and  the 
Member  States  for  the  exercise  of  the  powers  conferred  upon  them  by 
Community  'legislation  In  the  field of  medicinal  products  In  relation  to  the 
authorization  and  supervision of  medicinal  products; 
Whereas  It  Is  desirable  to  ensure  close  cooperation  between  the  Agency  and 
scientists working  within  the  Member  States; 
Whereas,  therefore,  the  exclusive  responslbl I lty  for  preparing  the  opinions 
of  the  Agency  on  all  matters  relating  to  medicinal  products  for  human  use 
should  be  entrusted  to  the  Committee  for  Proprietary  Medicinal  Products 
created  by  Second  Council  Direct lve  75/319/EEC;  whereas,  In  respect  of 
veterinary medicinal  products  this responslbl l lty should  be  entrusted to  the 
Committee  for  Veterinary  Medicinal  Products  created  by  Council  Directive 
81/851/EEC; 
Whereas  the  establ lshment  of  the  Agency  wll I  make  It  possible  to  reinforce 
the  scientific  role  and  Independence  of  these  two  Committees,  In  particular 
through  the  establ lshment  of  a  permanent  technical  and  administrative 
secretariat; 
Whereas  each  Committee  should  be  able  to request  the opinion of  a  Scientific 
Council  consisting  of  scientists  of  Internationally  recognised  standing  on 
difficult  questions  of  a  general  scientific  or  ethical  nature  relating  to 
the  authorization of  medicinal· products; - 62  -
Whereas  It  Is  also  necessary  to  make  provision  for  the  supervision  of 
medicinal  products  which  have  been  authorized  by  the  Community,  and  In 
particular  for  the  Intensive  monitoring  of  adverse  reactions  to  those 
medicinal  products  through  Community  pharmacovlgllance  activities  In  order 
to  ensure  the  rapid  withdrawal  from  the  market  of  any  medicinal  product 
which  presents an  unacceptable  level  of  risk under  normal  conditions of  use; 
Whereas  the  Agency,  working  In  close cooperation with  the  Commission,  should 
also  be  entrusted with  the  task of  coordinating  the  discharge of  the  various 
supervisory  responsibilities  of  t.Aember  States  and  In  particular  monitoring 
the  respect  of  good  manufacturing  practices,  good  laboratory  practices  and 
good  cl lnlcal  practices; 
Whereas  It  Is  necessary  to provide  for  the orderly  Introduction of  Community 
procedures  for  the  authorization  of  medicinal  products  alongside  the 
national  procedures of  the  t.Aember  States which  have  already  been  extensively 
harmonized  by  Directives 65/65/EEC,  75/319/EEC  and  81/851/EEC;  whereas  It  Is 
therefore  appropriate  In  the  first  Instance  to  limit  the  obligation  to  use 
the  new  CommunIty  procedure  to  medIc Ina I  products  whIch  are  produced  by 
means  of  specified  biotechnological  processes,  and  to  make  the  procedure 
available  on  an  optional  basis  only  to  high-technology  medicinal  products 
and  to  medicinal  products  containing  totally  new  active  substances;  whereas 
the  scope  of  the  Community  procedures  should  be  reviewed  In  the  light  of 
exper lence  at  the  latest  six  years  after  the  entry  Into  force  of  this 
Regulation; 
HAS  ADOPTED  THIS  REGULATION: - 63  -
TITLE 
PEFINITIONS  ANP  SCQPE 
Article  1 
The  obJective of  this  regulation  Is  to  Jay  down  Community  procedures  for  the 
authorization and  supervision of  medicinal  products  for  human  and  veterinary 
use  and  to  establish  a  European  Agency  for  the  Evaluation  of  t.tedlclnal 
Products. 
Article  2 
The  definitions  laid  down  In  Article  1  of  Directive  65/65/EEC  and  the 
definitions  laid down  In  Article 1  paragraph  2 of  Directive 81/851/EEC  shall 
apply  to this Regulation. 
Article  3 
1.  No  medicinal  product  which  Is  referred  to  In  Part  A of  the  Annex  shal 1 
be  placed  on  the  market  within  the  Community  unless  authorization  has 
been  granted  by  the  Community  In  accordance  with  the provisions of  this 
Regulation. 
2.  The  person  responsible  for  marketing  a  medicinal  product  referred  to  In 
Part  B  of  the  Annex  may  request  that  authorization  to  place  the 
medicinal  product  on  the  market  be  granted  by  the  Community  In 
accordance with  the  provisions of  this Regulation. - 64  -
Article  4 
1.  In  order  to  obtain  the  authorization  referred  to  In  Article  3,  the 
person  responsible  for  marketing  shall  submit  an  application  to  the 
European  Agency  for  the  Evaluation  of  Medicinal  Products,  hereinafter 
referred  to  as  "the Agency". 
2.  The  Community  shall  Issue  and  supervise  authorizations  to  place 
medicinal  products  for  human  use  on  the  market  In  accordance  with 
Title 2. 
3.  The  Community  shall  Issue  and  supervise  authorizations  to  place 
veterinary medicinal  products on  the  market  In  accordance  with Title 3. - 65  -
TITLE  2 
AUTHORIZATION  ANP  SUPERVISION 
OF  NEPICINAL  PBOPUCJS  FOR  HUNAN  USE 
CHAPTER  1 
Submission and examination of applications-
authorizations- renewal  of authorization 
Article 5 
The  Committee  for  Proprietary Uedlclnal  Products establ lshed  by  Article 8  of 
Directive 75/319/EEC.  In  this title referred  to as  "the Committee".  shall  be 
responsible  for  formulating  the  opinion  of  the  Agency  on  any  question 
reI at I  ng  to  the  grant,  amendment ,  suspensIon  or  wIt hdr awa I  of  an 
authorization  to  place  a  medicinal  product  for  human  use  on  the  market 
arising  In  accordance with  the  provisions of  this Regulation. 
Article 6 
1.  An  appl !cation  for  authorization  for  a  medicinal  product  for  human  use 
shall  be  accompanied  by  the  particulars  and  documents  referred  to  In 
Articles  4  and  4a  of  Directive  65/65/EEC  and  Article  2  of  Directive 
75/319/EEC. 
2.  The  app II cat Jon  sha I I  a I  so  be  accompanIed  by  the  fee  payab I  e  to  the 
Agency  for  the  examination of  the  appl lcatlon. 
3.  The  Agency  shall  ensure  that  the  opinion  of  the  Committee  Is  given 
within  210  days of  the  receipt of  a  valid  appl !cation. 
4.  The  Agency  shall,  In  consultation  with  Uember  States,  the  Commission 
and  interested parties,  draw  up  detal led  guidance  on  the  form  In  which 
appl !cations for  authorization are  to  be  presented. - 66  -
Art lc le 7. 
In  order  to prepare  lts·oplnlon,  the  Committee: 
a)  shal 1  verify  that  the  particulars and  documents  submitted  In  accordance 
with  Article  6  comply  with  the  requirements  of  Directives  65/65/EEC, 
75/318/EEC  and  75/319/EEC,  and  examine  whether  the  conditions  for 
Issuing  an  authorization  to  place  the  medicinal  product  on  the  market 
specified  In  this Regulation  are satisfied; 
b)  may  request  a  laboratory  designated  for  this  purpose  to  test  the 
medicinal  product,  Its  starting  materials,  and  If  need  be,  Its 
Intermediate  products or  other  constituent materials  In  order  to ensure 
that  the  control  methods  employed  by  the  manufacturer  and  described  In 
the application documents  are satisfactory; 
c)  may,  where  approprlate,  request  the  appl tcant  to  supplement  the 
particulars  accompanying  the  application.  Where  the  Committee  avails 
Itself  of  this option,  the  time  limit  laid  down  In  Article  6  shall  be 
suspended  unt II  such  t tme  as  the  supplementary  tnformat ton  ·requested 
has  been  provided.  Likewise,  this  time  limit  shall  be  suspended  for 
the  time  at lowed  to  the  appl lcant  to  prepare  oral  or  written 
explanations. 
Article 8 
1.  Upon  receIpt  of  a  wrIt ten  request  from  the  CommIt tee,  a  Member  State 
shal I  forward  the  Information  necessary  to verify  that  the manufacturer 
of  a  medicinal  product  or  the  Importer  from  a  third country  Is  able  to 
manufacture  the  medicinal  product  concerned  and/or  carry  out  the 
necessary  control  tests  In  accordance  with  the  particulars  and 
documents  suppl led  In  accordance with Article 6. - 67  -
2.  Where  It  considers  It  necessary  In  order  to complete  Its examination of 
an  appl lcatlon,  the  Committee  may  request  the  appl Jcant  to submit  to an 
Inspect Jon  of  the  manufacturIng  sIte  of  the  medIc Ina I  product 
concerned.  The  Inspection,  which  shal I  be  completed  within  the 
time  I lmlt  referred  to  In  Article 6,  shal I  be  undertaken  by  qual lfled 
pharmaceut lea I  Inspectors  from  the  Member  States  who  may,  If 
appropriate,  be  accompanied  by  an  Inspector  from  the  Agency. 
Article 9 
1.  Where  the opinion  of  the  Committee  Is  that: 
the  application  does  not  satisfy  the  criteria  for  authorization  set 
out  In  this  Regu~atlon, or 
the  summary  of  product  characteristics  proposed  by  the  appl lcant  In 
accordance  with  Article 6  should  be  amended,  or 
the  labelling. or  package  Insert  of  the  product  Is  not  In  compliance 
with  Directive  ..  / ..  /EEC,  or 
the  authorization  should  be  granted  subject  to  the  conditions 
provided  for  In  Article  13(2) 
the  Agency  shal I  forthwith  Inform  the  appl lcant. 
Within  15  days  of  the  receipt of  the opinion,  the  appl lcant  may  provide 
written  notice  to  the  Agency  that  he  wishes  to  appeal.  Within  60  days 
of  the  receipt  of  the  grounds  for  appeal,  the  Committee  shal I  consider 
whether  Its  opinion  should  be  revised,  and  the  reasons  for  the 
conclusions  reached  on  the  appeal  shal I  be  annexed  to  the  assessment 
report  referred  to  ln.paragraph  2. 
2.  Within  30  days  of  Its  adoption,  the  Agency  shall  forward  the  final 
opinion  of  the  Committee  to  the  Commission,  the  Member  States  and  the 
applicant  together  with  a  report  describing  the  assessment  of  the 
medicinal  product  by  the  Committee  and  stating  the  reasons  for  Its 
conclusions. - 68  -
3.  In  the  event  of  an  opinion  In  favour  of  granting  authorization  to 
market  the  medicinal  product  concerned,  the  following  documents  shal I 
be  annexed  to  t~ opinion: 
a)  a  draft  summary  of  the  product  character 1st lcs,  as  referred  to  In 
Article  4a  of  Directive 65/65/EEC; 
b)  detal Is of  any  conditions or  restrictions which  should  be  Imposed  on 
the  supply  or  use  of  the  medicinal  product  concerned,  Including  the 
conditions  under  which  the  medicinal  product  may  be  made  aval lable 
to  patients,  having  regard  to  the  criteria  laid  down  In  Council 
Directive  ..  / ...  /EEC  [concerning  the  legal  status  for  the  supply  of 
medicinal  products  for  human  use]; 
c)  the  draft  text  of  the  label I lng  and  package  leaflet  proposed  by  the 
appl lcant,  presented  In  accordance  with  Councl I  Directive  ..  / ...  / .. 
[on  the  Iabeii lng  of  medicinal  products  for  human  use  and  on  package 
leaflets]. 
Article  10 
1.  Within  30  days  of  the  receipt  of  the  opinion,  the  Commission  shall 
prepare  a  draft  of  the  Decision  to  be  taken  In  respect  of  the 
appl lcatlon,  taking  Into  account  the  objectives  of  Community  policies 
and  considering  alI  the  relevant  Information.  In  the  event  of  a  draft 
Decision  which  envisages  the  granting of  a  marketing  authorization,  the 
documents  referred  to  In  points  (a),  (b)  and  (c)  of  paragraph  3  of 
Article  9  shall  be  annexed.  The  Commission  shall  transmit  the  draft 
Decision  to  the  Member  States and  to  the  applicant. 
The  Commission  shall  explain  In  detai I  the  reasons  for  any  differences 
between  the draft  Decision  and  the opinion of  the  Committee. - 69  -
2.  The  Commission  shal I  adopt  the  Decision  to  be  taken  In  respect  of  the 
appl lcatlon  unless.  within  30  days,  It  has  received  a  reasoned  reQuest 
from  a  Member  State  to  reconsider  the  matter.  The  Member  State 
concerned  shal I  also  transmit  a  copy  of  Its  reQuest  to  the  other  Member 
States and  the appl lcant  within  the  same  time  I lmlt. 
3.  Within  the  time  limit  referred  to  In  paragraph  2.  the  applicant  may 
submit  written observations  on  the  draft  Decision  for  consideration  by 
the  Commission. 
4.  The  Commission  shall  examine  any  reasoned  reQuest  received  In 
accordance with  paragraph  2.  In  consultation with  the  Agency,  and  after 
consideration of  any  further  observations  submitted  by  the  appl lcant. 
If  the  Commission  considers  that  the  reQuest  raises  Questions  of  a 
scientific  or  technical  nature  reQuiring  further  examination,  It  may 
remit  the  matter  to  the  Agency.  In  this  case  the  Committee  shall  give 
a  second opinion within  a  time  I lmlt  of  60  days.  Within  30  days  of  the 
receipt  of  the  opinion,  the  Commission  shal I  adopt  the  Decision  to  be 
taken  In  respect  of  the  appl lcatlon. 
Otherwise  the  Decision  shal I  be  taken  In  accordance  with  the  procedure 
laid  down  In  Article  2b  and  2c  of  Directive 75/318/EEC. - 70  -
Article  11 
Without  prejudice  to  other  provisions  of  Community  law,  the  authorization 
provided  for  In  Article  3  shall  be  refused  If,  after  verification  of  the 
Information  and  particulars  submitted  In  accordance  with  Article  6,  It 
appears  that  the  qua I I ty,  the  safety  or  the  effIcacy  of  the  medIc Ina I 
product  have  not  been  adequately  demonstrated  by  the  appl lcant. 
Authorization  shall  likewise  be  refused  If  the  particulars  and  documents 
provided  by  the  appl lcant  In  acordance  with  Artlcl~ 6  of  this Regulation  are 
Incorrect  or  If  the  Iabeii lng  and  package  leaflets  proposed  by  the  appl lcant 
are  not  In  accordance  with  Directive  ..  / ...  / ... 
Article  12 
1.  Without  prejudice  to  Article  6  of  Directive  65/65/EEC,  a  marketing 
authorization  which  has  been  granted  In  accordance  with  the  procedure 
laid  down  In  this  Regulation  shall  apply  throughout  the  Community.  It 
shall  confer  the  same  rights  and  obligations  In  each  of  the  Member 
States  as  a  marketing  authorization  granted  by·that  Member  State  In 
accordance  with  Article  3  of  Directive 65/65/EEC. 
2.  The  refusal  of  a  Community  marketing  authorization  shal I  constitute  a 
prohibition  on  the  marketing  of  the  medicinal  product  concerned 
throughout  the  Community. 
3.  An  announcement  that  authorization  has  been  granted  shall  be  publ lshed 
for  Information  purposes  In  the  Official  Journal  of  the  European 
Communities. - 71  -
4.  Upon  request  from  any  Interested  person,  the  Agency  shal I  make 
aval lable  a  detailed summary  of  the  evaluation of  the  medicinal  product 
by  the  Committee  and  the  reasons  for  Its opinion  In  favour  of  granting 
authorization  after  deletion  of  any  Information  of  a  commercially 
confidential  nature. 
Article  13 
1 ..  Authorization  shal I  be  valid  for  five  years  and  shal I  be  renewable  for 
five  year  periods,  on  application  by  the  holder  at  least  three  months 
before  the  expiry  date. 
2.  In  exceptional  circumstances  and  following  consultation  with  the 
appl lcant,  an  authorization  may  be  granted  subject  to  such  conditions 
.as  appear  necessary  to  ensure  the  protection  of  publ lc  health, 
Including specific obi lgatlons  to conduct  further  studies  following  the 
granting  of  authorization  and  specific  obligations  In  respect  of  the 
reporting of  adverse  reactions  to  the  medicinal  product. 
3.  Medicinal  products  which  have  been  authorized  by  the  Community  In 
accordance  with  the  provisions  of  this  Regulation  shall  benefit  from 
the  ten  year  period  of  protection  referred  to  In  point  8  of  the  second 
paragraph of  Article  4 of  Directive 65/65/EEC. 
Art I  c I  e  14 
The  granting  of  authorization  shall  not  diminish  the  general  civil  and 
criminal  liability  In  the  Member  States  of  the  manufacturer  and,  where 
appl lcable,  of  the  person  responsible  for  placing  the  medicinal  product  on 
the  market. - 72  -
CHAPTER  2 
Supervision and  sanctions 
Article  15 
1.  After  an  authorization  has  been  Issued,  the  person  responsible  for 
placing  the  medicinal  product  on  the  market  must,  In  respect  of  the 
methods  of  production  and  control  provided  for  In  points  4  and  7  of  the 
second  paragraph  of  Article  4  of  Directive  65/65/EEC,  take  account  of 
technical  and  scientific progress and  Introduce  any  changes  that  may  be 
required  to enable  the medicinal  product  to  be  manufactured  and  checked 
by  means  of  generally  accepted  scientific  methods.  These  changes  must 
be  approved  In  accordance  with  this Regulation. 
2.  The  person  responsible  for  marketing  shal I  forthwith  Inform  the  Agency 
of  any  new  Information  which  might  ental I  the  amendment  of  the 
part lculars  and  documents  referred  to  In  Art lcle  6  or  In  the  approved 
summary  of  the  product  characteristics.  In  particular  the  person 
responsible  for  marketing  shall  forthwith  Inform  the  Agency  of  any 
prohibition  or  restriction  Imposed  by  the  competent  authorities of  any 
country  In  which  the  medicinal  product  Is  marketed  and  of  any  other  new 
Information  which  might  Influence  the  evaluation  of  the  benefits  and 
risks of  the medicinal  product  concerned. 
3.  If  the  person  responsible  for  marketing  proposes  to make  any  alteration 
to  the  Information  and  particulars  referred  to  In  Article  6,  he  shal I 
submit  an  appl lcatlon  to  the  Agency. 
4.  The  Agency  shall,  In  consultation  with  the  Commission,.  adopt 
appropriate  arrangements  for  the  examination  of  amendments  and 
variations  to  the  terms  of  a  marketing  authorization. - 73  -
Article 16 
When  a  marketing  authorization  Is  granted  In  accordance  with  this 
regu 1  at I  on,  one  or  more  of  the  t.4ember  States  sha II  act  as  the  competent 
supervisory  authorities  to  exercise  the  responsibilities  referred  to  In 
Article  17. 
In  the  case  of  medicinal  products  manufactured  within  the  Community,  the 
supervisory  authorities  shall  normally  be  the  competent  authorities  of  the 
t.4ember  State  or  t.4em~er  States  which  have  granted  the  manufacturing 
authorization  provided  for  In  Article  16  of  Directive  75/319/EEC  .In  respect 
of  the  manufacture of  the medicinal  product  concerned. 
In  the  case  of  medicinal  products  Imported  from  third  countries,  the 
supervisory  authorities  shall  be  the  competent  authorities  of  the  t.4ember 
States  in  which  the  controls  referred  to  In  Article  22  (1)  (b)  of  Dlr.ectlve 
75/319/EEC  are  carried  out  unless  appropriate  arrangements  have  been  made 
between  the  Community  and  the  exporting  countryG  to  ensure  that  those 
c 
controls  are  carried out  In  the  exporting  country  and  that  the  manufacturer 
appl_ies  standards  of  good  manufacturing  practice  at  least  equivalent  to 
those  I  aId  down  by  .the  CommunIty. 
Art lc le  11 
1.  The  supervisory  authorities  shal I  have  responslbl 1 lty  for  verifying  on 
behalf  of  the  Community  that  the  manufacturer  or  ths  Importer  from 
third  countries  satisfies  the  requirements  laid  down  In  Chapter  IV  of 
Directive  75/319/EEC,  and  for  exercising  supervision  over  persons 
responsible  for  marketing  medicinal  products  In  accordance  with 
Chapter  V of  Directive 75/319/EEC. - 74  -
2.  Upon  receipt  of  a  reasoned  request  by  any  Member  State,  or  on  Its  own 
Initiative,  the  Commission  may  request  the  manufacturer  or  Importer  to 
submit  to  an  Inspection  of  the  manufacturing  site  of  the  medicinal 
product  concerned,  giving  Its  reasons.  The  Inspection  shal I  be 
undertaken  by  qual If led  pharmaceutical  Inspectors  from  the  Member 
States who  may,  If  appropriate,  be  accompanied  by  an  Inspector  from  the 
Agency.  The  report  of  the  Inspectors  shall  be  made  available  to  the 
Commission,  the  Committee  and  the  applicant,.  In  the  case  of  an 
Inspection  conducted  within  the  Community,  the  host  Member  State  shal I 
provide  alI  the practical  support  necessary  to enable  the  Inspectors  to 
discharge  their  responslbl I ltles. 
Article  18 
1.  Where  the  supervisory  authorities  or  the  competent  authorities  of  any 
other  Member  State are of  the opinion  that  the manufacturer  or  Importer 
from  third  countries  Is  no  longer  fulfl I ling  the  obi lgatlons  laid  down 
In  Chapter  IV  of  Directive  75/319/EEC,  they  shall  forthwith  Inform  t~e 
Committee  and  the  Commission,  stating  their  reasons  In  detal I  and 
Indicating  the  course of  action  proposed. 
The  same  shall  apply  where  a  Member  State  considers  that  one  of  the 
measures  envisaged  In  Chapter  V  of  Directive  75/319/EEC  should  be 
appl led  In  respect  of  the  medicinal  product  concerned. 
2.  The  Commission  shall  In  consultation  with  the  Agency  forthwith  examine 
the  reasons  advanced  by  the  Member  State concerned.  It  may  request  the 
opinion  of  the  Committee  within  a  time  limit  to  be  determined  by  the 
Commission  having  regard  to  the  urgency  of  the  matter.  Whenever 
pr act I  cab I e,  the  person  respons I  b I  e  for  marketIng  sha I I  be  InvIted  to 
provide oral  or  written explanations. - 75  -
3.  The  Commission  shal I  prepare  a  draft  of  the  Decision  to  be  taken  which 
shal I  be  adopted  In  accordance  with  the  procedure  laid  down  In 
Article 10. 
However,  where  a  t.Aember  State  has  I  nvok:ed  the  prov Is I  ens  of 
paragraph  4,  the  time  limit  provided  for  In  Article  2  c,  paragraph  3 of 
Directive 75/318/EEC  shal I  be  reduced  to  15  calendar  days. 
4.  In  exceptional  cases,  where  action  Is  urgently  necessary  to  protect 
publ lc  health,  a  t.Aember  State may  suspend  the use on  Its territory of  a 
medicinal  product  which  has  been  authorized  In  accordance  with  this 
Regulation.  It  shal 1  Inform  the  Commission  no  la}er  than  the  following 
work:lng  day  of  the  reasons  for  Its  action.  The  Commission  shal I 
Immediately  consider  the  reasons  given  by  the  t.Aember  State  In 
accordance  wIth  paragraph  2  and  sha I I  InItIate  the  procedure  provIded 
for  in  paragraph  3. 
5.  A Member  State which  has  adopted  the  suspensive  measures  referred  to  In 
paragraph  4  may  maintain  them  In  force  untl I  such  time  as  a  definitive 
Decision  has  been  reached  In  accordance  with  the  procedure  laid down  In 
paragraph  3. - 76  -
CHAPTER  3 
Pharmacovlgllance 
Article  19 
For  the  purpose  of  this  Chapter,  the  definitions  given  In  Article  29b  of 
Directive 75/319/EEC  shal I  apply. 
Article  20 
The  Agency,  acting  In  close  cooperation  with  the  national  pharmacovlgl lance 
centres  establ lshed  In  accordance  with  Article  29a  of  Directive  75/319/EEC, 
shal I  be  responsible  for  the  col lectlon  and  evaluation of  Information  about 
adverse  reactions  to  medicinal  products  which  have  been  authorized  by  the 
Community  In  accordance with  this Regulation. 
The  competent  authorities  of  the  Member  States  and  the  person  respon~lble 
for  marketing  shal I  ensure  that  alI  relevant  Information  about  adverse 
reactions  to  medicinal  products  authorized  In  accordance  with  this 
Regulation  are  brought  to  the attention of  the  Agency  In  accordance  with  the 
provisions of  this Regulation. - 77  -
Article  21 
The  person  responsible  for  marketing  a  medicinal  product  authorized  by  the 
Community  In  accordance  with  the  provisions  of  this  Regulation  shall  have 
permanently  and  continuously  at  his  disposal  a  person  responsible  for 
pharmacovlgl lance.  This  person shall  be  responsible  for: 
a)  the  establ lshment  and  malntence  of  a  system  which  ensures  that 
Information  about  all  adverse  reactions  which  are  reported  to  the 
personnel  of  the  company,  Including  Its  sales  personnel  and  medical 
representat lves,  Is  collected  and  collated  so  that  It  may  be  accessed 
at  a  single point  within  the Community; 
b)  the  preparation and  submission of  the  reports  referred  to  In  Article  22 
to  the  competent  author It les  of  the  Member  States  and  the  Agency  In 
accordance  with  the  requirements of  this Regulation; 
c)  ensuring  that  any  request  for  the  provision  of  additional  Information 
necessary  for  the  evaluation  of  the  benefits  and  risks  of  a  medicinal 
product  Is  answered  fully  and  prompt I  y,  Inc lud 1 ng  the  provIsIon  of 
Information  about  the  volume  of  sales  or  prescriptions  for  the 
medicinal  product  concerned  where  relevant. - 78  -
Article  22 
1.  The  person  respons I  b I  e  for  marketIng  sha II  ensure  that  a II  suspected 
serious  adverse  reactions  to  a  medicinal  product  authorized  In 
accordance  with  the  provisions of  this  Regulation  which  are  brought  to 
his  attention  by  a  qualified  health  care  professional,  whether  arising 
within  the  Community  or  a  third  country,  are  recorded  and  reported  to 
the  Agency  within  15  days. 
2.  In  addition,  the  person  responsible  for  marketing  shal I  be  required  to 
maintain detal led  records of  alI  other  adverse  reactions arising within 
the  Community  which  are  reported  to  him  by  a  qualified  health  care 
professional.  Unless  other  requirements  have  been  laid  down  as  a 
condition  of  the  granting  of  authorization  by  the  Community,  these 
records  shal I  be  submitted  to  the Agency  Immediately  upon  request  or  at 
least  every  six  months  during  the  first  two  years  following 
authorization  and  once  a  year  for  the  following  three  years. 
Thereafter,  the  records  shall  be  subml tted  at  f lve  yearly  Intervals 
together  with  the  application  for  renewal  of  the  authorization,  or 
Immediately  upon  request. 
Article 23 
Each  Member  State  shal I  report  any  suspected  serious  adverse  reaction 
arising within  Its territory to  a  medicinal  product  authorized  In  accordance 
with  this  Regulation  to  the  Agency  and  the  person  responsible  for  marketing 
within  15  days  of  receipt  of  a  report  from  a  qualified  health  care 
professional. - 79  -
Article  24 
The  Agency  shall,  In  consultation  with  Member  States,  the  Commission  and 
Interested  parties,  draw  up  detailed  guidance  on  the  collection, 
verification and  presentation of  adverse  reaction  reports. 
Article  25 
1.  The  Agency  sha I I  pub I Ish  an  annua I  report  on  the  operatIon  of  the 
procedures  laid  down  In  this Chapter. 
2.  Within  six  years  of  the  entry  Into  force  of  this  Regulation,  the 
Commission  shall  publish  a  detailed  review  of  the  operation  of  the 
procedures  laid  down  In  this  Chapter  and  shal I  propose  any  amendments 
which  may  be  necessary  to  Improve  the  operation of  these  procedures. 
The  Counc I I  sha II  dec I de  on  the  CommIssIon  proposa I  wIth 1  n  one  year. - 80  -
TITLE  3 
AUTHQRIZATION  AND  SUPERVISION 
OF  VETERIHARY  MEPICIHAL  PBOPUCTS 
CHAPTER  1 
Submission  and  examination of applications-
authorization- renewal  of authorization 
Article 26 
The  Committee  for  Veterinary Medicinal  Products establ lshed  by  Article  16  of 
Directive 81/851/EEC,  In  this title referred  to as  "the Committee",  shall  be 
responsible  for  formulating  the  opinion  of  the  Agency  on  any  Question 
relating  to  the  grant,  amendment,  suspension  or  withdrawal  of  an 
authorization  to  place  a  veterinary  medicinal  product  on  the  market  arising 
In  accordance  with  the  provisions of  this Regulation. 
Article  27 
1.  An  application  for  authorzlatlon  for  a  veterinary  medicinal  product 
shall  be  accompanied  by  the  particulars  and  documents  referred  to  In 
Articles 5,  5a  and  7  of  Directive 81/851/EEC. 
2.  The  application  shall  also  be  accompanied  by  the  fee  payable  to  the 
Agency  for  the  examination of  the  appl lcatlon. 
3.  The  Agency  shall  ensure  that  the  opinion  of  the  Committee  Is  given 
within  210  days of  the  receipt  of  a  valid appl lcatlon. 
4.  The  Agency  shall~  In  consultation  with  Member  States,  the  Commission 
and  Interested parties,  draw  up  detal led  guidance  on  the  form  In  which 
appl lcatlons  for  authorization are  to  be  presented. - 81  -
Article  28 
In  order  to  prepare  Its opinion.  the  Committee: 
a)  shall  verify· that  the  particulars and  documents  submitted  In  accordance 
with  Article  27  comply  with  the  requirements  of  Directives  81/851/EEC 
and  81/852/EEC.  and  examine  whether  the  condlt Ions  for  Issuing  an 
authorization  to  place  the  veterinary  medicinal  product  on  the  market 
specified  In  t~ls Regulation are satisfied; 
b)  may  request  a  laboratory  designated  for  this  purpose  to  test  the 
veterinary  medicinal  product.  Its  starting  mater.lals.  and  If  need  be. 
Its  Intermediate  products.or  other  constituent  materials  In  order  to 
ensure  that  the  control  methods  employed  by  the  manufacturer  and 
described  In  the  application documents  are satisfactory; 
c)  may  request  a  laboratory  designated  for  this  purpose  to  verify.  using 
samples  provided  by  the  appl lcant.  that  the  analytical  detection method 
proposed  by  the  applicant  In  accordance  with  point  8  of  the  second 
paragraph  of  Article  5  of  Directive  81/851/EEC  Is  suitable  for  use  In 
routine  checks  to  reveal  the  presence  of  residue  levels  above  the 
maximum  residue  level  accepted  by  the  Community  In  accordance  with  the 
provisions  of  Council  Regulation  (EEC)  No  2377/90  of  26  June  1990 
I  ay I  ng  down  a  CommunIty  procedure  for  the  estab II shment  of  max I  mum 
residue  levels  for  veterinary medicinal  products<15); 
d)  may,  ·where  appropriate.  request  the  appl lcant  to  supplement  the 
particulars  accompanying  the  application.  Where  the  Committee  avails 
Itself  of  this option.  the  time  limit  laid  down  In  Article  28  shall  be 
suspended  unt II  such  t lme  as· the  supplementary  · lnformat ion  requested 
has  been  provided.  Likewise.  this  time  limit  shall  be  suspended  for 
the  time  allowed  to  the  applicant  to  prepare· oral  or  written 
explanations. 
(15)  OJ  No  L 224,  18.8.1990,  p.  1. - 82  -
Article  29 
1.  Upon  receIpt  of  a  wrItten  request  from  the·  CommIt tee,  a  Uember  State 
shal I  forward  the  Information  necessary  to verify  that  the manufacturer 
of  a  veterinary medicinal  product  or  the  Importer  from  a  third  country 
Is  able  to  manufacture  the  veterinary  medicinal  product  concerned 
and/or  carry  out  the  necessary  control  tests  In  accordance  with  the 
particulars and  documents  supplied  In  accordance  with  Article  27. 
2.  Where  It  considers  It  necessary  In  order  to  complete  Its examination of 
an  appl lcatlon,  the Committee  may  request  the  appl lcant  to submit  to an 
Inspection  of  the  manufacturing  site  of  the  veterinary  medicinal 
product  concerned.  The  Inspection,  which  shall  be  completed within  the 
time  I lmlt  referred  to  In  Article  27,  shal I  be  undertaken  by  qual I fled 
pharmaceutical  Inspectors  from  .the  Member  States,  who  may,  If 
appropriate  be  accompanied  by  an  Inspector  from  the  Agency. 
Article  30 
1.  Where  the opinion of  the Committee  Is  that: 
the  appl lcatlon  does  not  satisfy  the  criteria for  authorization  set 
out  In  this Regulation,  or 
the  summary  of  product  characteristics  proposed  by  the  appl lcant  In 
accordance with  Article  27  should  be  amended,  or 
the  label I lng  or  package  Insert  of  the  product  Is  not  In  compl  lance 
wlfh  Directive 81/851/EEC,  or 
the  authorization  should  granted  subject  to  the  conditions  provided 
for  In  Article -34(2), 
the  Agency  shal I  forthwith  Inform  the  appl lcant. - 83  -
Within  15  days  of  the  receipt of  the opinion,  the  appl lcant  may  provide 
written  notice  to  the  Agency  that  he  wishes  to  appeal.  Within  60  days 
of  the  receipt  of  the  grounds  for  appeal,  the  Committee  shal I  consider 
whether  Its  opinion  should  be  revised,  and  the  reasons  for  the 
conclusions  reached  on  the  appeal  shal I  be  annexed  to  the  assessment 
report  referred  to  In  paragraph  2. 
2.  Within  30  days  of  Its adoption,  the  Agency  shall  forward  the opinion of 
the  Committee  to  the  Commission,  the  t.Aember  States  and  the  applicant 
together  with  a  report  describing  the  assessment  of  the  veterinary 
medicinal  product  by  the  Committee  and  stating  the  reasons  for  Its 
conclusions. 
3.  In  the  event  of  an  opinion  In  favour  of  granting  authorization  to 
market  the  veterinary  medicinal  product  concerned,  the  following 
documents  shall  be  annexed  to  the opinion: 
a)  a  draft  summary  of  the  product  characteristics,  as  referred  to  In 
Article  Sa  of  Directive 81/851/EEC; 
b)  In  the  case  of  a  veterinary  medicinal  product  Intended  for 
administration  for  food  producing  animals,  a  statement  of  the 
maximum  residue  level  which  may  be  accepted  by  the  Community  In 
accordance  with  Regulation  (EEC)  ...  /90; 
c)  detal Is of  any  conditions or  restrictions which  should  be  Imposed  on 
the  supply  or  use  of  the  veterinary  medicinal  product  concerned, 
Inc I  ud I  ng  the  condItIons  under  whIch  the  medIc Ina I  product  may  be 
made  aval lable  to users; 
d)  the  draft  text  of  the  label I lng  and  package  leaflet,  proposed  by  the 
applicant,  presented  In  accordance  with  Chapter  VII  of  Directive 
81/851/EEC. - 84  -
Article  31 
1.  Within  30  days  of  the  receipt  of  the  opinion,  the  Commission  shall 
prepare  a  draft  of  the  Decision  to  be  taken  In  respect  of  the 
application  taking  Into  account  the  obJectives  of  Community  policies 
and  considering  all  relevant  Information.  In  the  event  of  a  draft 
Decision  which  envisages  the granting of  a  marketing  authorization,  the 
documents  referred  to  In  points  (a),  (b),  and  (c)  of  paragraph  3  of 
Art lcle  30  shall  be  annexed.  The  Commission  shall  transmit  the  draft 
Decision  to  the  Member  States and  to  the  appl lcant. 
The  Commission  shal I  explain  In  detail  the  reasons  for  any  differences 
between  the  draft  Decision  and  the opinion of  the  Committee. 
2.  The  Commission  shall  adopt  the  Decision  to  be  taken  In  respect  of  the 
appl lcatlon  unless,  within  30  days,  It  has  received  a  reasoned  request 
from  a  Member  State  to  reconsider  the  matter.  The  Member  State 
concerned  shal I  also  transmit  a  copy  of  Its  request  to  the other  Membe~ 
States and  the  applicant  within  the  same  time  I lmlt. 
3.  Within  the  time  limit  referred  to  In  paragraph  2,  the  applicant  may 
submit  written observations  on  the  draft  Decision  for  consideration  by 
the  Commission. - 85  -
4.  The  Commission  shal I  examine  any  reasoned  request  received  In 
accordance  with  paragraph  2,  In  consultation with  the  Agency,  and  after 
consideration of  any  further  observations submitted  by  the  appl lcant. 
If  the  CommIssIon  consIders  that  the  request  raIses  quest Ions  of  a 
scientific  or  technical  nature  requiring  further  examination,  It  may 
remit  the  matter  to  the  Agency.  In  this  case  the  Committee  shall  give 
a  second opinion within a  time  limit  of  60  days.  Within  30  days  of  the 
receipt  of  the  opinion,  the  Commission  shall  adopt  th~ Decision  to  be 
taken  In  respect  of  the  appl lcatlon. 
Otherwise  the  Decision  shal 1  be  taken  In  accordance  with  the  procedure 
laid  down  In  Article  2b  and  2c  of  Directive 81/852/EEC. 
Article  32 
Without  prejudice  to  other, provisions .. of  Community  -law,.  the  authorization 
provided  for  In  Article  3  shall  be  refused  If,  after  verification  of  the 
Information  and  particulars  submitted  In  accordance  with  Article  27,  It 
appears  that: 
1.  the  veterinary medicinal  product  Is  harmful  under  the  conditions of  use 
stated  at  the  time  of  the  appl lcatlon  for  authorization,  Is  not 
efficacious  or  the  applicant  has  not  provided  sufficient  proof  of 
efficacy  as  regards  the  species  of  animal  which  Is  to  be  treated,  or 
Its qual itatlve and  quantitative composition  Is  not  as  stated; - 86  -
2.  the  withdrawal  period  recommended  by  the  appl lcant  Is  not  long  enough 
to  ensure  that  foodstuffs  obtained  from  treated  animals  do  not  contain 
residues  which  might  constitute  a  health  hazard  for  the  consumer  or  Is 
Insufficiently substantiated; 
3.  the  veterinary  medicinal  product  Is  offered  for  sale  for  a  use 
prohibited  under  other  Community  provisions. 
Authorization  shall  likewise  be  refused  If  the  particulars  and  documents 
provided  by  the  applicant  In  accordance  with  Article  27  of  this  Regulation 
are  Incorrect  or  If  the  labelling  and  package  leaflets  proposed  by  the 
appl lcant  are  not  In  accordance with  Chapter  VI  I  of  Directive 81/851/EEC. 
Article  33 
1.  Without  preJudice  to  Article  4  of  Council  Directive  ..  / .. ./EEC 
[extending  the  scope  of  Directive  81/851/EEC  on  the  approximation  of 
the  laws  of  the  ~ember  States  relating  to  veterinary  medicinal 
products],  and  laying  down  additional  provisions  for  Immunological 
veterinary medicinal  products,  a  marketing  authorization which  has  been 
granted  In  accordance  with  the  procedure  laid  down  In  this  regulation 
shal I  apply  throughout  the  Community ..  It  shal I  confer  the  same  rights 
and  obllgat Ions  In  each  of  the  ~ember  States  as  a  market lng 
authorization granted  by  that  ~ember State  In  accordance  with  Article  4 
of  Directive 81/851/EEC. 
2.  The  refusal  of  a  Community  marketing  authorization  shal I  constitute  a 
prohibition  on  the  marketing  and  administration  to  animals  of  the 
veterinary medicinal  product  concerned  throughout  the  Community. 
3.  An  announcement  that  authorization  has  been  granted  shal I  be  publ lshed 
for  Information  purposes  In  the  Official  Journal  of  the  European 
Communities. - 87  -
4.  Upon  request  from  any  Interested  person,  the  Agency  shal I  make 
aval table  a  detal led  summary  of  the  evaluation  of  the  veterinary 
medicinal  product  by  the  Committee  and  the  reasons  for  Its  opinion  In 
favour  of  granting  authorization,  after  deletion of  any  Information  of 
a  commercially  confidential  nature. 
Article  34 
1.  Authorization  shal I  be  val ld  for  five  years  and  shal I  be  renewable  for 
five  year  periods,  on  application  by  the  holder  at  least  three  months 
before  the  expiry date. 
2.  In  exceptional  circumstances,  and  following  consultation  with  the 
appl lcant,  an  authorization  may  be  granted  subject  to  such  conditions 
as  appear  necessary  to ensure  the  protection of  human  or  animal  health, 
including specific obligations  to  conduct  further  studies  following  the 
granting  of  authorization  and  specific  obligations  In  respect  of  the 
reporting of  adverse  reactions  to  the veterinary medicinal  product. 
3.  Veterinary  medicinal  products  which  have  been  authorized  by  the 
Community  In  accordance  with  the  provisions  of  this  Regulation  shall 
benefit  from  the  ten  year  period  of  protection  referred  to  In  point  10 
of  the  second  paragraph of  Article  5 of  Directive 81/851/EEC. 
Article  35 
The  granting  of  authorization  shall  not  diminish  the  general,  civil  and 
cr lm Ina I  I I  ab I II ty  In  the  Member  States  of  the  manufacturer  and,  where 
applicable,  of  the  person  responsible  for  placing  the  veterinary  medicinal 
product  on  the  market. - 88  -
CHAPTER  2 
Supervision and  sanctions 
Article  36 
1.  After  an  authorization  has  been  Issued,  the  person  responsible  for 
placing  the  veterinary medicinal  product  on  the  market  must,  In  respect 
of  the  methods  of  production  and  control  provided  for  In  points  4  and  9 
of  the  second  paragraph  of  Article  5  of  Directive  81/851/EEC,  take 
account  of  technical  and  scientific  progress  and  Introduce  any  changes 
that  may  be  required  to  enable  the  veterinary  medicinal  product  to  be 
manufactured  and  checked  by  means  of  genera I I  y  accepted  scIentIfIc 
methods.  These  changes  must  be  accepted  by  the  Community. 
Upon  request  from  the  Commission,  the  person  responsible  for  placing 
the  veterinary ·medicinal  product  on  the  market  shall  also  review  the 
ana I  yt I  ca I  detect I  on  met hods  provIded  for  In  poInt  8  of  the  second 
paragraph  of  Article  5  of  Directive  81/851/EEC  and  propose  any  changes 
whIch  may  be  necessary  to  take  account  of  techn I  ca I  and  scIentIfIc 
progress. 
2.  The  person  responsible  for  marketing  shall  forthwith  Inform  the  Agency 
of  any  new  Information  which  might  ental I  the  amendment  of  the 
particulars  and  documents  referred  to  In  Article  27  or  In  the  approved 
summary  of  the  product  characteristics.  In  particular  the  person 
responsible  for  marketing  shall  forthwith  Inform  the  Agency  of  any 
prohibition or  restriction  Imposed  by  the  competent  authorities of  any 
country  In  which  the  veterinary  medicinal  product  Is  marketed  and  of 
any  other  new  Information  which  might  Influence  the  evaluation  of  the 
benefits  and  risks of  the medicinal  product  concerned. - 89  -
3.  If  the  person  responsible  for  marketln~ proposes  to make  any  alteration 
to  the  Information  and  particulars  referred  to  In  Article  27,  he  shal I 
submit  an  application  to  the Agency. 
4.  The  Agency  shall,  In  consultation  with  the  Commission,  adopt 
appropriate  arrangements  for  the  examination  of  amendments  and 
variations  to  the  terms  of  a  marketing  authorization. 
Article  37 
When  a  marketing  authorization  Is  granted  In  accordance  with  this 
regulation,  one  or ,more  of  the  t.4ember  States  shall  act  as  the  competent 
supervisory  authorities  to  exercise  the  responsibilities  referred  to  In 
Article  38. 
In  the  case  of  veterinary  medicinal  products  manufactured  within  the 
Community,  the  supervisory  authorltle.s  shall  normally  be  the  competent 
authorities  of  the  t.4ember  State  or  .Member  States  which  have  granted  the 
manufacturing_  authorization  provided  for  In  Article  24  of  Directive 
81/851/EEC  In  respect  of  the  manufacture  of  the  veterlnay  medicinal  product 
concerned. 
In  the  case  of  veterinary  medicinal  products  Imported  from  third  countries, 
the  supervisory authorities shall  be  the  competent  authorities of  the  t.4ember 
States  In  which  the  controls  referred  to  In  Article  30  (1)  (b)  of  Directive 
81/851/EEC  are  carr led  out  unless  appropr late  arrangements  have  been  made 
between.  the  CommunIty  and  the  exportIng  country  to  ensure  that  those 
controls  are  carried out  In  the  exporting  country  and  that  the  manufacturer 
applies  standards  of  good  manufacturing  practice  at  least  equivalent  to 
those  laid  down  by  the  Community. - 90  -
Article  38 
1.  The  supervisory  authorities  shall  have  responslbl I lty  for  verifying  on 
beha 1  f  of  the  CommunIty  that  the  manufacturer  or  the  Importer  from 
t h 1 rd  countrIes  satIsfIes  the  reQuIrements  I aId  down  In  Chapter  V of 
Directive  81/851/EEC,  and  for  exercising  supervision  over  persons 
respo'nslble  for  marketing  medicinal  products  In  accordance  with 
Chapter  VI  of  Directive 81/851/EEC. 
2.  Upon  receipt  of  a  reasoned  reQuest  of  any  Member  State,  or  on  Its  own 
Initiative,  the  Commission  may  reQuest  the  manufacturer  or  Importer  to 
submit  to  an  Inspection  of  the  manufacturing  site  of  the  veterinary 
medicinal  product  concerned,  giving  Its  reasons.  The  Inspection  shal I 
be  undertaken  by  Qualified  pharmaceutical  Inspectors  from  the  Member 
States who  may,  If  appropriate,  be  accompanied  by  an  Inspector  from  the 
Agency.  The  report  of  the  Inspectors  shall  be  made  available  to  the 
Commission,  the  Committee  and  the  appl lcant.  In  the  case  of  an 
Inspection  conducted  within  the  Community,  the  host  Member  State  shal~ 
provide  alI  the  practical  support  necessary  to enable  the  Inspectors  to 
discharge  their  responslbl I ltles. 
Article  39 
1.  Where  the  supervisory  authorities  or  the  competent  authorities  of  any 
other  Member  State are of  the  opinion  that  the manufacturer  or  Importer 
from  third  countries  Is  no  longer  fulfl I I lng  the  obi lgatlons  laid  down 
in  Chapter  V of  Directive  81/851/EEC  they  shall  forthwith  Inform  the 
Committee  and  the  Commission,  stating  their  reasons  In  detail  and 
Indicating  the  course of  action  proposed. - 91  -
The  same  sha I I  app I  y  where  a  Member  State  consIders  that  one  of  the 
measures  envisaged  In  Chapter  VI  of  Directive  81/851/EEC  should  be 
applied  In  respect  of  the  veterinary medicinal  product  concerned. 
2.  The  Commission  shal I  In  consultation  with  the  Agency  forthwith  examine 
the  reasons  advanced  by  the  Member  State concerned.  It  may  request  the 
opinion  of  the  Committee  within  a  time  limit  to  be  determined  by  the 
Commission  having  regard  to  the  urgency  of  the  matter.  Whenever 
practicable,  the  person  responsible  for  marketing  shal I  be  Invited  to 
provide oral  or  written explanations. 
3.  The  Commission  shal I  prepare  a  draft  of  the  Decision  to  be  taken  which 
shal I  be  adopted  In  accordance  with  the  procedure  laid  down  In 
Article  31. 
However,  where  a  Member  State  has  Invoked  the  provisions  of 
paragraph  4,  the  time  I lmlt  provided  for  In  Article  2  c,  paragraph  3 of 
Directive 81/852/EEC  shal I  be  reduced  to  15  calendar  days. 
4.  In  exceptional  cases,  where  action  Is  urgently  necessary  to  protect 
human  or  animal  health,  a  Member  State  may  suspend  the  use  on  Its 
territory  of  a  veterinary  medicinal  product  which  has  been  authorized 
In  accordance  with  this  Regulation.  It  shall  Inform  the  Commission  no 
later  than  the  following  working  day  of  the  reasons  for  Its  act ion. 
The  Commission  shall  Immediately  consider  the  reasons  given  by  the 
Member  State  In  accordance  with  paragraph  2  and  shall  Initiate  the 
procedure  provided  for  In  paragraph  3. 
5.  A Member  State which  has  adopted  the suspensive measures  referred  to  In 
paragraph  4  may  maintain  them  In  force  untl I  such  time  as  a  deflnttlve 
Decision  has  been  reached  In  accordance  with  the  procedure  laid  down  In 
paragraph  3. - 92  -
CHAPTER  3 
Pharmacovlgllance 
Article  40 
For  the  purpose  of  this  Chapter,  the  definitions  given  In  Article  42b  of 
Directive  81/851/EEC  shal I  apply. 
Article  41 
The  Agency,  acting  In  close  cooperation  with  the  national  pharmacovlgl lance 
centres  establ lshed  In  accordance  with  Article  42a  of  Directive  81/851/EEC, 
shal 1  be  responsible  for  the  collection  and  evaluation of  Information  about 
adverse  reactions  to  veterinary  medicinal  products  which  have  been 
authorized  by  the  Community  In  accordance  with  this Regulation. 
The  competent  authorities  of  the  Member  States  and  the  person  responsible 
for  marketIng  sha I I  ensure  that  a II  reI evant  InformatIon  about  adverse 
reactions  to  veterinary  medicinal  products  authorized  In  accordance  with 
this  Regulation  are  brought  to  the  attention  of  the  Agency  In  accordance 
with  the  provisions of  this Regulation. 
The  person 
authorized 
responsible  for 
by  the  Community 
Article  42 
marketing  a  veterinary  medicinal  product 
In  accordance  with  the  provisions  of  this 
Regulation  shal I  have  permanently  and  continuously  at  his  disposal  a  person 
responsible  for  pharmacovlgllance.  This  person  shal I  be  responsible  for: - 93  .... 
a)  the  establ lshment  and  maintenance  of  a  system  which  ensures  that 
Information  about  all  adverse  reactions  which  are  reported  to  the 
personnel  of  the·  company,  Including  Its  sales  personnel,  Is  collected 
and  collated  so  that  It  may  be  accessed  at  a· single  point  within  the 
CommunIty; 
b)  the  preparation and  submission of  the  reports  referred  to  In  Article 44 
to  the  competent  author It les  of  the  Member  States  and  the  Agency  In 
accordance  with  the  requirements of  this Regulation; 
c)  ensuring  that  any  request  for  the  provision  of  additional  Information 
necessary  for  the  evaluation of  the  benefits  and  risks of  a  veterinary 
medicinal  product  Is  answered  fully  and  promptly,  Including  the 
provision of  Information  about  the  volume  of  sales or  prescriptions  for 
the  veterinary medicinal  product  concerned,  where  relevant. 
Article 43 
1.  The  person  responsible  for  marketing  shall  ensure  that  all  suspected 
serious  adverse  reactions  to  a  veterinary  medicinal  product  authorized 
In  accordance  with  the  provisions  of  this  Regulation  which  are  brought 
to  his  attention  by  a  veterinarian,  whether  arising  within  the 
Community  or  a  third  country,  are  recorded  and  reported  to  the  Agency 
w  I thIn  15  days. - 94  -
2.  In  addition,  the  person  responsible  for  marketing  shal I  be  required  to 
maintain detal led  records of  alI  other  adverse  reactions arising within 
the  Community  which  are  reported  to  him  by  a  veterinarian.  Unless 
other  requirements  have  been  laid  down  as  a  condition  of  the  granting 
of  authorization  by  the  Community,  these  records  shal I  be  submitted  to 
the  Agency  Immediately  upon  request  or  at  least  every  six  months  during 
the  first  two  years  following  authorization  and  once  a  year  for  the 
following  three  years.  Thereafter,  the  records  shall  be  submitted  at 
five  yearly  Intervals  together  with  the  appl lcatlon  for  renewal  of  the 
authorization,  or  Immediately  upon  request. 
Article 44 
Each  Member  State  shal I  report  any  suspected  serious  adverse  reaction 
arising within  Its  territory  to  a  veterinary medicinal  product  authorized  In 
accordance  with  this Regulation  to  the Agency  and  the  person  responsible  for 
marketing within  15  days  of  receipt  of  a  report  from  a  qual If led  health  care 
professional. 
Article  45 
The  Agency  shall,  In  consultation  with  Member  States,  the  Commission  and 
Interested  parties,  draw  up  detailed  guidance  on  the  collection, 
verification  and  presentation  of  adverse  reaction  reports  to  veterinary 
medicinal  products. - 95  -
Article 46 
1.  The  Agency  shall  publish  an  annual  report  on  the  operation  of  the 
procedures  laid down  In  this Chapter. 
2.  Within  six  years  of  the  entry  Into  force  of  this  Regulation,  the 
Commission  shall  publish  a  detailed  review  of  the  operation  of  the 
procedures  laid  down  In  this  Chapter  and  shall  propose  any  amendments 
which  may  be  necessary  to  Improve  the operation of  these  procedures. 
The  Council  shal I  decide  on  the  Commission  proposal  no  later  than  one 
year  after  Its submission. - 96  -
I  ITLE  4-
THE  EUROPEAN  AGENCY  FOR  THE  EYALUATION  OF  MEPICIHAL  PROPUCTS 
CHAPTER 
Tasks of  the Agency 
Article  47 
A  European  Agency  for  the  Evaluation  of  Medicinal  Products,  hereinafter 
referred  to  as  "the Agency",  Is  hereby  establ !shed. 
Article  48 
In  order  to  promote  the  protection of  pub! lc  health  throughout  the  Community 
and  the  adoption  of  uniform  regulatory  decisions  based  on  scientific 
criteria  concerning  the  marketing  and  use  of  medicinal  products,the 
object lve  of  the  Agency  shall  be  to  provide  the  Member  States  and  the 
Institutions  of  the  Community  with  the  best  possible  scientific  advice  on 
any  question  relating  to  the  evaluation  of  the  quality,  the  safety  or  the 
efficacy of  medicinal  products  for  human  or  veterinary  use  which  Is  referred 
to  It  In  accordance  with  the  provisions of  Community  legislation  relating  to 
medicinal  products. 
In  particular,  the  Agency  shal I  undertake  the  following  tasks: 
a)  the  coordination  of  the  scientific  evaluation  of  the  quality,  safety 
and  efficacy  of  medicinal  products  which  are  subject  to  Community 
marketing  authorization procedures; 
b)  the  presentation 
characteristics, 
products; 
of 
labels 
assessment  reports,  summaries  of 
and  package  Inserts  for  these 
product 
medicinal - 97  -
c)  the  ~ontlnulng  supervision,  under  practical  conditions  of  use,  of 
medicinal  products  which  have  been  authorized  within  the  Community  and 
the  provision  of  advice  on  the  measures  necessary  to  ensure  the  safe 
and  effective  use  of  these  products,  In  particular  following  the 
evaluation of  reports of  adverse  reactions  (pharmacovlgl lance); 
d)  coordinating  the  discharge  of  the  various  supervisory  responslbl lltles 
whIch  have  been  conferred  on  the  CommunIty  and  the  t-4ember  States  In 
particular  In  respect  of  the  verification  of  compl lance  with  the 
principles of  good  manufacturing practice,  good  laboratory  practice and 
good  clinical  practice; 
e)  to  provide  technical  assistance  for  the  maintenance  of  a  data  base  on 
medicinal  products which  Is  available  for  publ lc use; 
f)  to  promote  technical  cooperation  between  the  Community,  Its  t-4ember 
States,  International  organizations  and  third  countries  on  scientific 
and  technical  Issues  relating  to  the evaluation of medicinal  products; 
g)  to  assIst  the  CommunIty  and  the  t-4ember  States  In  the  provIsIon  of 
Information  about  medicinal  products  to  the  public; 
h)  where  necessary,  to  advise and  to  allow  for  direct  dialogue  between  the 
appl lcant  and  the Agency  on  the  conduct  of  the  various  tests and  trials 
necessary  to  demonstrate  the  qual lty,  safety  and  efficacy of  medicinal 
products. 
I)  advising  on  the  maximum  levels  for  residues  of  veterinary  medicinal 
products  which  may  be  accepted  In  foodstuffs  of  animal  origin  In 
accordance with  Regulatlon·<EEC)  2377/90. - 98  -
CHAPTER  2 
Structure of  the Agency 
Article 49 
·1.  The  opinion  of  the  Agency  on  any  question  relating  to  the  quality, 
safety  or  efficacy  of  medicinal  products  for  human  use  shall  be  given 
by  the  Committee  for  Proprietary Medicinal  Products. 
2.  The  opinion  of  the  Agency  on  any  question  relating  to  the  quality, 
safety  or  efficacy  of  veterinary  medicinal  products  shal I  be  given  by 
the  Committee  for  Veterinary Medicinal  Products. 
3.  In  addition  to  a  permanent  technical  and  administrative  Secretariat, 
~ach Committee  may  arrange  to be  assisted  by  working  parties and  expert 
groups. 
The  Secretariat  shall  ensure  appropriate  coordination  between  the  work 
of  the  two  Committees. 
4.  The  Committee  for  Proprietary  Medicinal  Products  and  the  Committee  for 
Veterinary  Medicinal  Products  may,  If  they  consider  It  appropriate, 
seek  guidance  from  the  Scientific Councl I  referred  to  In  Article 65  on 
Important  questions of  a  general  scientific or  ethical  nature. - 99  -
Article 50 
1.  The  Committee  for  Proprietary Uedlclnal  Products  and  the  Committee  for 
Veterinary Uedlclnal  Products  shal I  each  consist of  scientific advisors 
nominated  by  Uember  States  for  a  term  of  three  years  which  shal I  be 
renewable.  They  shal I  be  chosen  by  reason  of  their  scientific 
expertise  and  their  role  and  experience  In  the  evaluation of  medicinal 
products  for  human  and  veterInary  use  as  appropr late.  Before 
nominating  members  to  the Committee,  the  Uember  States shal I  consult  to 
ensure  that  the  composition  of  each  Committee  reflects  the  various 
scientific  dlsclpl lnes  necessary  for  the  evaluation  o~  medicinal 
products. 
The  Executive  Director  or  his  representative and  representatives of  the 
Commission  shal I  be  entitled  to  attend  alI  meetings  of  the  Committees, 
their  working  parties and  expert  groups. 
Members  of  each  Committee  may  arrange  to  be  accompanied  by  experts. 
2.  In  addition  to  their  task  of  providing  an  obJective  scientific  advice 
to  the  Community  and  Uember  States  on  the  questions  which  are  referred 
to  them,  the  members  of  each  CommIt tee  sha I I  ensure  that  there  Is 
appropriate  coordination between  the  work  of  the Agency  and  the work  of 
scientific advisory  bodies established  In  Member  States. 
3.  The  Member  States  shall  refrain  from  giving  any  Instruction  to  Uembers 
of  the  Commltttees  which  Is  Incompatible  with  the  tasks  referred  to  In 
paragraph  2. - 100  -
Article  51 
1.  The  Member  States  shall  transmit  to  the  Executive  Director  a  list  of 
rapporteurs  and  experts with  proven  experience  In  the evaluation of  the 
quality,  safety  and  efficacy  of  medicinal  products,  together  with  an 
Indication of  their  qualifications and  specific areas of expertise. 
This ·I 1st  shal I  be  updated  as  necessary. 
2.  On  a  proposal  from  the  Committee  for  Proprietary Medicinal  Products or 
the  Committee  for  Veterinary Medicinal  Products,  the  Executive  Director 
may  entrust specific tasks  to  rapporteurs or  experts.  The  Provision of 
services  by  rapporteurs  or  experts  shall  be  governed  by  a  written 
contract  between  the  Agency  and  the  person  concerned,  or  where 
appropriate  between  the  Agency  and  his  employer.  The  person  concerned, 
or  his  employer,  shal I  be  remunerated  In  accordance  with  a  fixed  scale 
of  fees  to  be  e!?tabllshed  by  the  financial  regulation  adopted  by  the 
Management  Board. 
3.  The  Executive  Director  may  also  have  recourse  to  the  services  of 
experts  for  the  discharge  of  other  specific  responsibilities  of  the 
Agency,  In  particular  the  Inspections  referred  to  In  Articles 8,  17,  29 
and  38. - 101  -
Article 52 
1.  The  Membership  of  the  Committee  for  Proprietary Medicinal  Products  and 
the  Committee  for  Veterinary  Medicinal  Products  shal I  be  made  public. 
When  each  appointment  Is  publ lshed,  the  professional  qual lflcatlons of 
each  member  shall  be  specified. 
2.  Committee  members,  rapporteurs  or  experts  may  not  hold  financial  or 
. other  Interests  In  the  pharmaceutical  Industry which  could  affect  their 
Impartiality.  All  Indirect  Interests  which  could  relate  to  this 
Industry  shall  be  entered  In  a  register  held  by  the  Executive  Director 
which  the  public may  consult. 
Article  53 
1.  The  Executive  Director  shal I  be  appointed  by  the  management  board,  on  a 
proposal  from  the  Commission,  for  a  period  of  five  years,  which  shal I 
be  renewable. 
/,  l 
2.  The  E~.ec.u.t1 ~~  .D.,I r.ector  sha II  be  the  I  ega I representatIve of .the  Agency. 
He  shal I  be  responsible: 
' 
for  the  day  to day  administration of  the  Agency; 
for  the  provision  of  appropriate  scientific  and  technical  support 
for  the  Committee  for  Proprietary  Medicinal  Products  and  the 
Committee  for  Veterinary  Medicinal  Products,  and  their  working 
parties and  expert  groups; 
for  ensuring  that  the  time  I lmlts  laid  down  In  Community  legislation 
,.·for  the  adoption of Opinions  by  the  Agency  are  respected; 
for  ensuring  appropriate  coordination  between  the  Committee  for 
Proprietary  Medicinal  Products  and  the  Com~lttee  for  Veterinary 
Medicinal  Products; 
for  the  preparation  of  the  statement  of  revenue  and  expenditure  and 
the  execution of  the  budget  of  the  Agency; 
for  all  staff matters. - 102  -
3.  Each  year,  the  Executive  Director  shal I  submit  to  the  Management  Board 
for  approva I : 
a  draft  report  covering  the activities of  the  Agency  In  the  previous 
year,  Including  Information  about  the  number  of  applications 
evaluated  within  the  Agency,  and  the  time  taken  for  the  completion 
of  the  evaluation; 
a  draft  programme  of  work  for  the  coming  year; 
the  draft  annual  accounts  for  the  previous  year; 
the draft  budget  for  the  coming  year. 
4.  The  Executive  Director  shall  approve  alI  financial  expenditure  of  the 
Agency. 
Article  54 
f.  The  Management  Board  sha II  consIst  of  two  representatIves  from  each 
Member  State  and  two  representatives  of  the  Commission.  One 
representative  shall  have  specific  responsibilities  relating  to 
medicinal  products  for  human  use  and  one  relating  to  veterinary 
medicinal  products. 
2.  The  term  of  offIce  of  the  representatIves  sha I I  be  three  years.  It 
shal I  be  renewable. 
3.  The  Management  Board  shal I  elect  Its Chairman  for  a  term  of  three  years 
and  shal I  adopt  Its  rules of  procedure. 
Decisions  of  the  management  board  shall  be  adopted  by  a  two-thirds 
majorIty. 
4.  The  Executive  Director  shal I  provide  the  Secretariat  of  the  Management 
Board  and  shal I  be  entitled  to  attend  the  meetings  of  the  Board  unless 
It  decides  otherwise.  In  this  case,  a  representative of  the  Commission 
shal I  prepare  the  record of  the meeting. - 103  -
5.  Before  31  January  each  year,  the  Management  Board  sha I I  adopt  the 
genera I  report  on  the  actIvIt les  of  the  Agency  for  the  prev lous  year 
and  Its  programme  of  work  for  the  coming  year  and  forward  them  to  the 
Member  States,  the Commission,  the Councl I,  the  European  Parliament  and 
the Scientific Council. 
CHAPTER  3 
Financial  Provisions 
Article  55 
1.  The  revenues  of  the  Agency  sha II  consIst  of  a  contrIbutIon  from  the 
Community,  and  the  fees  paid  by  undertakings  for  obtaining  a  Community 
marketing  authorization and  for  other  services  provided  by  the  Agency. 
2.  The  expenditure  of  the  Agency  shall  Include  the  staff,  administrative, 
Infrastructure  and  operat lona I  expenses  and  expenses  resu It I  ng  from 
contracts entered  Into with  third parties. 
3.  Before  31  January  each  year  the  Management  Board  sha I I  draw  up  an 
estimate  of  revenue  and  expenditure  which  shal I  be  In  balance  for  each 
flnanclaf  year  which  shall  be  the  same  as  a  calendar  year.  This 
estimate shall  be  forwarded  to  the Commission  and  the  Member  States. 
4.  The  Commission  shall  Include  an  appropriate  contribution  to  the  Agency 
In  the  preliminary draft  budget  of  the  European  Communities.  The  budget 
of  the  European  Communities  shall  each  year  under  a  specific heading  In 
the  operational  part  Include  a  contribution  to  the  Agency. - 104  -
5.  The  Management  Board,  after  obtaining  the  opinion  of  the  Commission, 
shal 1  adopt  the  statement  of  revenue  and  expenditure  at  the  beginning 
of  the  financial  year  adjusting  It  to  the  contribution  granted  to  the 
Agency  and  to  Its other  resources. 
6.  The  Management  Board  shall  adopt  the  financial  regulations  of  the 
Agency,  In  agreement  with  the Commission. 
7.  Before  31  March  each  year,  the  Management  Board  shal I  transmit  to  the 
Commission  and  to  the  Court  of  Auditors  the  accounts ·for  alI  revenues 
and  expenditure  by  the  Agency  during  the  preceding  year.  The  Court  of 
Auditors  shal I  examine  the  accounts  In  accordance  with  the  provisions 
of  Article  206a  of  the  EEC  Treaty. 
8.  Before  31  October  each  year,  the  Commission  shal I  submit  the  accounts 
and  the  report  of  the  Court  of  AudItors  to  the  Counc I I  together  wIth 
Its  own  observations.  The  Management  Board  shall  be  discharged  In 
respect  of  the  Imp I  ementat I  on  of  the  budget  In  accordance  wIth  the 
procedure  laid  down  In  Article  206b  of  the  EEC  Treaty. 
Article 56 
The  fees  referred  to  In  Article  55,  paragraph  1,  shal I  be  establ lshed  by  the 
Councl I  on  a  proposal  from  the  Commission,  following  consultation  of 
organizations  representing  the  Interests  of  the  pharmaceutical  Industry  at 
the  Community  level. - 105  -
CHAPTER  4 
General  Provisions governing  the Agency 
Article 57 
The  Agency'shal I  have  legal  personal lty.  In  all  Member  States  It  shal I 
benefit  from  the  widest  powers  granted  by  law  to  legal  persons.  In 
particular  It  may  acquire  and  dispose of  real  property  and  chattels and 
Institute  legal  proceedings. 
Article  58 
1.  The  contractual  I labl I lty of  the  Agency  shall  be  governed  by  the  law 
ap~l lcable  to  the  contract  In  question.  The  Court  of  Justice of  the 
European  Communities  shal I  have  jurisdiction to give  Judgement  pursuant 
to  any  arbitration clause  contained  In  a  contract  concluded  by  the 
Agency. 
2.  In  the  case  of  non-contractual  llabl I lty,  the Agency  shal 1,  In 
accordance with  the  general  principles  common  to  the  laws  of  the Member 
States,  make  good  any  damage  caused  by  Itself or  by  Its servants  In  the 
performance of  their  duties. 
The  Court  of  Justice shal I  have  jurisdiction  In  any  dispute  relating  to 
compensation  for  such  damages. 
3.  The  personal  I labl llty of  Its servants  towards  the  Agency  shal I  be 
governed  by  the  relevant· conditions applying  to  the staff of  the 
Agency. - 106  -
Article  59 
Member  States,  members  of  the  Management  Board  and  third  parties  directly 
Involved  may  refer  to  the  Commission  any  act  of  the  Agency,  whether  express 
or  Imp I led,  for .the Commission  to examine  the  legal lty of  that  Act. 
Referral  to  the  Commission  shall  be  made  within  15  days  of  the  day  on  which 
the  party  concerned  first  became  aware  of  the  act  In  Question. 
The  Commission  shal I  take  a  Decision  within  one  month.  If  no  Decision  has 
been  taken  wIthIn  thIs  per lod,  the  case  sha I I  be  deemed  to  have  been 
dismissed. 
Article 60 
The  Protocol  on  the  Privl leges  and  Immunities  of  the  European  Communities 
shal I  apply  to  the  Agency. 
Article 61 
1.  Apart  from  officials  and  other  staff  seconded  by  an  Institution of  the 
European  Communities,  the  Agency  shal I  have  Its  own  personnel  to  whom 
wl  I I  be  appl led  a  special  regime,  to  be  decided  by  a  Counci I 
Regulation,  adopted  by  a  QUalified  majority  on  a  proposal  from  the 
Commission. 
2.  In  respect  of  Its personnel,  the Agency  shal I  exercise  the  powers  which 
have  been  devolved  to  the  Authority  Invested  with  the  power  of 
nomination. 
3.  The  Management  Board,  In  agreement  with  the  Commission,  shal I  adopt  the 
necessary  Implementing  provisions. - 107  -
Article 62 
Members  of  the  Management  Board,  the  ExecutIve  DIrector,  the  staff  of  the 
Agency,  the  members  of  Committees  attached  to  the  Agency  and  their  working 
parties,  experts  and  any  other  persons  participating  In  the  work  of  the 
Agency,  Including  observers,  shal I  be  obi lged,  even  after  their  duties  have 
ceased,  not  to disclose  Information of  the  kind  covered  by  the obi lgatlon of 
professional  secrecy. 
Article 63 
The  Management  Board  may,  In  agreement  with  the  Commission,  Invite 
representatives  of  International  organizations  with  Interest  In  the 
scientific and  technical  evaluation of medicinal  products such  as: 
- the  European  Pharmacopoeia, 
- the  European  Free  Trade  Association, 
- the  Nordic  Councl I  on  Medicines, 
-the World  Health  Organization, 
to participate as observers  In  the work  of  the Agency. 
Article 64 
The  Management  Board  shal I,  In  agreement  with  the  Commission,  develop 
appropriate  contacts  between  the  Agency  and  the  representatives  of  the 
Industry,  consumers  and  patients and  the  professions. - 108  -
Article 65 
1.  A Scientific Councl I  shall  be  established and  attached  to  the  Agency. 
2.  The  Scientific  Council  shall  consist  of  not  less  than  5  and  not  more 
than  9  persons  of  outstanding  and  Internationally  recognised  ability 
with  particular  knowledge  of  scientific  and  ethical  Issues  relating  to 
medicinal  products  for  human  or  veterinary use. 
3.  The  Members  of  the Scientific Council  shal I  be  nominated  by  the  Councl I 
on  a  proposal  from  the  Commission  for  a  term  of  4  years.  Their 
appointments  shal I  be  renewable. 
4.  The  Scientific  Councl I  shal I  advise  for  the  Committee  for  Proprietary 
Medicinal  Products  or  the  Committee  for  Veterinary  Medicinal  Products 
on  any  question which  Is  submitted  to  It  In  accordance  with  Article  49. 
In  addition,  the  Scientific  Council  shall  be  able  to  comment  on  the 
annua I  report  on  the  operatIon  of  the  Agency  prepared  In  accordance 
with  Article 55. 
Article 66 
The  Agency  shal I  take  up  Its  responslbll ltles on  1  January  1993. - 109  -
TITLE  5 
GENERAL  AND  FINAL  PROVISIONS 
Article 67 
AI  1  Decisions  to  grant,  refuse,  amend,  suspend,  withdraw  or  revoke  a 
marketing  ~uthorlzatlon which  are  taken  In  accordance  with  this  Regulation 
shal 1  state  In  detail  the  reasons  on  which  they  are  based.  Such  Decisions 
shal 1  be  notified  to  the  party_ concerned,  who  shal I  be  able  to exercise  the 
remedies  conferred  upon  him  under  the  EEC  Treaty. 
Article 68 
1.  An  authorization  to  market  a  medicinal  product  coming  within  the  scope 
of  this  Regulation  shall  not  be  refused,  amended,  suspended,  withdrawn 
or  revoked  except  on  the grounds  set  out  In  this Regulation. 
2.  An  authorization  to market  a  medicinal  product  coming  within  the  scope 
of  this  Regulation  shall  not  be  granted,  refused,  amended,  suspended, 
withdrawn  or  revoked  except  In  accordance  with  the  procedures  set  out 
In  this Regulation. 
Article 69 
In  respect  of  medicinal  products  coming  within  the  scope of  this Regulation, 
and  In  order  to  exercise  the  responsibilities  Imposed  ·upon  them  by  this 
Regulation,  the  competent  authorities  of  the  Community  shall  be  able  to 
exercise  alI  the  powers  conferred on  the  competent  authorities of  the  Member 
States  by  Directives 65/65/EEC,  75/319/EEC,  and  81/851/EEC. - 110  -
Article 70 
Without  prejudice  to  Article  68,  and  without  prejudice  to  the  Protocol  on 
the  Privileges  and  Immunities of  the  European  Communities,  each  Member  State 
shall  determine  the  penalties  to  be  applied  for  the  Infringement  of  the 
provisions of  this Regulation.  The  penalties shal I  be  sufficient  to promote 
compl lance' with  those measures. 
Member  States  shall  forthwith  Inform  the  Commission  of  the  Institution  of 
any  Infringement  proceedings. 
Article 71 
Within  three  years of  the entry  Into  force  of  this Regulation  the  Commission 
shal I  produce  a  report  on  whether  the  level  of  harmonization  achieved  by  the 
present  Regulation  and  by  Council  Directive  90/167/CEE  of  26  March  1990 
laying  down  the  conditions  governing  the  preparation,  placing  on  the  market 
and  use  of  medicated  feedlngstuffs(16)  Is  eQuivalent  to  that  provided  for 
In  Councl I  Directive  70/524/EEC  of  23  November  1970  concerning  additives  In 
animal  feedlngstuffs(17),  accompanied  If  necessary  by  the  proposals  to 
modify  the  status  of  the  coccldlostats  and  other  medicinal  substances 
covered  by  that  Directive. 
The  Councl I  shal I  decide  on  the  Commission  proposals  no  later  than  one  year 
after  their  submission. 
( 16)  0 J  No  L 92,  7. 4. 90,  p.  42. 
( 17)  0 J  No  L  270,  14. 12.70,  p.  1. - 111  -
Article 72 
Within  six  years of  the  entry  Into  force  of  this  Regulation,  the  Commission 
shal I  publIsh  a  general  report  on  the experience acquired as  a  result of  the 
operation  of  the  procedures  laid  down  In  this Regulation,  In  Chapter  I II  of 
Directive 75/319/EEC  and  In  Chapter  IV  of  Directive 81/851/EEC  together  with 
any  appropriate  proposals  for  amendments  to Article  3  and  the Annex  In  order 
to  extend  the  scope  of  the  procedures  laid  down  In  this  Regulation  to other 
categories of  medicinal  products,  on  an  obi lgatory or  a  voluntary  basis. 
The  Councl 1  shal 1  decide  on  the  Commission  proposals  no  later  than  one  year 
after  their  submission. 
Article 73 
This  Regulation  shall  enter  Into  force  on  the  third  day  following  Its 
publ lcatlon  In  the Official  Journal  of  the  European  Communities. 
Titles 1,2,  3  and  5  shal I  apply  from  1  January  1993. 
This  Regulation  shal I  be  binding  In  Its  entirety  and  directly  appl lcable  In 
alI  Member  States. 
Done  at Brussels  For  the  Counc I I - 112  -
PART  A 
Medicinal  products  developed  by  means  of  one  of  the  following 
biotechnological  processes: 
- recombinant  DNA  technology, 
-control led  expression  of  genes  coding  for  biologically  active  proteins  In 
prokaryotes  and  eukaryotes  Including  transformed  mammal  ian  cells, 
- hybrldoma  and  monoclonal  antibody methods. 
Veterinary  medicinal  products,  Including  those  not  derived  from 
biotechnology,  Intended  prlmarl ly  for  use  as  performance  enhancers  In  order 
to  promote  the  growth  of  treated  animals  or  to  Increase  yields  from  treated 
animals. 
PART  B 
Medicinal  products  developed  by  other  biotechnological  processes  which,  In 
/ 
the  opinion of  the  Agency,  constitute a  significant  Innovation; 
MedIc Ina I  products  admInIstered  by  means  of  new  de I I  very  systems  whIch,  In 
the opinion of  the  Agency,  constitute a  significant  Innovation; 
Medicinal  products  presented  for  an  entirely  new  Indication  which,  In  the 
opinion of  the  Agency,  Is  of  significant  therapeutic  Interest; 
Medicinal  products  based  on  radio-Isotopes  which,  In  the  opinion  of  the 
Agency,  are of  significant  therapeutic  Interest; 
New  medicinal  products derived  from  human  blood or  human  plasma; - 113  -
Medicinal  products  the  manufacture  of  which  employs  processes  which,  In  the 
opinion  of  the  Agency,  demonstrate  a  significant  technical  advance  such  as 
two-dimensional  electrophoresis under  micro-gravity; 
Medicinal  products  Intended  for  administration  to  human  beings  containing  a 
new  active  substance  which,  on  the  date  of  entry  Into  force  of  this 
regulation,  was  not  authorized  by  any  Member  State  for  use  In  a  medicinal 
product  Intended  for  use  In  human  beings; 
Veterinary  medicinal  products  Intended  for  use  In  food-producing  animals 
containing  a  new  active  substance  which,  on  the  date  of  entry  Into  force  of 
this  Regulation,  was  not  authorized  by  any  Member  State  for  use  In  food-
producing  animals. Bl 
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Propos  a I  for  a 
C.QUNCIL  DIRECTIVE  CEEC) 
amending  Directives  65/65/EEC,  75/318/EEC  and  75/319/EEC 
In  respect  of  medicinal  products 
.• - 117  -
Proposal  for  a 
COUNCIL  DIRECTIVE  CEECl 
amending  Directives 65/65/EEC,  75/318/EEC  and  75/319/EEC 
In  respect  of  medicinal  products 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to  the  Treaty  establishing  the  European  Economic  Community, 
and  In  particular Article  100a  thereof; 
Having  regard  to  the  proposal  from  the  Commlsslon<1>, 
In  cooperation with  the  European  Pari lament<2), 
Having  regard  to  the  opinion of  the  Economic  and  Social  Commlttee<3), 
Whereas  It  Is  Important  to  adopt  measures  with  the  aim  of  progressively 
establ lshlng  the  Internal  market  over  a  period expiring on  31  December  1992; 
whereas  the  Internal  market  shall  comprise  an  area  without  Internal 
frontiers  In  which  the  free  movement  of  goods,  persons,  services and  capital 
Is ensured; 
( 1) 
(2) 
( 3) - 118  -
Whereas  Article  15(2)  of  Second  Council  Directive  75/319/EEC  of  20  May  1975 
on  the  approximation  of  provisions  laid  down  by  law,  regulation  or 
administrative  action  relating  to  proprietary  medicinal  products<4)  as  last 
amended  by  Directive  89/381/EEc<5>,  provides  that  the  Commission  shal 1 
submIt  to  the  Counc I I  a  propos  a I  contaInIng  approprIate  measures  I  ead I  ng 
towards  the  abolition  of  any  remaining  barriers  to  the  free  movement  of· 
proprietary medicinal  products; 
Whereas  In  the  Interests  of  public  health  It  Is  necessary  that  decision  on 
the  authorization  to  place  medicinal  products  on  the  market  be  exclusively 
based  on  the  criteria  of  qual lty,  safety  and  efficacy;  whereas  these 
criteria  have  been  extensively  harmonized  by  Directive  65/65/EEC  of 
26  January  1965  on  the  approximation  of  provisions  laid  down  by  law, 
regulation  or  administrative  action  relating  to  medicinal  products<6>,  as 
last  amended  by  Directive  89/381/EEC,  and  by  Directive  75/319/EEC,  and  by 
Councl I  Directive 75/318/EEC  of  20  May  1975  on  the  approximation of  the  laws 
of  the  Member  States  relating  to  analytical,  pharmaco-toxlcologlcal  and 
c I In I  ca I  standards  and  protoco Is  In  respect  of  the  test 1 ng  of  med 1  c 1 na 1 
products<7)  as  I ast  amended  by  DIrectIve  89/341 /EEc(8);  whereas,  however 
Member  States  should  exceptionally  be  able  to  prohibit  the  use  on  their 
territory of  medicinal  products  which  Infringe  objectively  defined  concepts 
of  publ lc order  or  publ lc  moral lty; 
(4)  OJ  No  L  147,  9.6.1975,  p.  13. 
(5)  OJ  No  L  181 •  28 . 6 . 1989 •  p .  44. 
(6)  OJ  No  22,  9.2.65,  p.  369/65. 
(7)  OJ  No  L  147,  9.6.75,  p.  1 . 
(8)  OJ  No  L  142,  25.5 .1989,  p.  11 . - 119  -
Whereas,  with  the exception of  those medicinal  products which  are  subject  to 
the  centralized  Community  authorization  procedure  established  by  Council 
Regulation  (EEC)  ....  / .. ,of ..  / ...  / ..  laying  down  Community  procedures  for 
the  authorization  and  supervision  of  medicinal  products  for  human  and 
veterinary  use  and  establishing  a  European  Agency  for  the  Evaluation  of 
Medicinal  ProductsC9),  an  authorization  to  place  a  medicinal  product  on  the 
market  In  'one  Member  State  ought  In  principle  to  be  recognized  by  the 
competent  authorities  of  the  other  Member  States  unless  there  are  serious 
grounds  for  supposing  that  the  authorization  of  the  medicinal  product 
concerned  may  present  a  risk  to  public  health;  whereas,  In  the  event  of  a 
dIsagreement  between  Member  States  about  the  qua II t.y,  the  safety  or.  the 
efficacy  of  a  medicinal  product,  a  scientific  evaluation  of  the  matter 
should  be  undertaken  by  the  Committee  for  Propr letary  Medicinal  Products 
attached  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products, 
leading  to  a  single  decision  on  the  area  of  disagreement,  binding  on  the 
Member  States  concerned;  whereas  this Decision  should  be  adopted  by  a  rapid 
procedure  ensuring  close  cooperation  between  the  Commission  and  the  Member 
States,  In  particular  through  the  Standing  Committee  on  Medicinal  Products 
for  Human  Use  created by  Article  2b  of  Directive 75/318/EEC; 
Whereas  In  order  better  to  protect  pub I lc  health  and  avoid  any  unnecessary 
duplication  of  effort  during  the  examination  of  application  for 
authorization  to  place  medicinal  products  on  the  market,  Member  States 
should  systematically  prepare  assessment  reports  In  respect  of  each 
medicinal  product  which  Is  authorized by  them,  and  exchange  the  reports upon 
request;  whereas,  furthermore,  a  Member  State  should  be  able  to  suspend  the 
examination of  an  application  for  authorization  to place  a  medicinal  product 
on  the  market  which  Is  currently  under  active  consideration  In  another 
Member  State  with  a  view  to  recognizing  the  Decision  reached  by  the  latter 
Member  State; 
(9) - 120  -
Whereas  following  the  establ lshment  of  the  Internal  market,  specific 
controls  to guarantee  the  qual lty  of  medicinal  products  Imported  from  third 
countries  can  only  be  waived  If  appropriate  arrangements  have  been  made  by 
the  Community  to  ensure  that  the  necessary  controls  are  carried  out  In  the 
exporting  country; 
Whereas  It  Is  desirable  to  codify  and  Improve  the  cooperation  and  exchange 
of  Information  between  Member  States  relating  to  the  supervision  of 
medicinal  products  and  In  particular  the  monitoring  of  adverse  reactions 
under  practical  conditions  of  use  through  the  national  pharmacovlgllance 
centres, 
HAS  ADOPTED  THIS  DIRECTIVE: - 121  -
-- Art I  c I  e 
Directive 65/65/EEC  Is  hereby  amended  as  follows: 
1.  Article  3  Is  replaced  by  the  following: 
"Article 3 
No  medicinal  product  may  be  placed  on  the  market  of  a  Member  State 
unless  an  authorization  has  been  Issued  by  the  competent  authority  of 
that  Member  State or  by  the  Community. 
2.  In  the  second  paragraph  of  Article  4,  points  6  and  11  are  are  replaced 
by  the  following  : 
"6.  Posology,  pharmaceutical  form,  method  and  route of  administration 
and  expected  shelf  1 lfe. 
If  appl !cable,  reasons  for  any  precautionary  and  safety  measures 
to be.taken  for  the storage of  the  product,  Its administration  to 
patlents·and  for  the  disposal  of  waste  products,  together  with  an 
Indication  of  any  potential  rlsl<s  presented  by  the  product  for 
the  environment." - 122  -
"11.  Copy  of  any  authorization obtained  In  another  Member  State or  In 
a  third  country  to  place  the  relevant  medicinal  product  on  the 
market,  together  with  a  list  of  those  Member  States  In  which  an 
application  for  authorization  submitted  In  accordance  with  this 
Directive  Is  under  examination  and  copies  of  the  summary  of 
product  characterIstIcs  proposed  by  the  app I I  cant  In  accordance 
with  Article  4a  or  approved  by  the  comptetent  authorities  In 
accordance  with  Article  4b,  as  appropriate,  In  respect  of  each 
Member  State  concerned.  Detal Is  of  any  Decision  to  refuse 
authorIzatIon.  whether  In  the  CommunIty  or  a  thIrd  country  and 
the  reasons  for  that  Decision. 
This  Information  shal I  be  updated  at  regular  Intervals." 
3.  Article  4b  Is  replaced  by  the  following: 
"Article  4b 
When  the  marketing  authorization  referred  to  In  Article  3  Is  Issued, 
the  person  responsible  for  placing  that  product  on  ~he market  shal I  be 
Informed,  by  the  competent  authorities  of  the  Member  State  concerned, 
of  the  summary  of  the  product  characteristics  as  approved  by  them.  The 
competent  authorities  shal I  take  alI  necessary  measures  to  ensure  that 
the  Information  given  In  the  summary  Is  In  conformity  with  that 
accepted  when  the  marketing  authorization  Is  Issued  or  subsequently. 
The  competent  aurthorltles  shal I  forthwith  forward  a  copy  of  the 
summary  to  the  European  Agency  for  the  Evaluation of  Medicinal  Products 
,  (*)  establ lshed  by  Councl I  Regulation  (EEC)  ....  / .. - 123  -
Furthermore,  the  competent  authorities  shall  draw  up  an  assessment 
report  and  comments  on  the  dossier  as  regards  the  results  of  the 
analytical,  pharmaco-toxlcologlcal  tests and  the clinical  trials of  the 
medicinal  product  concerned.  The  assessment  report  shall  be  updated 
whenever  new  Information  becomes  available  which  Is  of  Importance  for 
the  evaluation  of  the  Quality,  safety  or  efficacy  of  the  medicinal 
product  concerned. 
(*)  OJ  No  L 
II 
4.  Article 6  Is  replaced  by  the  following: 
"Article 6 
This Directive shal I  not  affect  the  application of  national  legislation 
prohibiting  or  restricting  the  use  of  medIc Ina I  products  as 
The  Member  States  shal I  communicate  contraceptives  or  abortifacients. 
the  national  )eglsl~tlon  concerned  to  the  Commission." - 124  -
5.  Article 7  Is  replaced  by  the  following: 
"Article 7 
1.  Member  States shal 1  take all  appropriate measures  to ensure  that  the 
procedure  for  granting  an  authorization  to place  a  medicinal  product 
on  the market  Is  completed within  210  days  of  the  date of  submitting 
the  app I I  cat I  on. 
2.  Where  a  Member  State  notes  that  an  application  for  authorization 
submitted  after  1  January  1993  Is  already  under  active  examination 
In  another  Member  State,  the  former  Member  State  may  decide  to 
suspend  the  detailed  examination  of  the  application  In  order  to 
await  the  assessment  report  prepared  by  the  first  Member  State  In 
accordance  with  Article  4b." 
The  Member  State  concerned  sha II  Inform  the  fIrst  Member  State  and 
the  appl lcant  of  Its  Decision  to suspend  detailed examination of  the 
application  In  question.  As  soon  as  It  has  completed  the 
examination  of  the  application  and  reached  a  Decision,  the  first 
Member  State  sha II  forward  a  copy  of  Its  assessment  report  to  the 
Member  State concerned. 
Within  90  days  of  the  receipt  of  the  assessment  report,  the  Member 
State  concerned  shall  recognise  the  Decision  of  the  first  Member 
State.  However,  If  the  Member  State  concerned  considers  that  there 
are  serious  grounds  for  supposing  that  the  authorization  of  the 
medicinal  product  may  present  a  risk  to  public  health,  It  shall 
Inform  the  first  Member  State,  the  Committee  for  Proprietary 
Medicinal  Products  and  the  applicant  within  the  time  I lmlt  referred 
to  above,  stating  Its  reasons  In  detail,  and  apply  the  procedures 
laid  down  In  Chapter  I I I  of  Directive 75/319/EEC." - 125  -
6.  The  following  Article 7a  Is  Inserted: 
"Article 7a 
1.  With  effect  from  1  January  1996,  where  a  Member  State  Is  Informed  In 
accordance  with  point  11  of  the  second  paragraph  of  Article  4  that 
another  Member  State  has  authorized  a  medicinal  product  which  Is  the 
subject  of  an  appllcat lon  for  author lzat ion  In  the  Member  State 
concerned,  that  Member  State shall  forthwith  request  the  authorities 
of  the  Member  State  whIch  has  granted  the  authorIzatIon  of  the 
Member  State  whIch. has  granted  the  authorIzatIon  to  forward  to  It 
the  assessment  report  referred  to  In  the  second  paragraph  of 
Article  4b.  Within  90  days  of  the  receipt  of  the  assessment  report, 
the  competent  authorities  of  the  Member  State  concerned  shal 1 
recognise  the authorization granted  by  the other  Member  State. 
2.  Notwithstanding  paragraph  1,  If  the  Member  State concerned  considers 
that  there  are  serious  grounds  for  supposing  that  the  authorization 
of  the  medicinal  product  may  present  a  risk.  to  public  health,  It 
shall  Inform  the  Member  State  which  granted  the  lnlt lal 
authorization,  any  other  Member  States concerned  by  the  appl lcatlon, 
and  the  Committee  for  Proprietary  Medicinal  Products  and  the 
appl lcant  within  the  time  I lmlt  referred  to  In  paragraph  1,  stating 
Its  reasons  In  detal I,  and  apply  the  procedures  laid  down  in 
Chapter  I I I  of  Directive 75/319/EEC." - 126  -
7.  Article 9a  Is  replaced  by  the  following: 
"Article 9a 
After  an  authorization  has  been  Issued,  the  person  responsible  for 
pI acIng  the  product  on  the  market  must,  In  respect  of  the  methods  of 
production  and  control  provided  for  In  points  4  and  7  of  the  second 
paragraph  of  Article  4,  take  account  of  technical  and  scientific 
progress  and  Introduce  any  changes  that  may  be  required  to  enable  the 
medicinal  product  to  be  manufactured  and  checked  by  means  of  generally 
accepted  scIentIfIc  methods.  These  changes  must  be  accepted  by  the 
comptetent  authorities of  the  Member  State concerned. 
8.  Article  10  Is  replaced  by  the  following: 
"Article  10 
1.  Authorization  shal I  be  val ld  for  five  years  and  shal I  be  renewable 
for  five  year  periods,  on  application  by  the  holder  at  least  three 
months  before  the expiry date. 
2.  In  exceptional  circumstances,  and  following  consultation  with  the 
applicant,  an  authorization  may  be  granted  subject  to  such 
condItIons  as  appear  necessary  to  ensure  the  protect I  on  of  pub II c 
health,  Including  specific  obligations  to  conduct  further  studies 
following  the  granting  of  authorization  and  specific  obi lgatlons  In 
respect  of  the  reporting  of  adverse  reactions  to  the  medicinal 
product." - 127  -
Article  2 
In  Directive  75/318/EEC.  the  Committee  referred  to  In  Article  2b  Is  hereby 
renamed  "the Standing Committee  on  Medicinal  Products  for  Human  Use". - 128  -
Article  3 
Directive 75/319/EEC  Is  hereby  amended  as  follows 
1.  Chapter  I II  Is  replaced  by  the  following: 
"CHAPTER  I I I 
Committee  for  Proprietary Medicinal  Products 
Article 8 
1.  In  order  to  facilitate  the  adoption  of  common  Decisions  by  Member 
States on  the  authorization of  medicinal  products  for  human  use  on  the 
basis  of  the  scientific criteria of  Qual lty,  safety  and  efficacy,  and 
to  achieve  thereby  the  free  movement  of  medicinal  products,  within  the 
Community,  a  Committee  for  Proprietary  Medicinal  Products,  hereinafter 
referred  to  as  "the  Committee",  Is  hereby  set  up.  The  Committee  shall 
be  attached  to  the  European  Agency  for  the  Evaluation  of  Medicinal 
Products  established  by  Councl I  Regulation  (EEC)  ....  / .. ,(*) 
hereinafter  referred  to as  the  Agency. 
2.  In  addition  to  the  other  responslbl I ltles  conferred  upon  It  by 
Community  law,  the Committee  shal I  examine  any  Question  relating  to  the 
grant,  amendment,  suspension  or  withdrawal  of  authorization  for  a 
medicinal  product  which  Is  submitted  to  It  In  accordance  with  the 
provisions of  this Directive. 
3.  The  Committee  shal I  adopt  Its own  rules of  procedure. - 129  -
Article 9 
1.  In  order  to obtain  the  recognition  In  one  or  more  of  the  Member  States 
of  an  authorization  Issued  by  a· Member  State  In  accordance  with 
Article 3  of  Directive 65/65/EEC,  the  holder  of  the  authorization  shal I 
submit  an  appl lcatlon  to  the  competent  authorities of  the  Member  State 
or  Member  States  concerned,  together  with  the  Information  and 
particulars 
65/65/EEC. 
referred  to  In  Articles  4,  4a  and  4b  of  Directive 
He  shal 1  testify  to  the  Identity  of  the  dossier  with  that 
accepted  by  the  first  Member  State,  or  shall  Identify  any  additions  or 
modifications  It  may  contain.  In  the  latter  case.  he  shal I  certify that 
the  summary  of  product  characterIstIcs  proposed  by  h lm  In  accordance 
with  Article 4a  of  Directive 65/65/EEC  Is  Identical  to  that  accepted  by 
the  first  Member  State  In  accordance  with  Article  4b  of  Directive 
65/65/EEC.  Moreover,  he  shall  certify  that  all  the  dossiers  filed  as 
part  of  this procedure  are  Identical. 
2.  The  holder  of  the marketing  authorization shal I  notify  the  Committee  of 
thIs  app II cat I  on,  Inform  It  of  the  Member  States  concerned  and  of  the 
dates  of  submission  of  the  application  and  send  It  a  copy  of  the 
authorization granted  by  the  first  Member  State.  He  shal I  also send  the 
Committee  copies  of  any  marketing  authorization  which  may  have  been 
granted  by  the other  Member  States  In  respect  of  the  product  concerned, 
and  shall  Indicate  whether'  any  appllcat I  on  for  aulhor lzat ion  Is 
currently under  consideration  In  any  Member  State. - 130  -
3.  The  holder  of  the  authorization  shall  also  Inform  the  Member  State 
which  granted  the  Initial  authorization  that  an  application  Is  being 
made  In  accordance  with  this  Directive  and  shall  notify  It  of  any 
additions  to  the  original  dossier;  that  Member  State  may  require  the 
appl lcant  to  provide  It  with  alI  the  particulars  and  documents 
necessary  to enable  It to  check  the  Identity of  the  dossiers fl led  with 
the  dossier  on  which  It  took  Its  Decision.  In  addition  that  Member 
State  shal I  forward  to  the  Member  State  or  Member  States  concerned  by 
the  appl lcatlon  a  copy  of  the  assessment  report  establ lshed  In 
accordance  with  the  second  paragraph  of  Article  4b  of  Directive 
65/65/EEC. 
4.  Each  Member  State  concerned  shal I  recognise  the  marketing  authorization 
granted  by  the  first  Member  State  within  90  days  of  receipt  of  the 
application.  It shall  Inform  the  Member  State  which  granted  the  Initial 
author lzat lon,  the  other  Member  States  concerned  by  the  appllcat lon, 
the  Committee,  and  the  person  responsible  for  marketing  thereof. 
Article  10 
1.  Notwithstanding Article 9(4),  where  a  Member  State  considers  that  there 
are  serious  grounds  for  supposing  that  the  authorization  of  the 
medicinal  product  concerned  may  present  a  risk  to  public  health,  It 
shall  forthwith  Inform  the  applicant,  the  Member  State  which  granted 
the  Initial  authorization,  any  other  Member  States  concerned  by  the 
appl lcatlon  and  the  Committee.  The  Member  State  shall  state  Its reasons 
In  detail  and  shall  Indicate  what  action  may  be  necessary  to  correct 
any  defect  In  the  appl lcatlon. - 131  -
2.  A  II  the  Member  States  concerned  sha II  use  theIr  best  endeavours  to 
.reach  agreement  on  the  action  to  be  taken  In  respect  of  the 
appl !cation.  They  shall  provide  the  appl lcant  with  the  posslbll tty  to 
make  his  point  of  view  known  orally or  In  writing.  However,  If  within 
60  days  of  the  expiry  of  the  time  limit  referred  to  In  Article  9  (4), 
the  Member  States  have  not  been  ab I  e  to  reach  agreement  they  sha II 
forthwith  refer  the  matter  to  the  Committee  for  the  application  of  the 
procedure  laid  down  In  Article  13. 
3.  Within  the  time  limit  referred  to  In  paragraph  2,  the  Member  States 
concerned  shal I  provide  the  Committee  with  a  detailed  statement  of  the 
matters  on  which  they  have  been  unable  to  reach  agreement  and  the 
reasons  for  theIr  dIsagreement.  A  copy  of  thIs  InformatIon  sha I I  be 
provided  to  the  applicant. 
4.  As  soon  as  he  Is  Informed  that  the  matter  has  been  referred  to  the 
Committee,  the  applicant  shall  forthwith  forward  to  the  Committee  a 
copy  of  the  Information  and  particulars referred  to  In  Article 9  (1). 
Article  11 
If  several  applications  submitted  In  accordance  with  Articles  4  and  4a  of 
Directive  65/65/EEC  have  been  made  for  marketing  authorization  for  a 
particular  medicinal  product,  and  Member  States  have  adopted  divergent 
Decisions  concerning  the  authorization  of  the  medicinal  product,  or  Its 
suspension  or  withdrawal  from  the  market,  any  Member  State,  or  the 
Commission,  or  the  person  responsible  for  marketing  may  refer  the  matter  to 
the Committee  for  appl lcatlon of  the  procedure  laid down  In  Article  13. - 132  -
The  Member  State  concerned,  the  person  responsible  for  marketing  or  the 
Commission  shall  clearly  Identify  the  question  which  Is  referred  to  the 
Committee  for  consideration  and,  If  necessary,  shal I  Inform  the  person 
responsible  for  marketing. 
The  Member  States  and  the  person  responsible  for  marketing  shal I  forward  to 
the  Committee  alI  available  Information  relating  to  the matter  In  question. 
Article  12 
The  Member  States  or  the  Commission  may,  In  specific  cases  where  the 
Interests  of  the  Community  are  Involved,  refer  the  matter  to  the  Committee 
for  the  appl lcatlon of  the  procedure  laid  down  In  Article  13  before  reaching 
a  Decision  on  a  request  for  a  marketing  authorization  or  on  the  suspension 
or  revocation of  an  authorization,  or  on  any  other  amendment  to  the  terms  of 
a  marketing  authorization  which  appears  necessary,  In  particular  to  take 
account  of  the  Information  collected  In  accordance  with  Chapter  Va  of  this 
Directive. 
The  Member  State  concerned  or  the  Commission  shall  clearly  Identify  the 
question  which  Is  referred  to  the  Committee  for  consideration  and  shall 
Inform  the  person  responsible  for  marketing. 
The  Member  States  and  the  person  responsible  for  marketing  shal I  forward  to 
the  Committee  alI  aval lable  Information  relating  to  the  matter  In  question. - 133  -
Article 13 
1.  When  reference  Is  made  to  the  procedure  described  In  this Article,  the 
Committee  shall  consider  the  matter  concerned  and  Issue  a  Reasoned 
Opinion within  90  days  of  the  date on  which  the matter  was  referred  to 
lt. 
In  case  of  urgency,  on  a  proposal  from  Its  Chairman,  the  Committee  may 
agree  to  Impose  a  shorter  deadl lne. 
2.  In  order  to  consider  the  matter,  the  Committee  may  appoint  one  of  Its 
Members  to act  as  rapporteur.  The  Committee  may  also appoint  Individual 
experts  to ·advise  It  on  specific  questions.  When  appointing  experts, 
the  Committee  shall  define  their  tasks  and  specify  the  time  limit  for 
the  completion of  these  tasks. 
3.  In  the  cases  referred  to  in  Article  10  and  11,  before  Issuing  Its 
opinion,  the  Committee  shal I  provide  the  person  responsible  for 
marketing  with  an  opporturl~y to  present  ~rltten or  oral  explanations. 
In  the  case  referred  to  In  Article  12,  the  person  responsible  ~for 
placing  the  medicinal  product  on  the  market  may  be  asked  to  explain 
himself  orally or  In  writing. 
If  It  considers  It  appropriate;  the  Committee  may  Invite  any  other 
person  to provide  Information  relating  to  the matter  before  lt. 
The  Committee·  may  suspend  the  time  limit  referred  to  In  paragraph  1  In 
order  to  allow  the  person  responsible  for  marketing  to  prepare 
explanations. - 134  -
4.  Where  the opinion of  the  Committee  Is  that 
the  appl lcatlon  does  not  satisfy  the  criteria  for  authorization  set 
out  In  this Directive,  or 
the  summary  of  product  characteristics  proposed  by  the  applicant  In 
accordance with Article 4a  of  Directive 65/65/EEC  should  be  amended, 
or 
the  label I lng  or  package  leaflet of  the  product  Is  not  In  compl  lance 
with  Dlreclve  ..  / ...  /EEC,  or 
the  authorization should granted subject  to conditions,  or 
an  existing  marketing  authorization  should  be  suspended  amended  or 
withdrawn; 
the  Agency  shal I  forthwith  Inform  the  person  responsible  for  marketing. 
Within  15  days  of  the  receipt  of  the  opinion,  the  person  responsible 
for  marketing  may  provide  written  notice  to  the  Agency  that  he  wishes 
to  appeal.  Within  60  days  of  the  receipt  of  the  grounds  for  appeal, 
the  Committee  shal I  consider  whether  Its opinion  should  be  revised,  and 
the  reasons  for  the  conclusions  reached  on  the  appeal  shal I  be  annexed 
to  the  assessment  report  referred  to  In  paragraph  5. 
5.  w  1  thIn  30  days  of  Its  adopt I  on,  the  Agency  sha I I  forward  the  f Ina I 
opinion  of  the  Committee  to·the  Commission,  the  Member  States  and  the 
person  responsible  for  marketing  together  with  a  report,  describing  the 
assessment  of  the  medicinal  product  and  the  reasons  for  Its 
conclusions. 
In  the  event  of  an  opinion  In  favour  of  granting  or. maintaining  an 
authorization  to  market  the  medicinal  product  concerned,  the  following 
documents  shall  be  annexed  to  the opinion  : 
a)  a  draft  summary  of  the  product  characteristics,  as  referred  to  In 
Article  4a  of  Directive 65/65/EEC; - 135  -
b)  detal Is of  any  conditions or  restrictions which  should  be  Imposed  on 
the  supp I  y  or  use  of  the  medIc Ina I  product  concerned,  Inc I  uded  the 
conditions  under  which  the  medicinal  product  may  be  made  aval lable 
to  patients,  having  regard  to  the  criteria  laid  down  In  Directive 
..  / ...  /EEC  concerning  the  legal  status  for  the  supply  of  medicinal 
products  for  human  use; 
c)  the  draft  text  of  the  label I lng  and  package  leaflet,  proposed  by  the 
applicant  presented  In  accordance  with  Directive  ..  / ...  / ..  on  the 
Iabeii lng  of  medicinal  products  for  human  use  and  on  package 
leaflets. 
Article  14 
1.  Within  30  days  of  the  receipt  of  the  opinion  of  the  Committee,  the 
Commission  shal I  prepare  a  draft  of  the  Decision  to be  taken  In  respect 
of  the  appllcat lon  taking  Into  account  the  object lves  of  Community 
policies  and  considering  all  relevant  lnfqrmatlon.  In  the  event  of  a 
draft  Decision  which  envisages  the  granting  of  a  marketing 
authorization,  the  documents  referred  to  In  points  (a),  {b)  and  (c)  of 
Article  13(5)  shal I  be  annexed.  The  Commission  shal I  transmit  the  draft 
Decision  to  the  Member  States and  to  the  appl lcant. 
The  Commission  shal I  explain  In  detal I  the  reasons  for  any  differences 
between  the draft  Decision  and  the opinion of  the Committee. 
2.  The  Commission  shal I  adopt  the  Decision  to  be  taken  In  respect  of  the 
application unless,  within  30  days,  It  has  received  a  reasoned  request 
from  a  Member  State  to  reconsider  the  matter.  The  Member  State 
concerned  shal I  also  transmit  a  copy  of  Its  request  to  the other  Member 
States and  the  appl lcant  within  the  same  time  I lmlt. - 136  -
3.  Within  the  time  limit  referred  to  In  paragraph  2,  the  applicant  may 
submit  written observations  on  the  draft  Decision  for  consideration  by 
the  Commission. 
4.  The  Commission  shal I  examine  any  reasoned  request  received  In 
accordance  with  paragraph  2,  In  consultation with  the  Agency,  and  after 
consideration of  any  further  observations  submitted  by  the  appl lcant. 
If  the  Commission  considers  that  the  request  raises  questions  of  a 
scientific  or  technical  nature  requiring  further  examination,  It  may 
remit  the  matter  to  the  Agency.  In  this  case  the  Committee  shal I  give 
a  second opinion within  a  time  I lmlt  of  60  days.  Within  30  days  of  the 
receipt  of  the'oplnlon,  the  Commission  shall  adopt  the  Decision  to  be 
taken  In  respect  of  the  appl lcatlon. 
Otherwise  the  Decision  shal I  be  taken  In  accordance  with  the  procedure 
laid  down  In  Article  2b  and  2c  of  Directive 75/318/EEC. 
5.  A Decision  adopted  In  accordance  with  this  Article  shal I  be  addressed 
to  the  Member  States  concerned  by  the  matter  and  to  the  person 
responsible  for  marketing.  The  Member  States  shall  either  grant  or 
withdraw  marketing  authorization,  or  make  any  adjustment  to  the  terms 
of  a  marketing  authorization  which  may  be  necessary  to  comply  with  the 
Decision  within  30  days  of  Its  notification.  They  shall  Inform  the 
Commission  and  the  Committee  thereof. - 137  -
Article  15 
Any  appl lcatlon  by  the  person  responsible  for  marKeting  to  amend  the  terms 
of  a  marKeting  authorization  which  has  granted  In  accordance  with  the 
provisions of  this Chapter  shall  be  submitted  to alI  the  Member  States which 
have  previously  authorized  the medicinal  product  concerned. 
The  Agency  sha II,  In  consu I tat I  on  wIth  the  CommIssIon,  adopt  approprIate 
arrangements  for  the  examination  by  the  Committee  of  amendments  or 
variations  to  a  marKeting  authorization which  has  been  granted  In  accordance 
with  the  provisions of  this Chapter. 
The  procedures  I  aId  down  In  Art I  c I  es  13  and  14  sha I I  app I  y  by  ana I  ogy  to 
variations and  amendments  of  marketing  authorizations. 
Article  15a 
1.  Where  a  Member  State  consIders  that  the  amendment  of  the  terms  of  a 
marKeting  authorization  which  has  been  granted  In  accordance  with  the 
provisions  of  this  Chapter  or  Its  suspension  or  withdrawal  Is 
necessary,  the  Member  State  concerned  shal I  forthwith  refer  the  matter 
to  the  CommIt tee  for  the  app I I  cat I  on  of  the  procedures  I  aId  down  In 
Articles  13  and  14. 
2.  In  exceptional  cases,  where  action  Is  urgently  necessary  to protect 
publ lc  health,  untl I  a  definitive  decision  Is  adopted,  a  Member  State 
may  suspend  the  use  of  the  medicinal  product  concerned  on  Its 
territory.  It  shall  Inform  the  Commission  no  later  than  the  following 
worKing  day  of  the~reasons for  Its action. - 138  -
Article  15b 
Articles  15  and  15a  shall  apply  by  analogy  to medicinal  products  authorized 
by  Member  States  following  an  opinion  of  the  Committee  given  In  accordance 
with  Article 4  of  Directive 87/22/EEC  before  1  January  1993. 
Article  15c 
1.  The  Agency  shall  publish  an  annual  report  on  the  operation  of  the 
procedures  laid  down  In  this Chapter. 
2.  Within  six  years  of  the  date  referred  to  In  the  first  sub-paragraph  of 
Article  4  (1),  the  Commission  shall  publish  a  datal led  review  of  the 
operation of  the  procedures  laid  down  In  this chapter  and  shal I  propose 
any  amendments  which  may  be  necessary  to  Improve  the operation of  these 
procedures. 
The  Councl I  shall  decide  on  the  Commission  proposal  within  one  year  of 
Its submission. 
(*)  OJ  No  L 
II - 139  -
2.  The  third sub-paragraph of  paragraph  1 of  Article  22  Is  replaced  by  the 
fo I I  owl ng: 
"In  the  case of  medicinal  products  Imported  from  a  third country, ·where 
appropriate  arrangements  have  been  made  by  the  Community  with  the 
exporting  country. to  ensure  that  the  manufacturer  of  the  medicinal 
product  appl les  standards  of  good  manufacturing  practice  at  least 
equivalent  to  those  laid  down  by  the  Community  and  to  ensure  that  the 
controls  referred  to  under  (b)  have  been  carried  out  In  the  exporting 
country,  the  qualified  person  may  be  relieved  of  responsibility  for 
those  controls." 
3.  The  following  Chapter  Va  Is  Inserted after Article  29: 
"CHAPTER  Va 
Pharmacovlgllance 
Article 29a 
In  order  to  ensure  the  adopt I  on  of  approprIate  regu I  a tory  decIsIons 
concerning  the  continued authorization of  medicinal  products within  the 
Community,  having  regard  to  Information  obtained  about  adverse 
reactions  to  medicinal  products  under  practical  conditions  of  use,  the 
Membet  States shall  establIsh a  pharmacovlgllance  system  for  collecting 
Information  about  adverse  reactions  to  medicinal  products  In  human 
beings  and  for  the scientific evaluation of  such  Information. 
,. - 140  -
Article  29b 
For  the  purpose of  this Directive,  the  following  definitions shal I  apply: 
-"adverse  reaction"  shall  mean  a  reaction  which  Is  noxious  and  unintended 
and  which  occurs  at  doses  normally  used  In  man  for  the  prophylaxis, 
diagnosis  or  therapy  of  disease  or  for  the  modification  of  physiological 
function. 
- "serious  adverse  reaction"  shal I  mean  an  adverse  reaction  which  Is  fatal, 
1 lfe-threatenlng,  dlsabl lng,  Incapacitating,  or  which  results  In 
hospital lsatlon or  prolonged  hospitalisation. 
Article  29c 
The  person  responsible  for  marketing  shal I  have  permanently  and  continuously 
at  hIs  d I  sposa I  a  person  respons I  b I  e  for  pharmacov I  g II ance.  ThIs  person 
shall  be  responsible  for  : 
a)  the  establ lshment  and  maintenance  of  a  system  which  ensures  that1 
Information  about  alI  adverse  reactions  which  are  reported  to  the 
personnel  of  the  company,  Including  Its  sales  personnel  and  medical 
representatives,  Is  collected and  collated at  a  single point; 
b)  the  preparation  and  submission  to  the  competent  authorities  of  the 
reports  referred  to  In  Article  29d,  In  such  form  as  may  be  laid  down  by 
those  authorities. - 141  -
c)  ensuring  that  any  request  from  the  competent  authority  for  the 
provision of  additional  Information  necessary  for  the evaluation of  the 
benefits  and  risks  of  a  medicinal  product  Is  answered  fully  and 
promptly,  Including  the  provision  of  Information  about  the  volume  of 
sales  or  prescriptions  for  the  medicinal  product  concerned,  where 
relevant. 
Article  29d 
1.  The  person  responsible  for  marketing  shall  be  required  to  record  and  to 
report  alI  suspected  serious  adverse  reactions which  are  brought  to his 
attention  by  a  qualified  health  care  professional  to  the  competent 
authorities within  15  days  of  their  receipt. 
2.  In  addition,  the  person  responsible  for  marketing  shall  be  required  to 
maintain  detailed  records  of  all  other  adverse  reactions  which  are 
reported  to  him  by  a  qual If led  health  care  professional.  Unless  other 
requIrements  have  been  I  aId  down  as  a  condItIon  of  the  grant 1  ng  of 
authorization,  these  records  shal I  be  submitted  to  the  competent 
authorities  Immediately  upon  request  or  at  least  every  six  months 
during  the  first  two  years  following  authorization,  and  once  a  year  for 
the  following  three  years.  Thereafter,  the  records  shall  be  submitted 
at  five  yearly  Intervals  together  with  the  application  for  renewal  of 
the  authorization,  or  Immediately  upon  request. - 142  -
Article  29e 
The  ~ember  States  shall  take  alI  appropriate  measures  to  encourage  doctors 
and  other  hea I th  care  profess lona Is  to  report  adverse  react Ions  to  the 
competent  authority. 
The  ~ember States may  Impose  specific  requirements on  medical  practitioners, 
In  particular  In  respect  of  the  reporting  of  serious  or  unexpected  adverse 
reactions,  or  where  such  reporting  Is  a  condition  of  the  marketing 
authorization. 
Article  29f 
The  ~ember States shall  ensure  that  reports of  serious adverse  reactions  are 
brought  to  the  at tent I  on  of  the  Agency  and  the  person  respons I  b I  e  for 
marketing within  15  days  of  their  receipt. 
Article  29g 
In  order  to  facl I ltate  the  exchange  of  Information  about  pharmacovlgl lance 
within  the  Community,  the  Agency  shal I,  In  consultation  with  Member  States, 
the  Commission  and  Interested  parties,  draw  up  detailed  guidance  on  the 
col lectlon,  verification and  presentation of  adverse  reaction  reports. - 143  -
Article  29h 
Where  as  a  result  of  the  evaluation  of  adverse  reaction  reports,  a  Member 
State  Is  considering  amending  the  terms  of  a  marketing  authorization  or  Its 
suspensions or  withdrawal,  It  shal I  forthwith  Inform  the Agency. 
In  case of  urgency,  the  Member  State  concerned  may  suspend  the  marketing  of 
a  medicinal  product,  provided  the  Agency  Is  Informed  at  the  latest  on  the 
following  working  day." 
Article  4 
Member  States  shal I  take  alI  appropriate  measures  to  comply  with  the 
provisions  of  this  Directive,  with  the  exception  of  Article  1  (6),  before 
1  January  1993.  They  shal I  forthwith  Inform  the  Commission  thereof. 
Member  States  shall  take  all  appropriate  measures  to  comply  with 
Article  1  (6)  of  this  Directive  before  1  January  1996.  They  shal I  forthwith 
Inform  the  Commission  thereof. 
When  Member  States  adopt  these  provisions,  these  shall  contain  a  reference 
to  this  Directive  or  shall  be  accompanied  by  such  reference  at  the  time  of 
their  official  publ lcatlon.  The  procedure  for  such  reference  shal I  be 
adopted  by  Member  States. 
Article  5 
This  Directive  Is  addressed  to  the  Member  States. 
Done  at  Brussels  For  the  Counc I I .• 
- 145  -
Proposal  for  a 
CQUNCIL  DIRECTIVE 
amending  Directives 81/851/EEC  and  81/852/EEC 
In  respect  of  veterinary medicinal  products - 147  -
Proposa I  for  a 
COUNCIL  PIRECTIYE 
amending Directives 81/851/EEC  and  81/852/EEC 
In  respect  of  veterinary medicinal  products 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to  the  Treaty  establishing  the  European  Economic  Community,  and 
In  particular Article  100a  thereof; 
Having  regard  to  the  proposal  from  the Commlsslon<1>, 
In  cooperation with  the  European  Parllament<2>, 
Having  regard  to  the opinion of  the  Economic  and  Social  Commlttee<3>, 
Whereas  It  Is  Important  to  adopt  measures  with  the  aim  of  progressively 
establ lshlng  the  Internal  market  over  a  period  expiring  on  31  December  1992; 
whereas  the  Internal  market  shal I  comprise  an  area  without  Internal  frontiers 
In  which  the  free  movement  of  goods,  persons,  services  and  capital  Is  ensured; 
Whereas  despite  the  progress  achieved  by  Directive  81/851/EEC  of 
relating  to  veterinary  medicinal  products<4>,  as 
..  / ...  /EEC  of  •.••..••.  (5)  further  measures  are  necessary  to  abolish  the 
remaining- barriers  to  the  free  movement  of  veterinary  medicinal  products 
within  the Community; 
( 1) 
(2) 
(3) 
(4)  OJ  No  L 317,  6.11.1981,  p.  1. 
(5) - 148  -
Whereas,  with  the  exception  of  those  veterinary  medicinal  products  which  are 
subject  to  the  centralized  Community  authorization  procedure  established  by 
Counc I I  Regu I at I  on  (EEC)  ....  I .. ,  of  ..  I .. ./..  I  ay I  ng  down  CommunIty 
procedures  for  the  authorization  and  supervision  of  medicinal  products  for 
human  and  veterinary use  and  establ lshlng  a  European  Agency  for  the  Evaluation 
of  Medicinal  Products<6>,  an  authorization  to  place  a  veterinary  medicinal 
product  on  the  market  In  one  Memb~r State ought  In  principle  to  be  recognized 
by  the  competent  authorItIes  of  the  other  Member  States  un I  ess  there  are 
serious  grounds  for  supposing  that  the  authorization  of  the  veterinary 
medicinal  product  concerned  may  present  a  risk  to  human  or  animal  health,  or 
to  the  environment;  whereas,  In  the  event  of  a  disagreement  between  Member 
States about  the  Qual lty,  the safety or  the efficacy of  a  veterinary medicinal 
product,  a  scientific  evaluation  of  the  matter  should  be  undertaken  by  the 
Committee  for  Veterinary  Medicinal  Products  attached  to  the  European  Agency 
for  the  Evaluation of  Medicinal  Products,  leading  to  a  s_lngle  decision  on  the 
area  of  disagreement,  binding  on  the  Member  States  concerned;  whereas  this 
Decision  should  be  adopted  by  a  rapid  procedure  ensuring  close  cooperation 
between  the  Commission  and  the  Member  States,  In  particular  through  the 
Standing  Committee  on  Veterinary  Medicinal  Products  created  by  Article  2b  of 
Councl I  Directive  8118521EEC  of  28  September  1981  on  the  approximation  of  the 
laws  of  Member  States  relating  to  analytical,  pharmacotoxlcologlcal  and 
clinical  standards  and  protocols  In  respect  of  the  testing  of·  veterinary 
medicinal  products<7>,  as  last  amended  by  Directive 871201EEc<8>; 
(6) 
(7)  OJ  No  L  317,  6.11.81,  p.  16. 
(8)  OJ  No  L 15,  17.1.87,  p.  34. - 149  -
Whereas  In  order  better  to  protect  human  an  an I  ma I  hea I th  and  avoId  any 
unnecessary  dupl lcatlon  of  effort  during  the  examination  of  appl lcatlons  for 
authorization  to  place  veterinary  medicinal. products  on  the  market,  Member 
States  should  systematically  prepare  assessment  .reports  .In  respect  of  each 
veterinary  medicinal  product  which  Is  authorized  by  them,  and  exchange  the 
reports  upon  reQuest;  whereas,  furthermore,  a  Member  State  should  be  able  to 
suspend  the  examination  of  an  application  for  authorization  to place  a 
veterinary  medicinal  product  on  the  market  which  Is  currently  under  active 
consideration  In  another  Member  State  with  a  view  to  recognizing  the  Decision 
reached  by  the  latter Member  State; 
Whereas  following  the  establ lshment  of  the  Internal  market,  specific  control~ 
to  guarantee  the  Qual lty of  veterinary  medicinal  products  Imported  from  third 
countries can only  be  waived  If  appropriate  arrangements  have  been  made  by  the 
Community  to  ensure  that  the  necessary  controls  are  carried  out  In  the 
exporting  country; 
Whereas  It  Is  desirable  to  codify  and  Improve  the  cooperation  and  exchange  of 
Information  between  Member  States  relating  to  the  supervision  of  veterinary 
medicinal  products  and  In  particular  the monitoring of  adverse  reactions under 
practical  conditions of  use  through  the  national  pharmacovigl lance  centres; - 150  -
Whereas  In  order  to  Improve  the  protection of  publ lc  health  It  Is  necessary  to 
specify  that  foodstuffs  for  human  consumption  may  not  be  taken  from  animals 
which  have  been  used  In  cl lnlcal  trials  of  veterinary  medicinal  products 
unless  a  provisional  maximum  residue  level  has  been  laid  down  for  residues  of 
the  veterinary  medicinal  product  concerned  In  accordance  with  the  provisions 
of  Council  Regulation  (EEC)  2377/90  laying  down  a  Communlty,procedure  for  the 
establ lshment  of  maximum  residue  levels  for  residues  of  veterinary  medicinal 
products<9>, 
HAS  ADOPTED  THIS  DIRECTIVE 
(9)  OJ  No  L 224,  18.8.1990,  p.  1. - 151  -
Article 
Directive 81/851/EEC  Is  hereby  amended  as  follows 
1.  In  Article  4.  the  first  sub-paragraph  of  paragraph  1  Is  replaced  by  the 
following  : 
"No  veterinary medicinal  product  may  be  placed  on  the  market  of  ~Member 
State  unless  an  authorization  has  been  Issued  by  the  competent  authority 
of  that  Member  State or  by  the  Community." 
2.  In  Article  4.  the  following  sub-paragraph  Is  Inserted  at  the  end  of 
paragraph  2. 
"The  Member  States  sha II  not  permIt  foodstuffs  for  human  consumptIon  to 
be  taken  from  test  animals  unless  a  provisional  maximum  residue  level  has 
been  established ·by  the  Community  In  accordance  with  the  provisions  of 
Regulation  (EEC)  2377/90  (*)  and  an  appropriate  withdrawal  period  has 
been  estab II  shed  to  ensure  that  thIs  I eve I  w I I I  not  be  exceeded  In  trie 
foodstuffs. 
(*)  OJ  No  L  224.  18.8.1990.  p.  1." - 152  -
3.  In  the  second  paragraph  of  Article  5,  point  13  Is  replaced  by  the 
following  : 
13.  COP,Y  of  any  authorization  obtained  In  another  Member  State  or  In  a 
third  country  to  place  the  relevant  veterinary  medicinal  product  on 
the  market,  together  wIth  a  II st  of  those  Member  States  In  whIch  an 
appl lcatlon  for  authorization  submitted  In  accordance  with  this 
Directive  Is  under  examination  and  copies  of  the  summary  of  product 
character 1st lcs  proposed  by  the  applicant  In  accordance  wl th 
Article 5a  or  approved  by  the  competent  authorities  In  accordance  with 
Article 5b,  as  appropriate,  In  respect  of  each  Member  State concerned. 
Datal Is  of  any  Decision  to  refuse  authorization,  whether  In  the 
Community  or  a  third  country  and  the  reasons  for  that  Decision. 
This  Information  shal I  be  updated  at  regular  Intervals." - 153  -
4.  Article  5b  Is  replaced  by  the  following 
"Article  Sb 
When  the marketing  authorization  referred  to  In  Article  4  (1)  Is  Issued,  the 
person  responsible  for  placing  that  product  on  the  ma~ket shal I  be  Informed, 
by  the  competent  authorities  of  the  Member  state  concerned,  of  the  summary 
of  the  product  characteristics  as  approved  by  them.  The  competent 
authorities shal I  take  alI  necessary  measures  to ensure  that  the  Information 
given  In  the  summary  Is  In  conformity  with  that  accepted  when  the  marketing 
authorization  Is  Issued  or  subsequently.  The  competent  authorities  shall 
forthwl th  forward  a  copy  of  the  summary  to  the  European  Agency  for  the 
Evaluation  of  Medicinal  Products  established  by  Council  Regulation 
CEEC) ....  / ....  C*) 
Furthermore,  the  competent  auth·or It les  sha II  draw  up  an  assessment  report 
and  comments  on  the  dossier  as  regards  the  results  of  the  analytical, 
pharmaco-toxlcologlcal  tests  and  the  cl lnlcal  trials  of  the  veterinary 
medicinal  product  concerned.  The  assessment  report  shal I  be  updated 
whenever  new  Information  becomes  available  which  Is  of  importance  for  the 
evaluation  of  the  quality,  safety  or  efficacy  of  the  medicinal  product 
concerned. 
(*)  II - 154  -
5.  Article 8  Is  replaced  by  the  following 
"Article 8 
1.  Member  States  shall  take  all  appropr late  measures  to  ensure  that  the 
procedure  for  granting  an  authorization  to  place  a  medicinal  product  on 
the  market  Is  completed  within  210  days  of  the  date  of  submitting  the 
app I I  cat I  on . 
2.  Where  a  Member  State  notes  that  an  appl lcatlon  for  authorization 
submitted  after  1  January  1993  Is  already  under  active  examination  in 
another  Member  State,  the  former  Member  State  may  decide  to  suspend  the 
detailed examination  of  the  application  In  order  to  await  the  assessment 
report  prepared  by  the  first  Member  State  In  accordance  with  Article  5b." 
The  Member  State  concerned  sha II 
appl lcant  of  Its  Decision  to 
appl lcatlon  In  question. 
inform  the  first  Member  State  and  the 
suspend  detal led  examination  of  the 
As  soon  as  It  has  completed  the  examination  of  the  application  and 
reached  a  decision,  the  first  Member  State  shall  forward  a  copy  of  Its 
assessment  report  to  the  Member  State concerned. 
Within  the  90  days  of  the  receipt  of  the  assessment  report,  the  Member 
State  concerned  shall  recognise  the  decision  of  the  first  Member  State. 
However,  If  the  Member  State  concerned  consIders  that  there  are  serious 
grounds  for  supposing  that  the  authorization of  the  veterinary  medicinal 
product  may  present  a  risk  to  human  or  animal  health  or  the  environment, 
It  sha II  Inform  the  fIrst  Member  State,  the  CommIt tee  for  Vater I  nary 
Medicinal  Products  and  the  applicant  within  the  time  limit  referred  to 
above,  stating  Its  reasons  In  detal I,  and  apply  the  procedures  laid  down 
lnChapter  IV." - 155  -
6.  The  following Article Sa  Is  Inserted 
"Article Sa 
1.  With  effect  from  1  January  1996,  where  a  Member  State  Is  Informed  In 
accordahce  with  point  13 of  the  second  paragraph  of Arlcle  5  that  another  . 
Member  State  has  authorized  a  veterinary  medicinal  product  which  Is  the 
subject  of  an  application  for  authorization  In  the  Member  State 
concerned,  that  Member  State  shall  forthwith  request  the  authorities  of 
the  Member  State which  has  granted  the  authorization  to  forward  to  It  the 
assessment  report  referred  to  In  the  second  paragraph  of  Art lcle  5b. 
Within  90  days  of  the  receipt  of  the  assessment  report,  the  competent 
authorItIes  of  the  Member  State  concerned  sha II  recognise  the 
authorization granted  by  the  other  Member  State. 
2.  Notwithstanding  paragraph  1,  If  the  Member  State  concerned  considers  that 
there  are  ser lous  grounds  for  supposIng  that  the  authorIzation  of  the 
veterinary medicinal  product  may  present  a  risk  to  human  or  animal  health 
or  the  envIronment,  It  sha II  Inform  the  Member  State  wh.l ch  granted  the 
In It  I a I  authorIzation,  any  other  Member  States  concerned  by·  the 
appl lcatlon  and  the  Committee  for  Veterinary  Medicinal  Products  and  the 
appl lcant  within  the  time  I lmlt  referred  to  In  paragraph  1,  stating  Its 
reasons  In  detail,  and  apply  the  procedures  laid  down  In  Chapter  IV  of 
this Directive." - 156  -
7.  In  paragraph  1  of  Article  14,  the  first  sub-parapraph  Is  replaced  by  the 
following  : 
"After  an  authorization  has  been  Issued,  the  person  responsible  for  placing 
the  product  on  the  market  must,  In  respect  of  the  methods  of  production  and 
control  provided  for  In  points  4  and  9  of  the  second  paragraph  of 
Article  5,  take  account  of  technical  and  scientific  progress  and  Introduce 
any  changes  that  may  be  required  to  enable  the  veterinary  medicinal  product 
to  be  manufactured  and  checked  by  means  of  genera I I  y  accepted  scIentIfIc 
methods.  These  changes  must  be  accepted  by  the  competent  authorities of  the 
Member  States concerned. 
8.  Article  15  Is  replaced  by  the  following 
"Article  15 
1.  Authorization  shall  be  valid  for  five  years  and  shal I  be  renewable  for 
five  year  periods,  on  application  by  the  holder  at  least  three  months 
before  the  expiry date. 
2.  In  exceptional  circumstances,  and  following  consultation  with  the 
appl lcant,  an  authorization  may  be  granted  subject  to  such  condl~ions as 
appear  necessary  to  ensure  the  protection  of  human  and  animal  health  or 
the  environment,  Including  specific  obi lgatlons  to  conduct  further 
studies  following  the  granting  of  authorization  and  specific  obi lgatlons 
In  respect  of  the  reporting  of  adverse  reactions  to  the  medicinal 
product." - 157  -
9.  Chapter  IV  Is  replaced  by  the  following 
"CHAPTER  IV 
Committee  for  Veterinary Medicinal  Products 
Article  16 
1.  In  order  to  facilitate  the  adopt lon  of  common  Decisions  by  Member  States 
on  the  authorization of  veterinary medicinal  products on  the basis of  the 
scientific  crltlerla  of  quality,  safety  and  efficacy,  and  to  achieve 
thereby  the  free  movement  of  veterinary  medicinal  products  within  the 
Community,  a  Committee  for  Veterinary  Medicinal  Products,  hereinafter 
referred  to  as  "the  Committee",  Is  hereby  set  up.  The  Committee  shall 
consist  of  representatives  of  the  Member  States  and  of  the  Commission. 
The  Committee  shall  be  attached  to  the  European  Agency  for  the  Evaluation 
of  Medicinal  Products  establ lshed  by  Councl I  Regulation  ..  / ...  /EEC, 
hereafter  referred  to as  the  Agency. 
2.  In  addition  to  the  other  responsibilities  conferred  upon  It  by  Community 
law,  the  Committee  shall  examine  any  question  relating  to  the  grant, 
amendment,  suspensIon  or  wl thdrawa I  of  authorIzation  for  a  veterInary 
medicinal  product  which  Is  submitted  to  It  In  accordance  with  the 
provisions of  this Directive. 
3.  The  Committee  shall  adopt  Its own  rules of  procedure. - 1S8  -
Article  17 
1.  In  or~er  to obtain  the  recognition  In  one  or  more  of  the Member  States of 
an  authorization  Issued  by  a  Member  State  In  accordance  with  Article  4, 
the  holder  of  the  authorization  shal I  submit  an  appl lcatlon  to  the 
competent  author It les  of  the  Member  State  or  Member  States  concerned, 
together  with  the  Information  and  particulars  referred  to  In  Articles  s, 
Sa  and  Sb.  He  shall  testify  to  the  Identity  of  the  dossier  with  that 
accepted  by  the  first  Member  State,  or  shall  Identify  any  additions  or 
modifications  It  may  contain.  In  the  latter  case,  he  shal I  certify  that 
the  summary  of  product  characteristics proposed  by  him  In  accordance  with 
Article  Sa  Is  Identical  to  that  accepted  by  the  first  Member  State  In 
accordance  with  Article Sb. 
Moreover,  he  shall  certify  that  all  the  dossiers  flied  as  part  of  this 
procedure are  Identical. 
2.  The  holder  of  the  marketing  authorization  shall  notify  the  Committee  of 
this  application,  Inform  It  of  the  Member  States  concerned  and  of  the 
dates  of  submission  of  the  appl lcatlon  and  send  It  a  copy  of  the 
authorization  granted  by  the  first  Member  State.  He  shal I  also  send  the 
Committee  copies  of  any  marketing  authorizations  which  may  have  been 
granted  by  the  other  Member  States  In  respect  of  the  product  concerned, 
and  shall  Indicate whether  any  application  for  authorization  Is  currently 
under  con.slderatlon  In  any  Member  State. - 159  -
3.  The  holder  of  the  authorization  shal I  also  Inform  the  Member  State  which 
granted  the  Initial  authorization  that  an  application  Is  being  made  In 
accordance  with  this  Directive  and  shall  notify  It  of  any  additions  to 
the  o,rlglnal  dossier;  that  Member  State  may  require  the  applicant  to 
provide  It  with  all  the  particulars  and  documents  necessary  to  enable  It 
to  check  the  Identity  of  the  dossiers  fl led  with  the  dossier  on  which  It 
took  Its  decision.  In  addition  that  Member  State  shall  forward  to  the 
Member  State or  Member  States  concerned  by  the  appl !cation  a  copy  of  the 
assessment  report  establ lshed  In  accordance  with  the  second  paragraph  of 
Article 5b. 
4;  Each  Member  State  concerned  shall  recognise  the  marketing  authorization 
granted  by  the  first  Member  State  within  90  days  of  receipt  of  the 
application.  It  shall  Inform  the  Member  State  which  granted  the  Initial 
authorization,  the  other  Member  States  concerned  by  the  application,  the 
Committee,  and  the  person  responsible  for  marketing  thereof. 
Article  18 
1.  Notwithstanding  Article  17  (4),  where  a  Member  State considers  that  there 
are  serious  grounds  for  supposing  that  the  authorization  of  the 
veterinary  medicinal ·product  concerned  may  present  a  risk  to  human  or. 
animal  health  or  the  environment,  It  shall  forthwith  Inform  the 
applicant,  the  Member  State which  granted  the  Initial  authorization,  any 
other  Member  States  concerned  by  the  application  and  the  Committee.  The 
Member  State  shall  state  Its  reasons  tn  detail  and  shall  Indicate  what 
action may  be  necessary  to correct  any  defect  In  the  appl lcatlon. - 160  -
2.  AI  I  the  Member  States  concerned  shal I  use  their  best  endeavours  to  reach 
agreement  on  the  action  to  be  taken  In  respect  of  the  appl lcatlon.  They 
shall  provide  the  applicant  with  the  possibility  to  make  his  point  of 
view  .known  orally  or  In  writing.  However,  If  within  60  days  of  the 
expiry of  the  time  I lmlt  referred  to  In  Article  17(4),  the  Member  States 
have  n~t  been  able  to  reach  agreement  they  shall  forthwith  refer  the 
matter  to  the  Committee  for  the  appllcat ion  of  the  procedure  laid  down  In 
Article  21. 
3.  Within  the  time  I lmlt  referred  to  In  paragraph  2,  the  Member  State  which 
granted  the  Initial  authorization  and  the  other  Member  States  concerned 
by  the  appl lcatlon  shall  provide  the  Committee  with  a  detal led  statement 
of  the  matters  on  which  they  have  been  unable  to  reach  agreement  and  the 
reasons  for  their  disagreement.  A  copy  of  this  Information  shall  be 
provided  to  the  appl lcant. 
4.  As  soon  as  he  Is  Informed  that  the  matter  has  been  referred  to  the 
Committee,  the  appl lcant  shal I  forthwith  forward  to  the  Committee  a  copy 
of  the  Information  and  particulars referred  to  In  Article  17  (1). 
Article  19 
If  several  appl lcatlons  submitted  In  accordance  with  Articles  5  and  5a  have 
been  made  for  marketing  authorization  for  a  particular  veterinary  medicinal 
product,  and  Member  States  have  adopted  divergent  decisions  concerning  the 
authorization  of  the  veterinary  medicinal  product,  or  Its  suspension  or 
withdrawal  from  the  market,  any  Member  State  or  the  Commission,  or  the 
person  responsible  for  marketing  may  refer  the  matter  to  the  Committee  for 
. the  appl lcatlon of  the  procedure  laid  down  In  Article  21. - 161  -
The  Member  State  concerned,  the  person  respons I  b I  e  for  marketIng  or  the 
Commission  shall  clearly  Identify  the  question  which  Is  referred  to  the 
Committee  for  consideration  and,  If  necessary,  shall  Inform  the  person 
responsl~le for  marketing. 
The  Member  States  and  the  person  responsible  for  marketing  shal I  forward  to 
the Committee  alI  aval lable  Information  relating  to  the matter  In  question. 
Article  20 
The  Member  States  or  the  Commission  may,  ·In  specific  cases  where  the 
Interests  of  the  Community  are  Involved,  refer  the  matter  to  the  Committee 
for  the  appl lcatlon of  the  procedure  laid  down  In  Article  21  before  reaching 
a  decision  on  a  request  for  a  marketing  authorization  or  on  the  suspension 
or  revocation of  an  authorization,  or  on  any  other  amendment  to  the  terms  of 
a  marketing  authorization  which  appears  necessary,  In  particular  to  take 
account  of  the  Information  collected  In  accordance  with  Chapter  VIa  of  this 
Directive. 
The  Member  State  concerned  or  the  Commission  shall  clearly  Identify  the 
question  which  Is  referred  to  the  Committee  for  consideration  and  shall 
Inform  the  person  responsible  for  marketing. 
The  Member  States  and  the  person  responsible  for  marketing  shal I  forward  to 
the  Committee  alI  aval lable  Information  relating  to  the matter  In  question. - 162  -
Article  21 
1.  When  reference  Is  made  to  the  procedure  described  In  this  Article,  the 
Committee  shal I  consider  the  matter  concerned  and  Issue  a  Reasoned 
Opinion  within  90  days  of  the  date  on  which  the  matter  was  referred  to 
lt. 
In  case  of  urgency,  on  a  proposal  from  Its  Chairman,  the  Committee  may 
agree  to  Impose  a  shorter  dead I lne. 
2.  In  order  to  consider  the  matter,  the  Committee  may  appoint  one  of  Its 
Members  to  act  as  rapporteur.  The  Committee  may  also  appoint  Individual 
experts  to advise  It  on  specific questions.  When  appointing experts,  the 
Committee  shall  define  their  tasks  and  specify  the  time  limit  for  the 
completion of  these  tasks. 
3.  In  the  cases  referred  to  In  Articles  18  and  19,  before  Issuing  Its 
opinion,  the Committee  shal I  provide  the  person  responsible  for  marketing 
with  an  opportunity  to present  written or  oral  explanations. 
In  the  case  referred  to  Article  20,  the  person  responsible  for  placing 
the  medicinal  product  on  the  market  may  be  asked  to  explain  himself 
orally or  In  writing. 
If  It  considers  It  appropriate,  the  Committee  may  Invite  any  other  person 
to provide  Information  relating  to  the matter  before  lt. 
The  Committee  may  suspend  the  time  limit  referred  to  In  paragraph  1  In 
order  to  allow  the  person  responslb~e  for  marketing  to  prepare 
explanations. I) 
- 163  -
4.  Where  the opinion of  the  Committee  Is  that 
the  application  does  not  satisfy  the  criteria  for  authorization  set 
out  In  this directive,  or 
the  summary  of  product  character 1st lcs  proposed  by  the  applicant  In 
accordance  with Article Sa  should  be  amended,  or 
the  labelling  or  package  of  the  product  Is  not  In  compliance  with 
Chapter  VI I ,  or 
the  authorization  should  granted suject  to  conditions,  or 
an  exIstIng  marketIng  authorIzatIon  shou I d  be  suspended  amended  or 
withdrawn; 
the  Agency  shal I  forthwith  Inform  the  person  responsible  for  marketing. 
Within  15  days  of  the  receipt  of  the  opinion,  the  person  responsible  for 
marketing  may  provide  written  notice  to  the  Agency  that  he  wishes  to 
appea I .  w  1  thIn  60  days  of  the  receIpt  of  the  grounds  for  appea 1  ,  the 
Committee  shall  consider  whether  Its  opinion  shoud  be  revised,  and  the 
reasons  for  the  conclusions  reached  on  the  appeal  shall  be  annexed  to  the 
assessment  report  referred  to  In  paragraph  5. 
5.  Within  30  days.  of  Its  adoption,  the  Agency  shall  forward .the  final 
opinion  of  the  Committee  to  the  Commission  the  Member  States  and  the 
person  responsible  for  marketing  together  with  a  report,  describing  the 
assessment  of  the  veterinary  medicinal  product  and  the  reasons  for  Its 
conclusions. 
In  the  event  of  an  opInIon  In  favour  of  grantIng  or  rna I nta In I ng  an 
authorization  to  market  the  veterinary  medicinal  product  concerned,  the 
following  documents  shal I  be  annexed  to  the  opinion  : 
a>  a  draft  summary  of  the  product  character 1st lcs,  as  referred  to  ·In 
Article 5a; - 164  -
b)  detal Is  of  any  conditions  or  restrictions  which  should  be  Imposed  on 
the  supply  or  use  of  the  veterinary  medicinal  product  concerned, 
Including  the  conditions  under  which  the  veterinary  medicinal  product 
may  be  made  available  to users; 
c)  the  draft  text  of  the  Iabeii lng  and  package  leaflet,  proposed  by  the 
appl lcant  presented  In  accordance with  Chapter  VI  I. 
Article  22 
1.  Within  30  days  of  the  receipt  of  the  opinion  of  the  Committee,  the 
Commission  shal I  prepare  a  draft  of  the  Decision  to  be  taken  In  respect 
of  the  appl lcatlon  taking  Into  account  the  objectives  of  Community 
policies  and  considering  all  relevant  Information.  In  the  event  of  a 
draft  Decision  which  envisages  the granting of  a  marketing  authorization, 
the  documents  referred  to  In  points  (a),  (b)  and  (c)  of  paragraph  4  of 
Article  21  shall  be  annexed.  The  Commission  shall  transmit  the  draft 
Decision  to  the  Member  States and  to  the  appl lcant. 
The  Commission  shall  explain  In  detal I  the  reasons  for  any  differences 
between  the draft  Decision  and  the opinion of  the  Committee. 
2.  The  Commission  shall  adopt  the  Decision  to  be  taken  In  respect  of  the 
application  unless,  within  30  days,  It  has  received  a  reasoned  request 
from  a  Member  State  to  reconsider  the matter.  The  Member  State concerned 
shal I  also  transmit  a  copy  of  Its  request  to  the other  Member  States  and 
the  appl lcant  within  the  same  time  limit. 
3.  Within  the  time  limit  referred  to  In  paragraph  2,  the  applicant  may 
submit  written  observations  on  the  draft  Decision  for  consideration  by 
the  Commission. - 165  -
4.  The  Commission  shall  examine  any  reasoned  request  received  In  accordance 
with  paragraph  2,  In  consultation  with  the  Agency,  and  ·after 
consideration of  any  further observations  submitted by  the  applicant. 
If  the  Commission  considers  that  the  request  raises  questions  of  a 
scientific  or  technical  nature  requiring  further  examination,  It  may 
remit  the matter  to  the  Agency.  In  this case  the  Committee  shall  give  a 
secot:ld  opinion  within  a  time  limit  of  60  days.  Within  30  days  of  the 
receipt  of  the  opinion,  the  Commission  shall  adopt  the  Decision  to  be 
taken  In  respect  of  the  appl lcatlon. 
Otherwise  the  Decision  shall  be  taken  In  accordance  with  the  procedure 
laid down  In Article  2b  and  2c  of Directive 81/852/EEC. 
5.  A  Decision  adopted  In  accordance  with  this  procedure  shall  be  addressed 
to  the  Member  States  concerned  by  the.  matter  and  to  the  person 
. ' 
responsible  for  marketing.  The  Member  States  shall  either  grant  or 
withdraw marketing  authorization,  or  make  any  adjustment.to  the  terms of 
a  marketing  authorization  which  may  be  necessary  to  comply  with  the 
Decision  within  30  days  of  Its  notification.·  They  shall  Inform  the 
Commission  and  the  Committee  thereof. - 166  -
Article  23 
Any  application  by  the  person  responsible  for  marketing  to  amend  the  terms  of 
a  marketing  authorization  which  has  been  granted  In  accordance  with  the 
provisions  of  this  Chapter  shal 1  be  submitted  to  all  the  Member  States  which 
have  previously  authorized  the medicinal  product  concerned. 
The  Agency  shall,  In  consultation  with  the  Commission,  adopt  appropriate 
arrangements  for  the  examination  by  the  Committee  of  amendments  or  variations 
to  a  marketing  authorization  which  has  been  granted  In  accordance  with  the 
provisions of  this Chapter. 
The  procedures  laid  down  In  Articles  21  and  22  shal I  apply mutatis mutandis  to 
variations and  amendments  of  marketing  authorizations. 
Article  23a 
1.  Where  a  Member  State  considers  that  the  amendment  of  the  terms  of  a 
marketing  authorization  which  has  been  granted  In  accordance  with  the 
provisions  of  this  Chapter  or  Its  suspension  or  withdrawal  Is  necessary, 
the  Member  State  concerned  shal I  forthwith  refer  the  matter  to  the 
Committee  for  the  appl lcatlon of  the  procedures  laid  down  In  Article  21  and 
and  22. 
2.  In  exceptional  cases,  where  action  Is  urgently  necessary  to  protect  human 
or  animal  health  or  the  environment,  untl I  a  definitive  Decision  Is 
adopted,  the  Member  States  suspend  the  use  of  the  veterInary  medIc Ina I 
product  concerned  on  Its  territory.  It  shall  Inform  the  Commission  no 
later  than  the  following  working  day  of  the  reasons  for  Its action. - 167  -
Article  23b 
Articles  23  and  23a  shal I  apply  mutatis  mytandis  to  medicinal  products 
author I  zed  by  Uember  States  fo II owl ng  an  opInIon  of  the  Cornm It tee  gIven  In 
accordance with Article 4 of  Directive 87/22/EEC  before  1  January  1993. 
Article  23c 
1.  The  Agency  shall  publish  an  annual  report  on  the  operation  of  the 
procedures  laid  down  In  this Chapter. 
2.  Within  six  years  of  the  date  referred  to  In  the  first  sub-paragraph  of 
Art lcle  4  (1 >,  the  Commission  shall  publish  a  detailed  review  of  the 
operation of  the  procedures  laid  down  In  this chapter  and  shall  propose  any 
amendments  which  may  be  necessary  to  Improve  the  operation  of  these 
procedures. 
The  Councl I  shal I  decide  on  the  Commission  proposal  within  one  year  of  Its 
submission." - 168  -
10.  The  third  sub-paragraph of  paragraph  1 of  Article  30  Is  replaced  by  the 
following 
nln  the  case  of  veterinary  medicinal  products  Imported  from  a  third 
country,  where  appropriate  arrangements  have  been  made  by  the  Community 
with  the  exporting  country  to  ensure  that  the  manufacturer  of  the 
veterInary  medIc Ina I  product  app I I  es  standards  of  good  manufacturIng 
prac~lce at  least  equivalent  to  those  laid  down  by  the  Community  and  to 
ensure  that  the  controls  referred  to  under  (b)  have  been ·carr led  out  In 
the  exporting  country,  the  qualified  person  may  be  rei laved  of 
responsibility  for  those controls." 
11.  The  following  Chapter  VIa  Is  Inserted after Article 42 
"CHAPTER  Via 
Pharmacovlgllance 
Article 42a 
In  order  to  ensure  the  adoption  of  appropriate  regulatory  Decisions 
concerning  the  continued  authorization  of  veterinary  medicinal  products 
within  the  Community,  having  regard  to  Information  obtained  about 
adverse  reactions  to  veterinary  medicinal  products  under  practical 
conditions of' use,  the  Member  States shall  establish a  pharmacovlgl lance 
system  for  collecting  Information  about  adverse  reactions  to  veterinary 
medicinal  products  and  for  the  scientific  evaluation  of  such 
Information. ...,  169  -
Article 42b 
For  the  purpose of  this Directive,  the  following  definitions shal I 
apply  : 
-"adverse  ~eactlon"  shall  mean  a  reaction  which  Is  noxious  and 
unIntended  and  whIch  occurs  at  doses  norma I I  y  used  In  an I  rna Is  In 
accordance  with  the  terms  of  the  marketing  authorization·  for  the 
prophylaxis,  diagnosis  or  therapy  of  disease  or  for  the  modification 
of  physiological  function. 
- "serious  adverse  reaction"  shal I  mean  an  advers~  reaction  which 
results  In  death,  permanent  or  prolonged  signs  or  lesions  In  treated 
animals. 
Article 42c 
The  person  responsible  for  marketing  ~hall  have  permanently  and  continuously 
at  his disposal  a  person  responsible  for  pharmacovlgl  l~nce. ·  Thls  person  shal I 
be  responsible  for  ~ 
a)  the  establ lshment  and  maintenance  of  a  system  which  ensures  that 
Information  about .alI  adverse  reactions which  are  reported  to  the  personnel 
of  the  company,  Including  Its sales  personnel,  Is  collected and  collated at 
a  single point; 
b)  the  preparation  and  submission  to  the  competent  authorities of  the  reports 
referred  to  In  Article  42d,  In  such  from  as  may  be  laid  down  by  those 
authorities; - 170-
c)  ensuring  that  any  request  from  the  competent  authority  for  the  provision of 
additional  Information  necessary  for  the  evaluation  of  the  benefits  and 
rIsks  of  a  veterInary  medIc Ina I  product  Is  answered  fu I I  y  and  prompt I  y, 
Including  the  provision  of  Information  about  the  volume  of  sales  for  the 
veterinary medicinal  product  concerned,  where  relevant; 
Article  42d 
1.  The  person  responsible  for  marketing  shall  be  required  to  record  and  to 
report  all  suspected  serious  adverse  reactions  which  are  brought  to  his 
attention  by  a  qual If led  veterinarian  to  the  competent  authorities  within· 
15  days  of  their  receipt. 
2.  In  addition,  the  person  responsible  for  marketing  shall  be  required  to 
maintain detailed  records of  alI  other  adverse  reactions  which  are  reported 
to  him  by  a  veterinarian  health  care  professional.  Unless  other 
requirements  have  been  laid  down  as  a  condition  of  the  granting  of 
author I  zat Jon,  these  records  sha II  be  submItted  to  the  competent 
authorities  Immediately  upon  request  or  at  least  every  six  months  during 
the  first  two  years  following  authorization  and  once  a  year  for  the 
following  three  years.  Thereafter,  the  records  shal I  be  submitted  at  five 
yearly  Intervals  together  with  the  appl lcatlon  for  renewal  of  the 
authorization,  or  Immediately  upon  request. - 171  -
Article 42e 
The  Member  States  shal I  take  alI  appropriate  measures  to  encourage 
veterinarians  to  report  adverse  reactions  to  the  competent  authority. 
The  Member  States  may  Impose  specIfIc  requIrements  on  veterInarIans,  In 
partlcu!ar  In  respect  of  the  reporting  of  serious  or  unexpected  adverse 
reactions,  or  where  such  reporting  Is  a  condition  of  the  marketing 
authorization. 
Article  42f 
The  Member  States  shall  ensure  that  reports  of  serious  adverse  reactions  are 
brought  to  the  attention  of  the  Agency  and  the  person  responsible  for 
marketing within  15  days  of  their  receipt. 
Article 42g 
In  order  to  facilitate  the  exchange  of  Information  about  pharmacovlgllance 
within  the  Community,  the  Agency  shall,  In  consultation  with  Member  States, 
the  Gommlsslon  and  Interested  parties,  draw  up  datal led  guidance  on  the 
col lectlon,  verification and  presentation of  adverse  reaction  reports. - 172  -
Article 42h 
Where  as  a  resu It  of  the  evaluatIon  of  adverse  react I  on  reports,  a  Member 
State  Is  considering  amending  the  terms  of  a  marketing  authorization  or  Its 
suspension or  withdrawal,  It shall  forthwith  Inform  the Agency. 
In  case of  urgency,  the  Member  State concerned  may  suspend  the  marketing  of  a 
medicinal  product,  provided  the  Agency  Is  Informed  at  the  latest  on  the 
following  working  day." - 173  ...:; 
Article  29h 
Where  as  a  resu It  of  the  eva luat !on  of  adverse  react ion  r.eports,  a  Me.mber 
State  Is  considering  amending  the  terms  of  a  marketing  authorization  or  Its 
suspensions or  withdrawal,  It  shall  forthwith  Inform  the Agency. 
In  case  of  urgency,  the  Member  State  concerned  may  suspend  the  marketing  of 
a  medlclnai  product,  provided  the  Agency  Is  Informed  at  the  latest  on  the 
following  working  day." 
Article 4 
Member  States  shal I  take  alI  appropriate  measures  to  comply  with  the 
provisions  of  this  Directive,  with  the  exception  of  Article  1  (6),  before 
1  January  1993.  They  shall  forthwith  Inform  the  Commission  thereof. 
Member  States  shall  take  all  appropriate  measures  to  comply  with 
Article 1  (6)  of  this  Directive  before  1  January  1996.  They  shal I  forthwith 
Inform  the Commission  ther.eof. 
When  Member  States  adopt  these  provisions,  these  shall  contain  a  reference 
to  this  Directive  or  shal I  be  accompanied  by  such  reference  at  the  time  of 
their  official  publ !cation.  The  procedure  for  such  reference  shai I  be 
adopted  by  Member  States. 
Article  5 
Thl~ Directive  Is addre,sed  to  the  Member  States. 
Done  at  Brussels  For  the  Counc I I - 175  -
Proposal  for  a 
COUNCIL  PIRECIIVE 
repealing Directive 87/22/EEC  on  the  approximation  of 
national  measures  relating  to  the  placing on  the  markot 
of  high  technology  medicinal  products  particularly 
those  derived  from  biotechnology - 177  -
Proposal  for  a 
COUNCIL  PIRECTIYE 
repealing Directive 87/22/EEC  on  the  approximation of 
national  measures  relating  to  the  placing on  the market 
of  high  technology medicinal  products  particularly 
those  derived  from  biotechnology 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to  the  Treaty  establishing  the  European  Economic  Cbmmunlty, 
and  In  particular Article  100a  thereof; 
Having  regard  to  the  proposal  from  the  Commlsslon<1>, 
In  cooperatlori with  the  European  Parllament<2> 
Having  regard  to  the opinion of  the  Economic  and  Social  Commlttee<3> 
Whereas  the  provisions  of  Council  Directive  87/22/EEc(4) 
superseded  by  the  provisions  of·  Regulation  (EEC) ....  / ..  of 
have  now  been 
laying  down  Community  procedures  for  the  authorization  and  supervision  of 
medicinal  products  for  human  and  veterinary  use  and  establ lshlng  a  European 
Agency  for  the  Evaluation  of  Medicinal  Products<5)  and  by  Councl  1 
Directive  88/182/EEC  of  22  March  1988  amending  Directive  83/189/EEC  laying 
down  a  procedure  for  the  provision of  Information  In  the  field of  technical 
standards  and  regulatlons<6>; 
( 1) 
(2) 
(3) 
(4)  OJ  No  L 15,  17.1.1987,  p.  38. 
(5) 
(6)  OJ  No  L 81,  26.3.1988,  p.  75. - 178  -
Whereas  provision  has  been  made  In  council  Directive  ..  / ...  / ..  <7>  for  the 
continued management  of marketing  authorizations which  have  been  granted  by 
Uember  States  following  the  opinion  of  the  Committee  for  Proprietary 
Uedlclnal  Products  given  In  accordance with  Directive 87/22/EEC; 
Whereas,  furthermore,  provision  has  been  made  In  Councl I  Directive 
..  / ...  / ..  <8>  for  the  continued  management  of  marketing  authorizations 
which  have  been  granted  by  Uember  States  following  the  opinion  of  the 
Committee  for  Veterinary  Uedlclnal  Products  given  In  accordance  with 
Directive 87/22/EEC; 
Whereas  Directive 87/22/EEC  should  therefore  be  repealed; 
Whereas  In  the  Interests  of  legal  certainty,  provision  should  be  made  for 
the  continued examination of  applications  for  marketing  authorization which 
have  been  referred  to  Committee  for  Proprietary  Uedlclnal  Products  or  the 
Committee  for  Veterinary  Uedlclnal  Products  In  accordance  with  Directive 
87/22/EEC  before  1  January  1993, 
HAS  ADOPTED  THIS  DIRECTIVE 
(7) 
(8) - 179  -
Article  1 
With  effect on  1  January  1993,  Councl I  Directive 87/22/EEC  Is  repealed. 
Article  2 
App II cat Ions  for  marketIng  authorIzatIon  whIch  have  been  referred  to  the 
Committee  for  Proprietary  Medicinal  Products  or  to  the  Committee  for 
Veterinary  Medicinal  Products  before  1  January  1993  In  accordance  with 
Article  2  of  Directive  87/22/EEC  and  In  respect  of  which  the  Committee 
·concerned  has  not  given  an  opinion  by  1  January  1993  shal I  be  considered 
In  accordance  with  Regulation  (EEC) ....  / .. 
Article  3 
Member  States  shall  take  all  appropriate  measures  to  comply  with  this 
Directive  before  1  January  1993.  They  shall  forthwith  Inform  the 
Commission  thereof. 
When  Member  States  adopt  these  provisions,  these  shal I  contain  a  reference 
to  this Directive or  shal I  be  accompanied  by  such  reference  at  the  time  of 
their  ·official  publication.  The  procedure  for  such  reference  shall  be 
adopted  by  Member  States. 
Article 4 
This  Directive  Is  addressed  to  the  Member  States. 
Done  at  Brussels  For  the  Counc I I ' - 181  -
COMPETITIVENESS  AND  EMPLOYMENT  IMPACT  STATEMENT ~ 183  -
COMPETITIVENESS  AND  EMPLOYMENT  IMPACT  STATEMENT 
relating  to  the  proposals  for  the  future  system  for  the  free  movement  of 
medicinal  products  In  the  European  Community 
I.  What  Is  the main  reason  for  Introducing  the measures? 
Completion  of  the  Internal  market;  harmonization of  Individual 
administrative decisions  concerning  the  authorization  and  conditions 
of  use of  medicinal  products; 
establ lshment  of  Community  authorization procedures  for  certain 
categories of  Innovatory medicinal  products; 
establ lshment  of  a  European  Medicines  Evaluation  Agency  to  advise  the 
Community  Institutions and  Member  States on  scientific  Issues  relating 
to  the  qual tty,  safety  and  efficacy of  medicinal  products;  improvement 
of  the  protection of  pub! lc  health,  In  particular  in  respect  of  the 
monitoring  of  adverse  reactions  to medicinal  products 
(pharmacovlgi lance). 
I I.  Features of  the  business  In  question 
These  measures  primarily  concern  pharmaceutical  manufacturers. 
Because of  the  high  costs of  developing  new  medicinal  products,  In 
excess of  100  mi  II len  ECU  for  a  major  Innovatory  product, 
pharmaceutical  companies  are often  large multinational  companies,  and 
there  Is  currently  a  significant  Increase  In  concentration  In  this 
sector  as  companies  seek  to attain  the  "critical  mass"  perceived  as 
necessary  to  finance  research  and  development. 
There  are also a  number  of  smaller  or  medium  sized companies,  geared 
primarl ly  to  national  or  regional  markets,  manufacturing  conventional 
medicinal  products  or  copies of  products whose  patent  has  expired. - 184  -
In  addition,  there  are  a  very  limited  number  of  smal I,  highly 
Innovatory  research-based  companies,  concentrating on  basic  research 
Into  new  therapies. 
111.  What  direct obligations does  this measure  Impose  on business  1 
The  majority of  this  package  Is  procedural  and  It  Imposes  few  new 
direct  obi lgatlons on  business. 
Although  manufacturers  of  medicinal  products  derived  from 
biotechnology  wl  I I  be  required  to obtain authorization  from  the 
Community,  rather  than  Member  States,  It  should  be  noted  that  these 
products  are  already  subject  to  a  compulsory  Community  coordination 
procedure,  based  on  harmonized  Community  requirements,  and  the  new 
requirements  wl  I I  not  therefore  result ·in  any  Increase  In  the  cost  of 
preparing  appl !cations.  For  other  categories of  Innovatory  medicinal 
product,  the  central lzed  procedure  wl  I I  be  aval !able on  an  optional 
basis,  as  an  alternative  to  national  procedures. 
For  other  categories of  medicinal  products,  the  use  of  the 
decentralized  Community  procedure  wl  I I  become. cpmpulsory:after  1996. 
However,  since  the  requirements  for  the  preparation of  appl !cations 
for  authorization are  already  harmonized,  there  should  be  no  Increase 
In  the  overal I  costs of  obtaining authorization. 
Although  the  pharmaceutical  Industry  wl  I I  be  expected  to  pay  fees  for 
of  authorization,  the  detal led  fee  structure  wl  I I  only  be  adopted 
following  consultation of  the  Industry,  and  In  no  case  wl  I I  the  fees 
payable  to  the  Community  exceed  the  sum  of  the  fees  currently  payable 
to  the  Individual  Member  States. 
Finally,  each  company  wl  I I  be  required  to establIsh  a  system  for 
col lectlng  and  evaluating  reports of  adverse  reactions  (ADRs)  to  Its 
medicinal  products  and  for  reporting  ADRs  rapidly  to  the  regulatory 
authorities.  Although  such  requirements  are  new  at  the  Community - 185  -
level,  they already exist  In  most  Member  States,  and  even  where  formal 
requirements  are  not  laid  down,  most  reponslble  companies  have 
arrangements  for  collecting and  assessing  such  Information. 
IV.  What  Indirect obligations are  local  authorities  likely to  Impose  on 
business  ? 
None  ·foreseen. 
v.  Are  there any  special  measures  In  respect of  SMEs  ? 
.  No. 
VI.  What  Is  the  likely effect on 
a)  the competitiveness of  business  ? 
The  proposed  measures  wl  II  facll ltate the  access of  alI  medicinal 
products···to  a•CommunHy  scale market.·  They·are  likely  to be  of 
particular  benefit  to smaller  scale companies  who  lack  the 
resources  to establIsh  local  subsidiaries  In  the different  Member 
States  to  deal  directly with  national  regulatory authorities.  In 
consequence,  some  companies  may  have  to make  efforts  to maintain 
their  competitiveness vis-A-vis  companies  establ lshed  elsewhere  In 
the Community. 
b)  employment  ? 
No  significant effect  Is anticipated. - 186  -
VII.  Have  both sides of  Industry been  consulted on  these proposals? 
Extensive consultation  has  preceded  the  preparation of  these 
proposals.  In  Its March  1988  report  on  the activities of  the 
Committee  for  Proprietary Medicinal  Products  (COM  (88)  143)  the 
Commission  Invited alI  Interested parties  to  submit  comments  on  the 
general  orientation  to be  followed  In  these proposals.  In  addition, 
two  furhter  staff papers of  Apr I I  1989  and  December  1989  have 
summarized  the state of  the  consultation process  and  Invited  comments 
on  specific aspects of  the  proposals. 
Those  consulted  Include 
-associations of  the  pharmaceutical  Industry  (human  and  veterinary); 
-associations of  consumers; 
-associations of  veterinarians,  doctors  and  pharmacists; 
- chemical  Industry  trade  unions. - 187  -
,I. 
FINANCIAL  STATEMENT  · - 189  -
FINANCIAL  STATEMENT 
Future system for  the  free movement  of medicinal  products 
within  the  European  Community 
1.  Budget  Headings 
N°  A 1  and  A 2  Expenses  of officials and  other  staff 
N°  A  2510  Committee  (obi lgatory  consultation)  expenses 
N°  8  5300  [ex  B 7750]  and  8  5302  (*) 
Actions  for  the  Internal  market 
(*)  A new  budget  heading  to  be  Inserted  In  Part  B of  the  Budget  : 
"Operational  expenses of  the  European  Agency  for  the  Evaluation 
of  Medicinal  products." 
2.  Legal  basis 
Article  100  A of  the  EEC  Treaty. 
3.  Description of  the  project 
3.1.  General  objective 
Real lsatlon of  the  Internal  market  for  medicinal  pi6ducts  for  use  In 
human  beings or  animals.  Improvement  of  the  protection of  pub! lc 
health  throughout  the  Community. - 190  -
3.2.  Specific objectives 
a)  the establ lshment  of  a  new  autonomous  European  Agency  for  the 
Evaluation of  Medicinal  Products;  the  new  Agency  wl  I I  be  made  up  of 
the exlstlng·commlttee  for  Proprietary Medicinal  Products  (CPMP) 
and  the  Committee  for  Veterinary Medicinal  Products  (CVMP),  with 
substantial  additional  logistical  and  administrative  support.  The 
expenses  for  these  two  committees  (CPMP  and  CVMP)  currently  In  the 
budget  (I lne  2510)  wl  I I  therefore  become  part  of  the Agency  budget 
(cost  In  1989  was  117,000  ECU).  Its  task  wl  I I  be  to  coordinate  the 
work  of  evaluation and  supervision of  medicinal  products  being 
conducted  In  Member  States  to  avoid  dupl lcatlon of effort,  but  at 
the  same  time  ensure  that  alI  relevant  factors  are  taken  Into 
consideration  during  the  authorization  process; 
b)  the  creation of  a  new  central lzed  Community  procedure,  compulsory 
for  biotechnology  products  and  veterinary medicines  used  as 
performance  enhancers,  and  aval lable on  an  oplonal  basts  for  other 
Innovatory medicinal  products,  leading  to  a  Community 
authorization,  val ld  throughout  alI  12  Member  States,  which  wl  I I 
subsequently  be  managed  and  supervised  by  the  Community 
Institutions; 
c)  the  creation of  a  new  decentral lzed  procedure,  based  on  the 
principle of  mutual  recognition,  which  wl  I I  allow  the  progressive 
extension of  a  marketing  authorization  from  one  Member  State  to  the 
others,  with  important  safeguards  to  ensure  that  there  Is  no 
dl Iutton of  the strict standards of  qual tty,  safety  and  efficacy. 
In  the event  of  a  disagreement  between  Member  States about  the 
qual tty,  safety or  efficacy of  a  medicinal  product,  the  Agency  wl  I I 
provide  an  lndependant  scientific evaluation of  the  issues 
Involved,  and  a  binding arbitration procedure  at  Community  level 
wi  11  follow.  However,  the  monitoring of  the  product  wl  11  remain 
the  responslbl lity of  the  Individual  Member  States. 
d)  the establ lshment  of  reinforced Community  procedures  for  the 
collection and  evaluation of  adverse  reaction  reports  about 
medicinal  products  and  for  the  adoption of  appropriate  regulatory 
action  about  such  reports. 4. 
• 
- 191-
e)  coordination of  the  exercise  by  Member  States of  the  various 
supervisory  responslbl I ltles concerning  the manufacture  and  testing 
of  medicinal  products,  In  part·lcular 
, '· 
good  manufacturing  practrces · 
-good  laboratory  practices 
good  clinical  practices 
..... 
f)  th~ maintenance of  a  pharmaceutical  data  base which  Is available 
for  pub I I  c  use. 
g)  the  provision of  scientific advice on  maximum  residue  levels  for 
veterinary medicines which  may·be  accepted  In  foodstuffs  of  animal 
origin without  risk  for  the  consumer. 
Justification of  the  project  I  ' 
4.1.  Justification of  the  type of  project  proposed. 
The  experience  acquired  during  the operation of  the existing Community 
concertatlon procedure  for  high  technology/biotechnology medicinal 
-products  (Directive  87/22/EEC)  has  clearly demonstrated  the  need  to 
pool  .the  resources  of  the  Member  States  In  o~der  to  ensure  the  rapid 
but  exhaustive evaluation of  appl.lcatlons.  The  sheer  complexity of 
appl lcatlons  for  authorization  for  these  types of  products,  which  cost 
over  100  ml  I I Jon  ECUs  to  assemble  and  run  to  tens of  thousands of 
pages  means  that  the  dupl lcatlon of  effort  and  waste of  scarce 
scientific resources  resulting  from  lndependant  national -evaluations 
can _no  longer  be  tolerated.  It  Is  therefore necessary  to  br lng 
together  the  best  aval !able scientific experts currently working 
within  the Member  States  to  evaluate applications on  behalf  of  the 
Community  as  a  whole  within  the  framework  of  a  European  Medicines 
Evaluation Agency. - 192  -
For  other  categories of  medicines,  experience  suggests  that.a 
decentralized  procedure,  based on  the  principle of  mutual  recognition 
may  be  feasible.  However,  because of  the  Important  public  health 
Issues  Involved,  It  Is  clear  that  Important  safeguard clauses are 
required  by  Member  States,  and  there  can  be  no  question of  automatic 
mutual  recognition.  The  continued  need  for  safeguard  clauses  lmpl les 
that  the  Community  must  be  provided  with  the administrative,  technical 
and  scientific resources  to arbitrate  In  the  event  of  a  disagreement 
between  Member  States,  leading  to binding  decisions. 
For  practical  and  managerial  reasons,  It  Is  considered  that  the  task 
of  preparing  the  necessary  advice should  be  devolved  to  an  autonomous 
Agency.  However,  the  final  decisions  to  be  taken  must  be  reached 
within  the existing  Institutional  mechanisms. 
4.2.  Interest  In  the  project  at  Community  level 
The  real lsatlon of  the  Internal  market  lmpl  les  that  al 1 categories of 
Industrially prepared medicinal  products  should  be  allowed  to 
circulate freely  throughout  the  Community.  The  Community  must 
therefore  be  provided  with  the  means  to  reconcl le  differences  between 
Member  States  regarding  the  acceptance  of  products,  whl  le  maintaining 
the  high  standards  necessary  for  the  protection of  the  European 
patient. 
5.  F I  nanc I  a I  Imp I I  cat Ions 
5.1.  General  remarks 
a)  The  operational  expenses of  the  new  Agency  wl  I I  be  covered 
In  part  by  fees  paid  by  pharmaceutical  enterprises  for  the 
evaluation of  applications.  The  Commission  Intends  to  propose  to 
Councl I  a  special  financial  regulation  for  the  Agency  which  wl  I I 
Include  a  scheme  of  fee  Income  for  marketing authorization.  It  Is 
Intended  that  fee  Income  wl  I I  ultimately provide  the major  source 
of  financing  for  the  Agency; - 193  -
t·. 
In  part  by  funding  from  the  Community  budget,  through  a  new 
budgetary  1 lne  to  be  Inserted  In  the operational  part  of  the  budget 
(Part  B).  The  form  of  Community  funding  of  the Agency  wl  I I  be 
defined  by  the  Commission  proposal  for  the Agency's  financial 
regulation. 
b)  Approximative estimates of  the  financial  expenditure  Involved  are 
given  for  lllustrat lve  purposes  In  sect lon  5.2.  below.  In  order  to 
provide more  precise estimates of  the cost  of  the  Agency,  and  the 
anticipated  Income  from  fees  paid  by  the  Industry, •  study  wl1  I  be 
requested  from  an  external  consultant; to be  completed  before  the 
end  of  1991.  The  estimates  In  section 5.2  In  no  way  prejudge  the 
level  of  Community  financing  once  the  Agency  Is operational.· 
c)  The  Commission  Itself wl 1 I  also  have  new  tasks  resulting  from  the 
Introduction of  the  new  procedures,  and  It  Is  therefore necessary 
to  provide  the  resources  required  (section 5.3.  below). 
d) .Both  the  level  of  Community  funding  of .the  Agency  and  the  resources 
requIred  from  the  adm:l nl strat lve  approprIatIons· of  the  Comm Iss 1  on 
wl  I I  be  determined  annually  1n  the  course of  the  budgetary 
procedure  and  will  be  entirely compatible wlth .. flnanclal 
perspectives. 5.2.  Financial  Imp I I  cat Ions 
Medicinal  Products 
Year  No 
1991  8  5300 
[ex  B 7750] 
1992  B 5306  (*) 
1993  B 5306  (*) 
(*).  New  budgetary  I lne 
- 194  -
The  European  Agency  for  the  Evaluation of 
Amount 
200.000  ECU 
2.000.000  ECU  (**) 
p.m. 
Purpose 
Preliminary  study 
Estab I I shment  of  the 
Agency 
Contribution  from  the 
Community  to  the 
operational  expenses of 
the  Agency. 
(**)  This  Is  an  Indicative  amount  which  wl  I I  be  proposed  In  the 
course  of  the  1992  budgetary  procedure  by  the  Commission. 
The  operational  expenses of  the  Agency  wl  I I  be  estimated  In  datal I 
following  the  pre I lmlnary  study  which  Is  to  be  completed  before  the 
end  of  1991.  Approximative  costs and  estimates of  the  resources 
necessary  are  given  below  for  I I lustratlve purposes  on  an  annual 
basis. 
5. 3.  F I  nanc I  a I  Imp I I  cat Ions  services of  the  Commission 
The  new  procedures  require  that  the  Commission,  assisted by  a 
regulatory  committee,  adopt  the  final  decisions on  the grant,  refusal 
or  amendment  of  auhorlzatlon,  pharmacovlgllance alerts,  tolerances  for 
residues of ·veterinary medicinal  products,  etc.  Additional  resources 
wl  11  be  required  for  this  purpose,  to  be  provided either  through 
Internal  redeployment  or  within  the  framework  of  the  budgetary 
procedure. - 195  -
The  number  of  decisions  to  be  taken  each  year  has  been  evaluated  as 
follows  : 
Community  authorizations  :  human 
and  veterinary  (centr~l lzed 
procedure) 
Variations to Community 
authorizations 
Arbitrations  (decentral lzed 
procedure) 
Pharmacovlgllance alerts 
Tolerances  for  residues of 
veterinary medicines 
1993  . 1994  1995 
30  45  60 
20.  60  150 
100  150  120 
50  75  100 
20  30  .  40 
The  estimated  additional  requirements  are 
1.  Personna I  (N°  A 1  and  A 2) 
1991  +  2A  +  18  +  2C  Preparation  and  establ lshment  of  t~e Agency; 
part lclpat lon  In  the  preliminary  study 
1992  +  2A  +  18  +  2C  ..  Estab II shment  of  fhe  Agency 
1993 
Total 
+  1A  +  18  +  1C 
5A  38  5C 
Management  of  centralized and  decentral lzed 
decisions. 
Total  cost  (at  80.000  ECU  per  average)  Is  400.000  ECU  In  1991; 
800.000  ECU  In  1992  and .1.040.000, ECU  from  1993. - 196  -
2.  Meetings  (N°  A 2510) 
In  the  event  of  an  objection  from  one  or  more  Member  States,  the  draft 
Commission  decision  wl  II  have  to  be  submitted  to a  regulatory 
committee  for  approval.  Two  new  regulatory  committees  are  necessary 
from  1993,  one  for  medicinal  products  for  human  use,  one  for 
veterinary medicinal  products,  meeting  at  approximately  2  monthly 
Intervals. 
1993  120.000  ECU  (10.000  ECU  x  12  meetings). ..,. 
PRICE 
ISSN 0254-1475 
COM(90) 283 final 
_:i-
.  \J 
\ 
06  02 
Catalogue numl;>er ':  CB~i.~C0-90-576-EN  -C 
-tsSN.-92-77 -66016-3 
1 -30 pages: 3,~0 ECU  per additionallO pages: 1.25 ECU 
.. 
Office for Official Publications of the European Communities 
L-2985 Luxembourg 
.  -- . 